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Steroids: The basic science and clinical aspects covers the modern understanding and 
clinical use of steroids. The history of steroids is richly immersed and runs long and 
deep. The modern history of steroids started in the early 20th century, but its use has 
been traced back to ancient Greece. We start by describing the basic science of steroids. 
We then describe different clinical situations where steroids play an important role. We 
hope that this book will contribute further to the literature available about steroids and 
enables the reader to further understand this interesting and rapidly evolving science.
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Preface 
The history of steroids is richly immersed and runs long and deep. The modern 
history of steroids started in the early 20th century, but its use has been traced back to
ancient Greece where athletes ingested animal testicles to boost their energy and 
performance. This book covers the modern understanding and clinical use of steroids.
We divided the  book into two sections. The first section contains information about 
steroids in the human body. The second section will cover the relationship of steroids.
Topics covered in the first section include the concentration of the steroids in various
parts of the body, effects of steroids on body composition of athletes,  the metabolic 
syndromes, and  the effect of steroids on the development of the male reproductive 
system. The second section contains various clinical scenarios that involve steroids.
We hope that this book will contribute further to the literature available about steroids
and enables the reader to further understand this interesting and rapidly evolving
science.
Hassan Abduljabbar
Professor of Obstetrics and Gynecology,
King Abdulaziz University, 
Kingdom of Saudi Arabia
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The Concentration of Steroid Hormones 
in Blood and Peritoneal Fluid 
 Depends on the Site of Sampling 
N. Einer-Jensen1, R.H.F. Hunter2 and E. Cicinelli3 
1Institute of Molecular Medicine, University of Southern Denmark, Odense M, 
2Institute for Reproductive Medicine, Hannover Veterinary University, Hannover, 





The concentration of steroid hormones in arteries varies according to the site of blood 
sampling. The hormone concentration is higher in the ovarian and testicular arteries than in 
the aorta resulting in a high impact on the target organs, opening a route for local hormonal 
regulation between organs. Local application of drugs may induce a potential method for 
semi-specific treatments. Vaginal application of hormones will therefore induce relatively 
higher concentrations in the uterus and urinary bladder area than a peripheral application. 
Likewise, nasal application will induce a higher relative concentration in brain arterial blood 
than peripheral application. This is due to local counter-current transfer between venous 
and arterial blood, and between the lymphatic and arterial vessels. Similarly, the 
concentration of steroids in peritoneal fluid varies according to the site of sampling.  
2. The third way of humoral communication: local counter-current transfer 
Humoral communication between cells can be either through local diffusion in the 
interstitial fluid between neighbouring cells or through the vascular system. The present 
paper will discuss a third possibility that is part of the vascular distribution. The paper will 
concentrate on local communication between organs belonging to the reproductive system 
and steroid hormones, but will also touch other organs (the adrenal, the brain and the 
peritoneal cavity) where local transfer of steroids seem to be involved in the physiological 
regulation.  
McCracken et al. (1972) initiated the hormonal transfer investigations in the female. The 
anatomical structure had, however, been known for hundreds of years (Blancardi 1687, 
published in 1739). Ginther (1967) described the functional importance of a close 
connection between the ovarian artery and veins. The work involving steroid transfer in 
males was started by Jacks and Setchell (1973) and Einer-Jensen (1974). The 
documentation comes from investigations in several animal species as well as in man (see 
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Einer-Jensen et al., 1989; see Krzymowski, 1990; see Einer-Jensen and Hunter, 2005). 
Despite the anatomical differences between the species (one ovulation versus 10-20 
ovulations, large uterine body and small uterine horns versus small uterine body and 
large horns), the picture of transfer is similar.  
 
 
Fig. 1. The human genital organs and their vascular supply. The plexus formed by the 
ovarian artery and vein can be seen (arrows). (From Blancardi 1687). 
The Concentration of Steroid Hormones 
in Blood and Peritoneal Fluid Depends on the Site of Sampling 5 
Signal substances such as hormones produced in an organ will diffuse to the surrounding 
lymph and blood capillaries. Thus the signal substance will be present in the content of local 
lymph and blood vessels removing fluid and blood from the organ. The concentration will, 
of course, be high here compared to the peripheral fluids since no dilution has taken place 
(Einer-Jensen and Hunter, 2005).  
In some hormone producing organs, the vessels removing the fluid from the organ are 
very intimately arranged with the artery supplying the organ. This is the case for steroid 
producing organs such as the gonads in both male and female. It is well known that the 
temperature in the extra-abdominal testis is a few degrees Centigrade lower than the 
general body temperature due to cooling through the scrotal wall and maintenance of the 
temperature gradient by counter-current transfer of heat energy. The transfer is expected 
to take place between the venous plexus (the Pampiniform plexus) and the convoluted 
testicular artery. The efficacy of the heat transfer is very high, close to 100% (Glad 
Sørensen et al., 1991), thus the cooling through the scrotal wall can be kept at a low level – 
which will diminish the waste of energy from the body. In most mammals, the testis is an 
organ positioned outside the abdomen, but even in animals with intra-abdominal testes 
the close apposition between the vessels is found, e.g. in small whales (Einer-Jensen, pers. 
com.). This strongly suggests that cooling is not the only reason for the vascular 
arrangement  
The ovaries are always positioned in the abdomen and one would not expect temperature 
gradients within their tissues. The vessels to and from the ovary are closely apposed in a 
way similar to the male, indicating the potential for of a transfer system. However, the 
temperature of the pre-ovulatory follicles tends to be lower than deep body temperature 
(Hunter and Einer-Jensen, 2005; Hunter et al., 2006). Heat “consuming” proteins induce 
lower temperature and the temperature decrease is maintained by a very local heat-
exchange mechanism in the vessels to and from the follicle. 
3. Counter-current exchange 
When blood or lymph flows through arteries, and veins and lymph vessels, and the vessels 
are in close contact, the flow can be described as counter-current flow.  
Counter-current exchange along with Concurrent exchange comprise the mechanisms used 
to transfer some property of a fluid from one flowing current of fluid to another across a 
semipermeable membrane or thermally-conductive material between them. The property 
transferred could be heat, concentration of a chemical substance, or others. Counter-current 
exchange is a key concept in chemical engineering thermodynamics and manufacturing 
processes, for example in extracting sucrose from sugar beet roots. (Wikipedia, the figure 
below is also from Wikipedia). 
The present authors expect the transfer to be passive; no active transfer mechanisms have 
been detected or proposed (to the best knowledge of the authors). The laws of physics, the 
respective rates of flow, the diffusion distance between the vessels, the chemical nature of 
the substances, especially the lipophility, will determine the rate of exchange. In general, a 
system will transfer heat at almost 100% (Glad Sørensen et al., 1991), whereas the 
exchange of tritiated water may be 20%, and the rate of steroid hormone transfer a few 
per cent. 
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Fig. 2.  
Many of the first experiments evaluating the transfer were performed with radioactive gases 
(133Xenon and 85Krypton). The efficacy of the transfer is similar to that of tritiated water. The 
advantage of using gas was the lack of recirculation since more than 95% of the gas is 
cleared during the first passage.  
Even a limited transfer of steroids may have a marked physiological impact. Only non-
protein bound steroids are biologically active. The hormone transferred will reach the 
arterial blood as free hormone and, because the binding takes some time (seconds), the 
steroid may reach the capillaries before it is bound to the plasma proteins (Einer-Jensen, 
1984, 1989). 
4. Steroid transferred from the gonads will reach the epididymis and the 
Fallopian tube 
Like heat energy, substances may be transferred in areas with a close connection between 
lymph vessels, veins and arteries. The gonads are typical examples. The close connection 
between the winding testicular artery and the Pampiniform plexus is well known. It is 
not, however common knowledge that the blood supply to the first part of the epididymis 
also originates from the testicular artery. Thus, the epididymis is involved in the local 
transfer system and transfer of steroids will act to stimulate the epididymis more than 
indicated by the content of testosterone in peripheral blood. An intramuscular injection of 
testosterone may produce a high peripheral concentration of the hormone and produce a 
strong negative feedback on the pituitary gland. However, it will not produce the 
concentration difference between the blood in the testicular artery and any other arterial 
sample. 
The Concentration of Steroid Hormones 
in Blood and Peritoneal Fluid Depends on the Site of Sampling 7 
In the female, the arterial supply to the Fallopian tube and the proximal part of the uterus 
originates from the ovarian artery. Any hormone in or transferred to the ovarian artery will 
also reach the tube and part of uterus (Stefańczyk-Krzymowska et al., 1998; Einer-Jensen et 
al., 2002; Cicinelli et al., 2004a). The ovarian production of individual steroids is cyclic and 
the amount of hormone transferred will therefore fluctuate (Cicinelli et al., 2004c). The 
increased production of oestradiol shortly before ovulation and of progesterone in the days 
after ovulation may be especially important, since transfer to the blood supply of the 
Fallopian tube and proximal part of uterus will influence tissue function. The transfer has 
been documented in both experimental animals and in man. The border between the blood 
supply from the uterine and tubal arteries shifts during the ovulatory cycle in man, 
probably due to the local vasodilatory effect of oestrogens in the tubal artery (Cicinelli et al., 
2004b; Cicinelli et al., 2005). 
Cooling of the vagina induces a temperature fall in the vesica and corpus of uterus but not 
the tubal part, probably through a counter-current transfer mechanism (Einer-Jensen et al., 
2001a). Application of steroids in the vagina will induce a semi-selective effect in the vesica 
and uterus (Cicinelli et al., 2001). Cycle dependent variations in transfer of 133Xenon from 
vagina to uterus was found in rats (Zhao and Einer-Jensen, 1998). 
5. Other organs may also have a local transfer mechanism 
An important steroid producing gland, the adrenal, does not have the external artery-veins 
complex needed for a counter-current transfer. It is, however, known that glycogenic steroids 
potentiate the production of adrenalin. It is tempting to think that a local exchange mechanism 
exists within the adrenal gland. There is some anatomical evidence, but the hypothesis has not 
been documented sufficiently to exclude doubt (Einer-Jensen and Carter, 1995). 
Local counter-current transfer between the brain blood vessels has been found in 
experimental animals (Krzymowski, 1992; Einer-Jensen and Larsen, 2000a and b; Einer-
Jensen et al., 2001b; Einer-Jensen et al., 2002). The brain is (probably) not a steroid producing 
organ, but some neurons have steroid receptors. Nonetheless, the effect on the brain may be 
semi-selective when treated with nasal application of steroids as based on the following 
knowledge. When animals exercise intensively, the body temperature tends to increase. The 
brain is the first body organ to be damaged after a rather small increase of 3-5o Centigrade. 
Nature has developed a brain cooling mechanism. Large airflows through the nose will cool 
the nasal mucous membrane and the capillary blood. The venous blood will leave the head 
either through a superficial or a deep vein before reaching the jugular vein, the route being 
decided by an autoregulated mechanism. The higher the temperature, the more blood will 
reach the deeper vein. This vein is at one point in close connection with the carotid. In some 
animals, an arterial plexus (Rete Mirabile) is formed by the carotid creating a very effective 
transfer system which decreases the temperature of the carotid blood and therefore of the 
brain. Transfer of steroid hormones has been found in experiments involving nasal 
application in isolated, perfused heads from pigs (Skipor et al., 2003). The transfer 
mechanism may also be present in man.  
6. The importance of high progesterone concentrations in peritoneal fluid 
The peritoneal cavity, its lining membrane and fluids are active participants in local 
regulation of the reproductive processes. In women, peritoneal fluid was collected during 
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abdominal surgery by means of cotton swaps in nine women all with an active corpus 
luteum. Several samples were collected during the same operation (over the active corpus 
luteum, over the opposite ovary, at the right left and right paracolic gutter and at the pouch 
of Douglas). Progesterone concentrations close to the corpus luteum were 4 times (range 1.4 
– 9.2) higher than in the other peritoneal samples and, on average, 5 times higher than in the 
systemic blood (Cicinelli et al., 2009). Progesterone would be expected to enter the 
peritoneal cavity locally (close to the corpus luteum). The authors know of no similar 
investigations in farm or experimental animals. One may speculate on the physiological 
importance:  
Nonetheless, female genital tissues and their mesenteries are bathed in fluid with an 
elevated concentration of steroid hormones and, in many species, peritoneal fluid also 
enters the Fallopian tube ostium around the time of ovulation. This is principally due to the 
ab-ovarian beat of the cilia on the inner surface of the fimbriated infundibulum. In addition, 
evidence from pigs indicates that vital dyes irrigated onto the mesometrium and 
mesosalpinx enter the lymphatic vessels bordering the genital tract of oestrous animals 
(Hunter, 2011). There is little doubt that steroid hormones would do likewise, eventually 
influencing the activity of the endosalpinx and its secretions at a time when gametes and/or 
embryos could be present in the lumen. 
The contralateral ovary is bathed in the high progesterone-containing fluid, which may 
influence follicular development. Other steroids such as oestrogens may behave 
comparably. Although alternating ovulation between the two ovaries is far from obligatory, 
signal transfer via the peritoneal fluid may have an influence on such a phenomenon 
(Hunter et al., 2007). 
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1. Introduction 
Androgenic-anabolic steroid hormones (AAS) are synthetic derivatives of the male hormone 
testosterone and for many years have been popular among athletes both for performance 
enhancement, due to physiological and psychological effects, and for aesthetic reasons 
(Evans 2004; Hartgens & Kuipers 2004). The anabolic action of AAS is particularly 
interesting since its affects protein metabolism by stimulation of protein synthesis and 
inhibition of protein breakdown, which could induce muscle growth and enhance 
adaptation to resistance training (Yesalis & Bahrke 1995; Brown et al. 2006). Since the AAS 
use in sport is banned, different nutritional strategies have been developed in the past 
decades to circumvent this problem and administer other exogenous testosterone analogues 
(King et al. 1999).  
In the past 2o years, different steroid prohormones or prosteroids (e.g. androstenedion, 
dehydroepiandrosterone, androstenediol, 19-nor androstenediol, 19-nor androstenedione, 1-
testosterone) have been developed and aggressively marketed in athletic environment as 
legal nutritional supplements that are expected to convert to active anabolic steroid 
hormones in the body and enhance exercise performance (Brown et al. 1999; Brown et al. 
2000; Earnest et al. 2000; Leder et al. 2000; Brown et al. 2001; Kanayama et al. 2001). The 
efficacy and safety of these prohormones are not well established but are highly promoted 
to have the same androgenic effects on building muscle mass and strength as AAS (Baulieu 
et al. 2000; Brown et al. 2006). A typical steroid prohormone is intended to be a precursor to 
both testosterone and estrogens, through different biochemical pathways (Figure 1), 
typically resulting in the action of dehydrogenases in skeletal muscle, adipose tissue, skin, 
prostate and adrenal gland (Griffin 2004).  
Dehydroepiandrosterone (3β-hydrohy-5-androsten-17-one; DHEA) seems to be the master 
steroid prohormone due its precursor function and its conversion to other hormones (Brown 
et al. 2006). Although the mechanism of action of DHEA or other prosteroids is not 
completely understood, it could be hypothesized that DHEA could increase testosterone 
production (at least as an acute response) if supplemented in diet, and due to its anabolic 
action may affects nitrogen balance and protein synthesis (Morales et al. 1998).  
Testosterone is synthesized through either the Δ-4 or Δ-5 pathway (Broeder 2003) with the 
effects of newly synthesized testosterone in humans occur by way of 2 main mechanisms: by 
activation of the androgen receptor (directly or as 5α-dihydrotestosterone), and by 
conversion to estradiol and activation of estrogen receptors (Wilson 1988). Free testosterone 
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Fig. 1. Androgens biosynthesis from cholesterol to testosterone/dihydrotestosterone and 
estrogens (estrone and estradiol) via prohormone precursors (e.g. DHEA, androstenedione, 
androstenediol). Abb. DHEA – dehydroepiandrosterone. 
is transported into the cytoplasm of target tissue cells, where it can bind to the androgen 
receptor, or can be reduced to 5α-dihydrotestosterone (DHT) by the cytoplasmic enzyme 5-
alpha reductase (Hartgens & Kuipers 2004). DHT binds to the same androgen receptor even 
more strongly than testosterone, so that its androgenic potency is about 5 times that of 
testosterone (Breiner et al. 1986). The testosterone-receptor or DHT-receptor complex 
undergoes a structural change that allows it to move into the cell nucleus and bind directly 
to specific nucleotide sequences of the chromosomal desoxiribonucleic acid. The areas of 
binding are called hormone response elements, and influence transcriptional activity of 
certain genes, producing the anabolic effects (Saartok et al. 1984). Theoretically, the fewer 
interconversion steps a prohormone must complete in the syntheisis pathway to 
testosterone, the greater potential for enhancing active hormone production (Broeder 2003); 
for example, androstenedione converts to testosterone more rapidly than DHEA.  
Existing data suggest that acute oral ingestion of DHEA, androstenediol or androstenedione 
modestly and transiently increase serum testosterone concentration; however, this is 
accompanied by greater increase in other steroids as well (i.e. estrogens, luteinizing 
hormone) (Ziegenfuss et al. 2002). Yet, it is questionable if this acute elevation in 
testosterone concentration induced by prosteroids necessarily result in enhanced 
transcriptional activity (Broeder 2003). Furthermore, research has shown that prosteroids 
may have significant biological activity by itself (Ostojic et al. 2009, Ostojic et al. 2010), 
affecting resting metabolic rate through futile cycling (Tagliaferro et al. 1986), increasing the 
flux of fatty acids through β-oxidation (Mohan et al. 1988), and alter the level of serotonin 
and dopamine (Cleary 1991; Ebeling et al. 1994; Kroboth 1999). Yet, the mechanism of action 
of prosteroids may differ between compounds because of variations in the steroid molecules 
(Hartgens & Kuipers 2004). These differences could be responsible for differences in the 
specificity of binding to receptor proteins or to interactions with various steroid-
metabolizing enzymes (Wilson 1988; Creutzberg & Schols 1998) with future research needed 
to clarify the explaining physiological effects due to prosteroids use in humans. 
 
Steroid Prohormones: Effects on Body Composition in Athletes 
 
13 
2. History of steroid prohormones use in sport and exercise 
Although the first documented reports of misuse of AAS by athletes stem from the 1950s 
(Yesalis 1999), the use of prosteroids in the athletic environment is rather new. Prosteroids 
were indirectly introduced with US Anabolic Steroid Control Act of 1990 (21 USCS Section 
802), which defined anabolic steroids as “…any drug or hormonal substance that promotes 
muscle growth in a manner physiologically similar to testosterone…”, while steroid prohormones 
were not classified as anabolic steroids and could be purchased legally as dietary 
supplements (Broeder 2003; Brown et al. 2006). This document didn’t appear to make a 
significant decrease in the use of anabolic steroids (Brainum 2008), but concern about the 
side effects linked to steroid use did lead to the development of another popular anabolic 
offering: prohormone nutritional supplements (Brown et al. 2003).  
In December of 1996, androstenedione became available for over-the-counter sales in United 
States (Ziegenfuss et al. 2002), with subsequent availability of several other prohormones 
(e.g. androstenediol, DHEA, norandrostenedione). The non-critical promotion era of 
prosteroids in sport began with the disclosure of androstenedione use by Mark McGwire in 
1998, who at the time was elite baseball player, which stimulated extensive media attention 
and dramatically increased the sales of prohormones among recreative and professional 
athletes (Brown et al. 2003, Brown et al. 2006).  
In the past decades, prohormones have been highly marketed in the field of sport as lean 
body mass builders, fat reduction agents, and anticatabolic compounds. Recently, concerns 
over the safety of the prohormones use induced changes in US Anabolic Steroid Control Act 
in 2004 (21 USCS Section 802, amended), redefining anabolic steroids and classify 
prohormones as controlled substances. While the 2004 amendment specifically mentioned 
most of the current prohormones by name, that didn’t stop some companies from marketing 
at least one anabolic steroid that the lawmakers had overlooked (Brainum 2008).  
At the moment, it seems that legal status of prohormones is different throughout the world. 
In USA, Canada or Australia prosteroids are recognized as controlled substances and it is 
illegal to own or sell the product without prescription. On the other hand, no prescription is 
required for prosteroids purchase in several European countries, Russia or Japan, with 
products recognized as over-the-counter dietary supplements.   
3. Epidemiology of steroids use among athletes: scope of the problem 
Anabolic steroid usage has been recognized as a serious health and ethical problem among 
athletes for several decades (Foster & Housner 2004). Numerous examples of steroid usage 
rules violations have been highly publicized and have lead to the suspension and stripping 
of medals from international athletes, as well as many professional athletes (International 
Olympic Committee 1997; Wroble et al. 2002). Elite athletes are not the only population of 
individuals that use steroids. Recreational athletes also use steroids to enhance performance 
and to improve personal appearance (Wroble et al. 2002). Furthermore, evidence indicates 
that steroid usage often starts during high school (Yesalis et al, 1989; Kerr and Congeni 
2007). Use of anabolic steroids is widespread in the athletic environment, particularly in 
power events and disciplines (e.g. football, track and field, body building, power lifting) 
(Foster & Housner 2004).  
It seems that athletes have used AAS for more than 50 years, with first anecdotal evidence of 
use of animal testicular extracts even in 1890s (Yesalis 1999). Despite educational and 
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preventive measures, steroid use increases (Windsor & Dumitru 1988). The prevalence of 
AAS abuse has been reported in several populations. The highest estimates have come from 
male bodybuilders with even more than 50% regularly using steroids (Tricker et al. 1989; 
Lindstrom et al. 1990). Lower rates have been reported among intercollegiate athletes, 
ranging from 15% to 20% (Dezelsky et al. 1985). Rates of steroids use vary greatly across 
individual sports and are used in higher frequency and higher doses by strength athletes 
(Sturmi & Diorio 1998). By contrast, only 1% of their nonathletic university student 
counterparts reported steroids use (Dezelsky et al. 1985). Perhaps the most surprising and 
alarming finding is the rather high rate of steroids abuse among high school students 
(Mulcahey et al. 2010). The typical rate reported in male students is between 5% and 6%, but 
rates as high as 11% have been reported (Johnson et al 1989). The most recent estimate 
reported a range of 5% to 15% for steroids use among high school boys. In female high 
school students, steroids abuse rates tend to be lower, but quite worrisome at 1% to 3% 
(Harmer 2010). Wroble and co-workers (2002) indicated that less than one percent (0.7%) of 
youth sports participants reported current or previous usage of anabolic steroids; the rate of 
usage was higher in males than females. Three percent of athletes had been offered steroids 
at some time with 22% of them admitted to using steroids. Of the reported anabolic steroid 
users, 27% admitted they used anabolic steroids for athletic performance; 18% used to 
improve personal appearance; 18% used for bodybuilding; and 18% took due to peer 
pressure. Twelve percent of all athletes said that they personally know someone who was 
using or had used steroids.  
Although several prohormones are considered as AAS, and are banned by many sports 
governing bodies, including the International Olympic Committee (IOC), they are semi-legal 
substances available from many retail outlets, including internet health food stores. The 
overall prevalence of prohormones use is not known, although several reports indicated that 
prohormones are among the most popular dietary supplements especially in adolescent 
athletes (Smurawa & Congeni 2007). Even though usage has decreased by over 50% since 
1989, steroid use in sport is still a serious problem. Insufficient knowledge and 
inappropriate attitudes regarding the benefits and risks of using anabolic steroids is also a 
major concern (Schwingel et al. 2011). 
4. Testosterone production and musculotrophic effects of prosteroids 
The most prevalent reason for athletes initiating AAS or prosteroids use is to promote 
muscle mass and strength (Yen et al. 1995). From long list of previous studies (for review see 
Hartgens & Kuipers 2004) it could be concluded that steroids administration may increase 
muscle mass. Exogenous testosterone administration (> 125 mg/week), with and without 
strength training program, may lead to increments of muscle volume and/or muscle fibre 
size. Yet, lower doses of testosterone (e.g. 25, 50 or 100 mg/week) had no effect on muscle 
fibre cross-sectional area. It seems that musculotrophic effect of steroids is dose-dependent. 
Therefore, the effects of prosteroids on muscle size and/or strength is highly influenced by 
its potential to increase serum testosterone after administration.  
Existing data on testosterone-boosting effects of prosteroids are equivocal; it seems that age 
and basal serum testosterone concentration may influence the response to prosteroids intake 
(Brown et al. 2000). Several studies reported that serum sex steroid levels in both mature 
and young men were not significantly affected by prohormone supplementation, with only 
a minimal amount converted to testosterone and more to estrogen (Vogiatzi et al. 1996; 
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Morales et al. 1998; Kroboth et al. 1999; Yamada et al. 2007). No changes in levels of 
testosterone and estradiol were observed for men after supplementation with 50 mg of 
DHEA for 3, 6 and 12 months (Von Muhlen et al. 2008). In 19 young men (23 ± 1 yr old) 
participating in an 8-week resistance training, ingestion of 150 mg/day of DHEA did not 
affect serum testosterone and estrogen concentrations (Bowers 1999). On the other hand, 
ingesting 100 mg of androstenedione t.i.d. for 28 days increases serum-free testosterone 
concentration by 40% (Brown et al. 2000; Brown et al. 2001), while 200 mg of 
androstenediione increases testosterone area under the curve by approximately 15% during 
the 90 min post-administration (Earnest et al. 2000). In recent study (Ostojic et al. 2010) 
intake of DHEA resulted in significant increase of total testosterone in treated subjects after 
28-days of supplementation. Accordingly, Wolf et al. (1997) reported 1.3-fold increase in 
testosterone levels after supplementation with 50 mg oral DHEA for 2 weeks in 25 men. 
Furthermore, serum estradiol levels were significantly elevated, indicating that a significant 
portion of the ingested prosteroids underwent aromatization. It seems that both the 
magnitude of the dose administered and the route of administration affect the extent of 
change in concentrations of sex hormones (Ziegenfuss et al. 2002). Furthermore, several 
studies confirm the importance of extraadrenal and extragonadal 3ß-hydroxysterodi 
dehydrogenase activity in the synthesis of androgens and estrogens after prohormones 
administration (Nestler et al. 1991; Kroboth et al. 1999).  
Not all subjects respond to prohormones in same fashion, suggesting that additional factors 
(i.e. age, gender, diet, type and intensity of exercise) influence these responses. For example, 
research demonstrates that prohormone supplementation may acutely increase testosterone 
levels in women, thus producing a virilizing effect (Bahrke & Yesalis 2004). Furthermore, 
exercise could result in increased DHEA and DHEA-S concentrations (Bernton et al. 1995) 
and these elevated levels in athletes could influence response to supplementation, which 
requires further investigation. The recent study (Ostojic et al. 2010) reported an increase of 
total testosterone and estradiol while free testosterone is normal. These data can be 
consistent with an increase of sex hormone binding globulin (SHBG) by prosteroids 
administration (Nestler et al. 1991). Total testosterone was increased to keep normal free 
testosterone or in alternative free testosterone was normal due to an increase activation of 5-
alpha reductase. Measuring SHBG luteinizing and folicle-stimulating hormone in future 
studies should prove these hypotheses. However, it is important to point out that simply 
producing an acute elevation in a particular hormone concentration (i.e. testosterone) does 
not necessarily result in increases in muscle mass or lean body mass. Prosteroids do not 
appear to have functional benefits when taken in daily concentrations up to 300 mg per day 
in young, middle-aged or older men (Wallace et akl. 1999; Ballantyne et al. 2000; Broeder 
2003). Although oral DHEA intake enhanced testosterone production for 30%, Ostojic and 
co-workers (2010) did not found changes in total muscle mass or regional muscularity.  
It seems that effect of prosteroids on serum hormones was not mediated by an effect on 
body composition. Increasing DHEA or other prohormones levels may not provide the 
optimal anabolic environment desired in spite of elevated total testosterone level, due to 
several possible mechanisms (i.e. genetic polymorphism of the androgen receptor, potential 
hormonal interconversions at the paracrine level) (Nestler et al. 1991). Whether the increase 
of testosterone after intake of prohormones translates into a meaningful change in body 
composition or rates of muscle protein synthesis is debatable. Studies must be evaluated in 
terms of the relative potency of various testosterone enhancers with varying effects on 
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different tissues according to receptor-binding properties of the compound and its 
metabolites (Ebeling & Koivisto 1994). The relative potency of prosteroids seems to be small 
with inconsiderable advantageous anabolic properties. Several authors hypothesized that an 
important part of the musculotrophic effect of prosteroids may not be directly mediated 
through androgen receptors but instead involves interference with catabolic effects 
produced by glucocorticoid hormones binding to their specific receptors (Bernton et al. 1995; 
Morales et al. 1998). With an incomplete understanding of how prohormones exert their 
effects on skeletal muscle, further studies should analyze nitrogen balance indicators as 
noninvasive approximate index of muscle protein status.  
5. Fat mass alteration and steroid prohormones intake   
In the field of sports and exercise nutrition, prosteroids (DHEA in particular) are often 
promoted as fat-burning agent that could enhance body physique and estetize appearance 
(Kroboth et al. 1999). However, clear evidence supporting the use of prosteroids in athletic 
environment remains less clear. It is well known that age-related decreases in DHEA are 
associated with increases in obesity and a decline in fat free mass (Morales et al. 1998) yet 
the potential usefulness of DHEA as a slimming agent is mostly indicated by previous 
research in animals, particularly lower mammals (Cleary 1991). In the rat plasma 
concentration of DHEA ranges between 14 and 80 nM while in the plasma of humans 
DHEA-concentration ranges between 5 and 24 nM and DHEAS-concentration is up to 9 μM 
(Svec & Porter 1998).  The anti-obesity effect of DHEA in animals could be due to several 
possible mechanisms (Cleary 1991; Ebeling & Koivisto 1994; Kroboth et al. 1999). However, 
studies that have investigated the effects of oral prosteroids supplementation on body 
composition in humans produced equivocal results, particularly in young men.  
Nestler et al. (1988) reported that 28-day supplementation with DHEA (1600 mg/day) 
reduced body fat by 31% with no change in body mass in five normal men. Serum total 
testosterone, free testosterone, sex hormone-binding globulin, estradiol, and estrone levels 
did not change while serum DHEA-S and androstenedione rose 2.0- to 3.5-fold in DHEA 
group. Morales et al. (1998) founded that 100 mg of DHEA for 6 months induced decrease in 
body fat mass (6.1 ± 2.6%) in healthy non-obese men. On the other side, several investigators 
showed that body composition was not affected by prosteroids treatment in young and 
adult men, both obese and non-obese (Usiskin et al. 1990; Welle et al. 1990; Wallace et al. 
1999). Vogiatzi et al. (1996) suggested that DHEA 40 mg administered sublingually twice 
daily for 8 weeks has no positive effects on body composition in obese young adults. In 
recent DAWN trial (Von Muhlen et al. 2008) no beneficial effects of 50 mg daily oral DHEA 
supplementation on body composition were found in 110 healthy mature men. In 
accordance with above research, the recent study (Ostojic et al. 2010) failed to show any 
beneficial effects of oral DHEA administration on body mass and body composition in non-
obese young athletes. Authors did not found significant reduction in body fat of young 
soccer players after DHEA supplementation. Other indicators of body fatness (i.e. body 
mass index, waist-to-hip ratio) remained unchanged during the study in both DHEA and 
placebo group, indicating that treatment with DHEA does not result in significant changes 
to justify its use as an antiobesity or slimming agent. As in the case of cognition, negative 
results in healthy volunteers can be attributed either to a true lack of DHEA effect or to body 
composition too close to ideal at the study start to detect changes in the small numbers of 
subjects studied.  
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Although most studies found no beneficial effects of prosteroids supplementation on body 
composition in athletes, several investigators underlined possible beneficial effects of 
prosteroids supplementation for elderly. Hernandez-Morante et al. (2008) demonstrated for 
the first time in vitro that DHEA-S stimulates lipolysis in 85 obese patients, preferably in 
subcutaneous fat in women and in visceral fat in men. A study by Ho et al. (2008) suggested 
that low DHEA-S is associated with increased waist-to-hip ratio and reduced insulin 
sensitivity with aging while Hsu et al. (2008) had reported that body composition and 
insulin sensitivity can change with aging in early lifetime. Benefits of prosteroids 
supplementation in this regard for early middle-aged people requires more clinical 
investigation.  
Although the body composition changes induced by steroids or prosteroids administration 
are rather small, after the drug withdrawal the alterations of body composition fade away in 
slow manner, but may be presented in part for period up to 3 months (Kuipers et al. 1991; 
Hartgens et al. 2001; Brown et al. 2006). Yet, the final net results of short-term steroids or 
prosteroids administration on body composition seems to be minute (Hartgens & Kuipers 
2004). This is particularly true for all athletes who are not capable of maintaining the 
nutritional intake and training workload of the level required for significant body 
composition changes (Hartgens et al. 1996). It may be important that steroid cessation is 
followed by a period of hypogonadism, while testicular function gradually returns to 
normal, over a period of weeks or several months (Hartgens & Kuipers 2004). Although this 
has not been specifically studied, reduced circulating androgen during this period may help 
to accelerate the loss of any anabolic steroid-induced gains. How much of the gain can be 
sustained by physical training following drug cessation remains to be studied (Yesalis & 
Bahrke 2000). 
6. Known and potential health risks of prosteroids administration 
During the past 20 years, researches suggested that potential risk factors associated with 
prosteroids use were similar to those observed with anabolic steroids (Broeder 2002). The 
altered hormonal milieu caused by prohormone intake is similar to the hormonal milieu 
observed in men with gynecomastia, prostate cancer, testicular cancer and pancreatic cancer 
(Fyssas et al. 1997; Chang et al. 2005). Yet, no documented cases exist of these endocrine-
related diseases caused by prohormone supplementation (Brown et al. 2006). Furthermore, it 
seems that athletes who regularly use prosteroids experienced several side effects (e.g. 
fatigue, headache, nasal congestion, acne, increased aggressiveness, increased blood 
pressure, masculinization in women, gynecomastia and testicular wasting in men) (Broeder 
et al. 2000). Although prohormones induces small decreases in high-density lipoprotein 
cholesterol (HDL-C), long-term implications of transient negative changes in blood lipids 
(e.g. 3-6 mg/dL reductions in HDL-C) have yet to be elucidated as the risk of sustaining a 
cardiac event (Ziegenfuss et al. 2002).  
Regarding unfavourable body composition changes, it has been noted that prohormones 
could lead to changes in hydration of the fat free mass (via sodium and water retention), 
which could be interpreted as hyperhydration effect (Casaburi et al. 1996). Whether more 
prolonged (> 8-12 weeks) prohormones supplementation is safe or useful remains uncertain, 
but appears unlikely (Ziegenfuss et al. 2002). Although some health risks have been noted, 
thus far none of the prohormones tested appear to be overly toxic as no elevations in 
clinically relevant tissue enzymes (e.g. alanine aminotransferase, creatine kinase, aspartate 
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sensitivity with aging while Hsu et al. (2008) had reported that body composition and 
insulin sensitivity can change with aging in early lifetime. Benefits of prosteroids 
supplementation in this regard for early middle-aged people requires more clinical 
investigation.  
Although the body composition changes induced by steroids or prosteroids administration 
are rather small, after the drug withdrawal the alterations of body composition fade away in 
slow manner, but may be presented in part for period up to 3 months (Kuipers et al. 1991; 
Hartgens et al. 2001; Brown et al. 2006). Yet, the final net results of short-term steroids or 
prosteroids administration on body composition seems to be minute (Hartgens & Kuipers 
2004). This is particularly true for all athletes who are not capable of maintaining the 
nutritional intake and training workload of the level required for significant body 
composition changes (Hartgens et al. 1996). It may be important that steroid cessation is 
followed by a period of hypogonadism, while testicular function gradually returns to 
normal, over a period of weeks or several months (Hartgens & Kuipers 2004). Although this 
has not been specifically studied, reduced circulating androgen during this period may help 
to accelerate the loss of any anabolic steroid-induced gains. How much of the gain can be 
sustained by physical training following drug cessation remains to be studied (Yesalis & 
Bahrke 2000). 
6. Known and potential health risks of prosteroids administration 
During the past 20 years, researches suggested that potential risk factors associated with 
prosteroids use were similar to those observed with anabolic steroids (Broeder 2002). The 
altered hormonal milieu caused by prohormone intake is similar to the hormonal milieu 
observed in men with gynecomastia, prostate cancer, testicular cancer and pancreatic cancer 
(Fyssas et al. 1997; Chang et al. 2005). Yet, no documented cases exist of these endocrine-
related diseases caused by prohormone supplementation (Brown et al. 2006). Furthermore, it 
seems that athletes who regularly use prosteroids experienced several side effects (e.g. 
fatigue, headache, nasal congestion, acne, increased aggressiveness, increased blood 
pressure, masculinization in women, gynecomastia and testicular wasting in men) (Broeder 
et al. 2000). Although prohormones induces small decreases in high-density lipoprotein 
cholesterol (HDL-C), long-term implications of transient negative changes in blood lipids 
(e.g. 3-6 mg/dL reductions in HDL-C) have yet to be elucidated as the risk of sustaining a 
cardiac event (Ziegenfuss et al. 2002).  
Regarding unfavourable body composition changes, it has been noted that prohormones 
could lead to changes in hydration of the fat free mass (via sodium and water retention), 
which could be interpreted as hyperhydration effect (Casaburi et al. 1996). Whether more 
prolonged (> 8-12 weeks) prohormones supplementation is safe or useful remains uncertain, 
but appears unlikely (Ziegenfuss et al. 2002). Although some health risks have been noted, 
thus far none of the prohormones tested appear to be overly toxic as no elevations in 
clinically relevant tissue enzymes (e.g. alanine aminotransferase, creatine kinase, aspartate 
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aminotransferase, gamma-glutamyltransferase, lactate dehydrogenase) have been observed 
(Brown et al. 2000; Ziegenfuss et al. 2002). However, due to the lack of efficacy of oral 
prosteroids supplementation in athletes, its theoretical risks seem to fat outweight any 
potential benefits on body composition and should be discouraged (Earnest 2001).  
7. Summary 
In the past 2o years, different steroid prohormones or prosteroids have been aggressively 
marketed in athletic environment as legal nutritional supplements that are expected to 
convert to active anabolic steroid hormones in the body and enhance exercise performance. 
Although the mechanism of action of prosteroids is not completely understood it has been 
promoted that prosteroids increases testosterone production if supplemented in diet and 
due to its anabolic action may affects nitrogen balance and protein synthesis. Although 
popular among athletes, studies have demonstrated repeatedly that acute and long-term 
administration of these oral testosterone precursors does not effectively increase serum 
testosterone levels and fails to produce any significant changes in lean body mass, muscle 
strength, or performance improvement compared with placebo. It seems that increasing 
prohormone levels in athletes may not provide the optimal anabolic environment desired in 
spite of elevated total testosterone level (at least acutely), due to several possible 
mechanisms (i.e. genetic polymorphism of the androgen receptor, potential hormonal 
interconversions at the paracrine level). The relative potency of prosteroids seems to be 
small with inconsiderable advantageous anabolic properties. Furthermore, recent studies 
indicates that treatment with prosteroids does not result in significant changes to justify its 
use as an antiobesity or slimming agent. Not all subjects respond to prohormones in same 
fashion, suggesting that additional factors (i.e. gender, diet, type and intensity of exercise) 
influence these responses. Although some health risks have been noted, thus far none of the 
prohormones tested appear to be overly toxic. Yet, due to the lack of efficacy of oral 
prosteroids supplementation in athletes, its theoretical risks seem to far outweight any 
potential benefits on body composition and should be discouraged. Although the 
understanding of testosterone precursors as performance-enhancing drugs continues to 
advance, there are likely to be more revelations as scientific investigations continue. 
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11β-Hydroxysteroid Dehydrogenase 
Type 1 and the Metabolic Syndrome 
Cidália D. Pereira, Maria J. Martins, Isabel Azevedo and Rosário Monteiro 
Dept. of Biochemistry (U38/FCT), Faculty of Medicine, University of Porto, 
Portugal 
1. Introduction 
In the past few years, efforts are being made to unravel the mechanisms endowed with the 
metabolic disturbances associated with obesity that predispose to the metabolic syndrome 
(MetSyn). The special pathogenic role of liver and visceral adipose tissue (VAT) functions 
has been particularly intriguing, and many hypotheses have been advanced to explain this 
association. Tissue-specific actions of glucocorticoids (GCs) go far beyond the circulating 
levels of the hormones and can be controlled by local intracellular enzymes. In the past few 
years, evidence is being gathered not only on the relevance of such enzymes to GC 
physiological actions but also on their involvement in the pathophysiology of certain 
chronic disease states, in which circulating GC levels are not necessarily altered. These 
enzymes are 11β-hydroxysteroid dehydrogenases (11β-HSDs, EC 1.1.1.146) which 
interconvert inactive GCs, such as cortisone and dehydrocorticosterone, and the active 
hormones, cortisol and corticosterone.  
2. Brief overview of the hypothalamus-pituitary-adrenal (HPA) axis 
The regulation of tissue GC levels is critical for the maintenance of homeostasis, playing a 
central role in essential physiological processes, such as stress responses, energy 
metabolism, electrolyte levels, blood pressure, immunity, cell proliferation and 
differentiation and cognitive functions (Atanasov & Odermatt, 2007). Cortisol release by the 
adrenal gland is under the control of the HPA axis. Briefly, corticotrophin releasing 
hormone (CRH) is produced by parvicellular hypothalamic neurons and acts on anterior 
pituitary cells increasing the production and release of adenocorticotrophic hormone 
(ACTH) into the blood stream in a pulsatile fashion and with circadian rhythm: peak in the 
morning and valley later in the afternoon (Gathercole & Stewart, 2010; White B., 2008b). 
Cortisol is synthesized in the cells of the zona fasciculata of the adrenal cortex. Under the 
influence of ACTH, cholesterol esters, stored in the foamy cytoplasm of these cells, are 
unsterified by cholesterol ester hydrolase and converted to cortisol (Tomlinson et al., 2004; 
White B., 2008a). GCs are able to bind and activate GC receptors (GR) and mineralocorticoid 
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rodents, corticosterone, are active steroids whereas cortisone and 11-dehydrocorticosterone, 
the latter in rodents, are inactive (Tomlinson et al., 2004). Cortisol is metabolized in the liver 
 
Steroids – Clinical Aspect 
 
24
Ziegenfuss, T.N., Berardi, J.M., Lowery, L.M & Antonio, J. (2002). Effects of Prohormone 
Supplementation in Humans: A Review. Canadian Journal of Applied Physiology, 
Vol.27, No.6, (December 2002), pp. 628-645, ISSN 1066-7814. 
3 
11β-Hydroxysteroid Dehydrogenase 
Type 1 and the Metabolic Syndrome 
Cidália D. Pereira, Maria J. Martins, Isabel Azevedo and Rosário Monteiro 
Dept. of Biochemistry (U38/FCT), Faculty of Medicine, University of Porto, 
Portugal 
1. Introduction 
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influence of ACTH, cholesterol esters, stored in the foamy cytoplasm of these cells, are 
unsterified by cholesterol ester hydrolase and converted to cortisol (Tomlinson et al., 2004; 
White B., 2008a). GCs are able to bind and activate GC receptors (GR) and mineralocorticoid 
receptors (MR), which are ligand-regulated nuclear receptors and members of the steroid 
hormone receptor family (Gathercole & Stewart, 2010). Cortisol and the principal GC in 
rodents, corticosterone, are active steroids whereas cortisone and 11-dehydrocorticosterone, 
the latter in rodents, are inactive (Tomlinson et al., 2004). Cortisol is metabolized in the liver 
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through conjugation with glucuronide and sulfate for posterior renal excretion (Tomlinson 
et al., 2004; White B., 2008a). Moreover, in the liver, 5α- and 5β-reductases inactivate cortisol 
and cortisone, in conjunction with 3α-HSD, to tetrahydrometabolites: 5α-tetrahydrocortisol 
(5α-THF), 5β-tetrahydrocortisol (5β-THF) and tetrahydrocortisone (THE) (Campino et al., 
2010).     
3. 11β-HSDs – enzymology, tissue expression and physiological role 
3.1 11β-HSD type 2 (11β-HSD2) 
Because cortisol and aldosterone have the same in vitro affinity for the MR (Gathercole & 
Stewart, 2010), 11β-HSD2, that catalyzes the inactivation of cortisol to inert cortisone, in 
humans, or of corticosterone to 11-dehydrocorticosterone, in rodents, avoids MR actions of 
GCs. 11β-HSD2 was the first isoform to be identified and is a NAD+ dependent 
dehydrogenase. 11β-HSD2 is present in high amounts in the distal convoluted tubule of the 
kidney, colon, salivary and sweat glands as well as in other locations such as the human 
placenta and vascular wall to avoid deleterious actions of active GC overstimulation 
(Anagnostis et al., 2009; Andrews et al., 2003; Edwards et al., 1988; Ferrari, 2010; Funder et al., 
1988; Gathercole & Stewart, 2010; Palermo et al., 2004). The importance of 11β-HSD2 activity is 
illustrated in the case of congenital deficiency of 11β-HSD2 in humans (Gathercole & Stewart, 
2010; Stewart et al. 1996), transgenic deletion in mice (Kotelevtsev et al., 1999) or by its 
pharmacological inhibition which produces the apparent mineralocorticoid excess (AME) 
syndrome in which the lack of cortisol inactivation in the kidney allows its mineralocorticoid 
action, producing sodium retention, hypertension and hypokalemia, despite normal 
circulating levels of cortisol and an intact HPA axis (Anagnostis et al., 2009; Andrews et al., 
2003; Edwards et al., 1988; Gathercole & Stewart, 2010; Monder et al., 1986; Mune et al., 1995; 
Palermo et al., 2004; Quinkler & Stewart, 2003; Stewart et al., 1996; Walker & Andrew, 2006). 
Thus AME has been considered ‘Cushing’s disease of the kidney’ where there are normal 
circulating levels of cortisol but a tissue-specific excess at the site of MR action (Stewart, 2005).  
3.2 11β-HSD type 1 (11β-HSD1) 
Pre-receptor metabolism of GCs by 11β-HSD1 amplifies intracellular levels of GCs, through 
the reduction of inactive cortisone in humans (11-dehydrocorticosterone in rodents) back 
into active cortisol (corticosterone in rodents) (Anagnostis et al., 2009; Espindola-Antunes & 
Kater, 2007). 11β-HSD1 is mostly expressed in the liver, adipose tissue (AT), bone, lung and 
central nervous system. However, its expression can be present in other tissues including 
pancreas, kidney cortex, adrenal cortex, cardiac myocytes, bone, placenta, uterus, testis, 
oocytes and luteinized glanulosa cells of the ovary, eye, pituitary, fibroblasts and immune, 
skeletal and smooth muscle cells (Anagnostis et al., 2009; Bujalska et al., 1997; Cooper & 
Stewart, 2009; Espindola-Antunes & Kater, 2007; Stewart & Krozowski, 1999; Tomlinson et 
al., 2004; Whorwood et al. 2001). This enzyme is located in the endoplasmic reticulum, 
facing the lumen (Gathercole & Stewart, 2010), where there is a high concentration of 
NADPH owing to the activity of hexose-6-phosphate dehydrogenase (H6PDH), that 
regenerates NADPH from NADP+ (Atanasov et al., 2008; Bujalska et al., 2005; Draper et al., 
2003).  
11β-HSD1 is bidirectional, able to act as both a reductase (activating GCs) and a 
dehydrogenase (inactivating GCs) (Cooper & Stewart, 2009; Tomlinson et al., 2004). 
However, its main function is as a reductase on intact cells such as hepatocytes (Jamieson et 
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al., 1995), myocytes (Whorwood et al., 2001) and adipocytes (Bujalska et al., 2002a; Bujalska 
et al., 2002b), supported by a higher affinity for cortisone than cortisol (Stewart et al., 1994). 
In vitro, when deprived of NADPH regeneration (Seckl & Walker, 2001; Walker & Andrew, 
2006) or in certain physiological or developmental states, it may work as a dehydrogenase. 
For example, in human omental adipose stromal cells, 11β-HSD1 switches from a 
dehydrogenase to a reductase upon differentiation (Bujalska et al., 2002a; Bujalska et al., 
2002b). In the H6PDH null mouse, hepatic or AT, 11β-HSD1 acts mainly as a dehydrogenase 
(Bujalska et al., 2008b; Lavery et al., 2006). Most studies on the regulation of 11β-HSD1 have 
been performed on rodent tissues showing that GCs, CCAAT/enhancer binding proteins, 
peroxisome proliferator-activated receptor (PPAR) agonists and some pro-inflammatory 
cytokines [tumor necrosis factor- (TNF-) and interleukin-1β] increase 11β-HSD1 
expression. On the other hand, growth hormone (via insulin-like growth factor-1) and liver 
X receptor (LXR) agonists inhibit its expression. Some other factors that may influence 11β-
HSD1 expression include sex steroids, insulin and thyroid hormone, but effects vary in 
different tissues and between species (Tomlinson et al., 2004). 
Human 11β-HSD1 congenital deficiency has been described as the apparent cortisone 
reductase deficiency syndrome (Phillipov et al., 1996). The phenotype is related to the lack 
of regeneration of cortisol in peripheral tissues with compensatory activation of the HPA 
axis. This results in increased secretion of androgens by the adrenals, and affected females 
present hirsutism and oligomenorrhea. 11β-HSD1 congenital deficiency does not appear to 
protect against obesity. The syndrome does not seem to arise only from mutations of 
HSD11B1, but rather from the co-inheritance of deleterious mutations in both HSD11B1 and 
H6PDH (Draper et al., 2003), decreasing NADPH supply and switching 11β-HSD1 to the 
dehydrogenase activity (Lavery et al., 2006).  
4. Chronic GC deficiency or excess  
The involvement of GCs in human obesity, particularly visceral obesity, and its related 
metabolic complications, is becoming increasingly evident. As we will discuss further, this is 
evident not only in subjects with disturbances in the HPA axis, but also in conditions where 
tissue GCs are locally modified. To illustrate the first case, two conditions reflect the 
involvement of circulating cortisol on body weight regulation in opposite extremes: Addison's 
disease (hypocortisolism) and Cushing's syndrome (hypercortisolism) (Rutters et al., 2010). As 
to the second case, the clinical entity that aggregates visceral obesity along with several 
metabolic abnormalities in glucose and lipid metabolism as well as in blood pressure, and 
known as the MetSyn (Reaven, 2011), may constitute the best example. Chronically elevated 
GC levels cause obesity, type 2 diabetes mellitus (T2DM), heart disease, mood disorders and 
memory impairments (Wamil & Seckl, 2007). This is demonstrated in Cushing’s syndrome, in 
which elevated GC levels are a result of increased pathological secretion from the adrenal 
cortex (endogenous) or from prolonged anti-inflammatory GC treatment (iatrogenic) (Newell-
Price et al., 2006). A particular case of Cushing’s syndrome is Cushing´s disease that consists of 
hypercortisolism driven by increased ACTH secretion from pituitary adenoma (Cushing, 1932; 
Stewart, 2005). Patients with Cushing’s syndrome are hypertensive, have visceral obesity, 
insulin resistance (IR; 50% develop T2DM or impaired glucose tolerance) and may present 
hepatic steatosis (Stewart, 2005), muscle weakness, dyslipidemia, mood disturbances and 
infertility as well as features more specific to Cushing's syndrome (e.g. easy bruising, facial 
plethora and violaceous striae) (Carroll & Findling, 2010; Newell-Price et al., 2006). 
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2010; Stewart et al. 1996), transgenic deletion in mice (Kotelevtsev et al., 1999) or by its 
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3.2 11β-HSD type 1 (11β-HSD1) 
Pre-receptor metabolism of GCs by 11β-HSD1 amplifies intracellular levels of GCs, through 
the reduction of inactive cortisone in humans (11-dehydrocorticosterone in rodents) back 
into active cortisol (corticosterone in rodents) (Anagnostis et al., 2009; Espindola-Antunes & 
Kater, 2007). 11β-HSD1 is mostly expressed in the liver, adipose tissue (AT), bone, lung and 
central nervous system. However, its expression can be present in other tissues including 
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oocytes and luteinized glanulosa cells of the ovary, eye, pituitary, fibroblasts and immune, 
skeletal and smooth muscle cells (Anagnostis et al., 2009; Bujalska et al., 1997; Cooper & 
Stewart, 2009; Espindola-Antunes & Kater, 2007; Stewart & Krozowski, 1999; Tomlinson et 
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facing the lumen (Gathercole & Stewart, 2010), where there is a high concentration of 
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2006) or in certain physiological or developmental states, it may work as a dehydrogenase. 
For example, in human omental adipose stromal cells, 11β-HSD1 switches from a 
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2002b). In the H6PDH null mouse, hepatic or AT, 11β-HSD1 acts mainly as a dehydrogenase 
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been performed on rodent tissues showing that GCs, CCAAT/enhancer binding proteins, 
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cytokines [tumor necrosis factor- (TNF-) and interleukin-1β] increase 11β-HSD1 
expression. On the other hand, growth hormone (via insulin-like growth factor-1) and liver 
X receptor (LXR) agonists inhibit its expression. Some other factors that may influence 11β-
HSD1 expression include sex steroids, insulin and thyroid hormone, but effects vary in 
different tissues and between species (Tomlinson et al., 2004). 
Human 11β-HSD1 congenital deficiency has been described as the apparent cortisone 
reductase deficiency syndrome (Phillipov et al., 1996). The phenotype is related to the lack 
of regeneration of cortisol in peripheral tissues with compensatory activation of the HPA 
axis. This results in increased secretion of androgens by the adrenals, and affected females 
present hirsutism and oligomenorrhea. 11β-HSD1 congenital deficiency does not appear to 
protect against obesity. The syndrome does not seem to arise only from mutations of 
HSD11B1, but rather from the co-inheritance of deleterious mutations in both HSD11B1 and 
H6PDH (Draper et al., 2003), decreasing NADPH supply and switching 11β-HSD1 to the 
dehydrogenase activity (Lavery et al., 2006).  
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The involvement of GCs in human obesity, particularly visceral obesity, and its related 
metabolic complications, is becoming increasingly evident. As we will discuss further, this is 
evident not only in subjects with disturbances in the HPA axis, but also in conditions where 
tissue GCs are locally modified. To illustrate the first case, two conditions reflect the 
involvement of circulating cortisol on body weight regulation in opposite extremes: Addison's 
disease (hypocortisolism) and Cushing's syndrome (hypercortisolism) (Rutters et al., 2010). As 
to the second case, the clinical entity that aggregates visceral obesity along with several 
metabolic abnormalities in glucose and lipid metabolism as well as in blood pressure, and 
known as the MetSyn (Reaven, 2011), may constitute the best example. Chronically elevated 
GC levels cause obesity, type 2 diabetes mellitus (T2DM), heart disease, mood disorders and 
memory impairments (Wamil & Seckl, 2007). This is demonstrated in Cushing’s syndrome, in 
which elevated GC levels are a result of increased pathological secretion from the adrenal 
cortex (endogenous) or from prolonged anti-inflammatory GC treatment (iatrogenic) (Newell-
Price et al., 2006). A particular case of Cushing’s syndrome is Cushing´s disease that consists of 
hypercortisolism driven by increased ACTH secretion from pituitary adenoma (Cushing, 1932; 
Stewart, 2005). Patients with Cushing’s syndrome are hypertensive, have visceral obesity, 
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infertility as well as features more specific to Cushing's syndrome (e.g. easy bruising, facial 
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The increase of AT in states of GC excess, such as Cushing’s syndrome, may not seem 
straightforward. Indeed, one might predict from cortisol metabolic actions that it would 
increase the availability of energetic substrates, as is seen with its lipolysis-stimulating effects. 
However, in these settings, particularly if there is positive energy balance, the chronic increase 
in GCs is concomitant with the increase in insulin (Dallman et al., 2004). This favors fatty acid 
re-esterification over lipolysis, which, along with pro-adipogenic effects of insulin and GCs 
(Rosen & MacDougald, 2006), increases AT depots. This is seen particularly on VAT depots, 
rather than other AT locations, probably for two reasons: higher expression of GR (Bronnegard 
et al., 1990) and increased reactivation of circulating cortisone due to high 11β-HSD1 
expression and/or activity (Alberti et al., 2007; Simonyte et al., 2009). 
Diagnostic features of GC excess in Cushing's syndrome overlap many of the MetSyn 
components suggesting that GCs may contribute to the pathogenesis of both states 
(Anagnostis et al., 2009; M. Wang, 2011). It has been demonstrated that circulating cortisol 
concentrations are higher in patients with MetSyn compared with healthy subjects, both in 
basal conditions and during dynamic stimulation (Duclos et al., 2005; Misra et al., 2008; 
Phillips et al., 1998; Sen et al., 2008; Weigensberg et al., 2008). Furthermore, increased 11β-
HSD1 activity in VAT may generate increased cortisol levels within AT and liver and 
thereby promote features of the MetSyn (Walker & Andrew, 2006). This effect has been 
termed ‘Cushing’s disease of the omentum’ (Bujalska et al., 1997; Stewart, 2005).  
5. MetSyn definition 
In the past few decades, there has been a worldwide increase in the prevalence of obesity 
and associated metabolic disorders including glucose intolerance, IR, dyslipidemia and 
hypertension. In the clinical practice, the presence of these conditions defines the MetSyn, 
which comprises an increased risk of atherosclerotic cardiovascular events and T2DM (or is 
associated with T2DM) and, additionally, is characterized by a pro-inflammatory and a pro-
thrombotic state and occurrence of non-alcoholic fatty liver disease (NAFLD) (Feldeisen & 
Tucker, 2007; Gathercole & Stewart, 2010; Johnson & Weinstock, 2006; Reaven, 2011). 
Distinct organizations have established their own definitions of the MetSyn: the World 
Health Organization (WHO), in 1998, the Adult Treatment Panel III (ATP III) of the National 
Cholesterol Education Program (NCEP), in 2001 (updated in 2005), and the International 
Diabetes Federation (IDF), in 2005 (Johnson & Weinstock, 2006; Reaven, 2011). In the 
attempt to harmonize MetSyn definitions, ATP III and IDF, joined by several other 
prestigious organizations, reviewed the criteria. Meeting any three of the following criteria is 
sufficient for the diagnosis: elevated waist circumference (abdominal obesity), triglycerides, 
blood pressure and fasting glucose (glucose intolerance) and low HDL-cholesterol levels. 
The cut points for an elevated waist circumference are not the same for all population 
groups (with population-specific reference values) and drug treatment is sufficient to meet 
the criteria for the other four components. The latest WHO report states that the ‘MetSyn 
should not be a clinical diagnosis’, but rather viewed as ‘a pre-morbid condition, and should 
thus exclude individuals with established T2DM or cardiovascular disease’ (Reaven, 2011). 
6. 11β-HSD1 and MetSyn components: evidence from human and animal 
studies 
Evidence has been accumulated that strongly argues for an etiological role of 11β-HSD1 in 
obesity, T2DM and MetSyn (Cooper & Stewart, 2009; Gathercole & Stewart, 2010; London & 
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Castonguay, 2009; Masuzaki & Flier, 2003; Morton, 2010; Staab & Maser, 2010; Tomlinson & 
Stewart, 2007; van Raalte et al., 2009; Wamil & Seckl, 2007).  
Initial studies in obese humans, that measured the ratio of cortisol to cortisone metabolites in 
urine as an indirect index of total body 11β-HSD activity, produced inconsistent results (such 
ratios, however, are inadequate as they may be influenced by other enzymes involved in 
cortisol metabolism). Recently, more trustworthy results from various more tissue-specific 
measures were obtained (Andrews et al., 2002; Andrews et al., 2003; Desbriere et al., 2006; 
Gathercole & Stewart, 2010; Karlsson et al., 2010; Morton, 2010; Paulmyer-Lacroix et al., 2002; 
Rask et al., 2001; Rask et al., 2002; Sandeep et al., 2005; Stewart & Tomlinson, 2009; R.  Stimson 
et al., 2011; Tomlinson et al., 2008; Valsamakis et al., 2004; Wamil & Seckl, 2007). After studies 
in men and women, representing a wide range of body compositions and insulin sensitivities 
(but without T2DM), 11β-HSD1 activity is found selectively increased in the abdominal 
subcutaneous AT (SAT) in obese humans (Rask et al., 2001; Rask et al., 2002; Sandeep et al., 
2005), to a similar degree as the increase in transgenic overexpressing mice (Andrews et al., 
2003), but impaired in the liver (Rask et al., 2001; Rask et al., 2002; Stewart et al., 1999). This 
decrease in hepatic tissue may represent a compensatory mechanism to preserve insulin 
sensitivity and to decrease hepatic glucose output (Gathercole & Stewart, 2010; Morton, 2010; 
Valsamakis et al., 2004; Wamil & Seckl, 2007). Increased adipose 11β-HSD1 activity results 
from increased 11β-HSD1 mRNA expression (Desbriere et al., 2006; Paulmyer-Lacroix et al., 
2002) in the abdominal SAT in adipocytes, and also in the VAT in both adipocytes and stroma 
(Paulmyer-Lacroix et al., 2002). Valsamakis et al. report a lack of inhibition of 11β-HSD1 
activity with increasing body mass index (BMI) in diabetic patients versus non-diabetic BMI- 
and age-matched controls (where the inhibition is closely associated with VAT mass), and 
suggest that a reduction in 11β-HSD1 activity might act as an autocrine protective mechanism 
to prevent increasing adiposity and increased hepatic glucose output with advancing obesity. 
This adaptive mechanism of reduced cortisol regeneration does not occur in obesity-associated 
T2DM and might contribute to the underlying pathogenesis of the disease (Gathercole & 
Stewart, 2010; Morton, 2010; Valsamakis et al., 2004; Wamil & Seckl, 2007). In contrast, in lean 
patients with T2DM (controlled by diet alone) a relatively small decrease in hepatic 11β-HSD1 
activity, and no change in gluteal SAT enzyme activity, has been reported, but only by one 
group (Andrews et al., 2002; Andrews et al., 2003). Abdominal SAT 11β-HSD1 expression is 
higher in obese women with impaired glucose tolerance than in obese women with normal 
glucose tolerance, despite AT (total and regional) being similar between the two groups, and 
positively correlated with glucose area under curve levels across an oral glucose tolerance 
testing (Tomlinson et al., 2008). Whole-body 11β-HSD1 activity is increased in obese men with 
T2DM, compared to healthy normal-weight control subjects, whereas liver 11β-HSD1 activity 
is sustained, unlike in euglycemic obesity (R.  Stimson et al., 2011). The evidences presented 
raise the hypothesis that hepatic 11β-HSD1 inhibition in obese people who develop impaired 
glucose tolerance may protect from progression to T2DM (Gathercole & Stewart, 2010; Morton, 
2010; Wamil & Seckl, 2007). Additionally, in line with this, myotubes established from obese 
T2DM subjects show an increased expression of 11β-HSD1 mRNA compared to healthy obese 
subjects (Abdallah et al., 2005). SAT 11β-HSD1 mRNA levels decrease during very low calorie 
diet (16 weeks) and anthropometric measurements and metabolic parameters are associated 
with 11β-HSD1 mRNA levels in obese subjects without the MetSyn (following the WHO 
definition). However, in obese subjects with the MetSyn these associations were lost or in the 
opposite direction. In another cohort, this difference is also observed in skeletal muscle (vastus 
lateralis) between subjects with T2DM or with normal glucose tolerance (Karlsson et al., 2010).  
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Diagnostic features of GC excess in Cushing's syndrome overlap many of the MetSyn 
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hypertension. In the clinical practice, the presence of these conditions defines the MetSyn, 
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attempt to harmonize MetSyn definitions, ATP III and IDF, joined by several other 
prestigious organizations, reviewed the criteria. Meeting any three of the following criteria is 
sufficient for the diagnosis: elevated waist circumference (abdominal obesity), triglycerides, 
blood pressure and fasting glucose (glucose intolerance) and low HDL-cholesterol levels. 
The cut points for an elevated waist circumference are not the same for all population 
groups (with population-specific reference values) and drug treatment is sufficient to meet 
the criteria for the other four components. The latest WHO report states that the ‘MetSyn 
should not be a clinical diagnosis’, but rather viewed as ‘a pre-morbid condition, and should 
thus exclude individuals with established T2DM or cardiovascular disease’ (Reaven, 2011). 
6. 11β-HSD1 and MetSyn components: evidence from human and animal 
studies 
Evidence has been accumulated that strongly argues for an etiological role of 11β-HSD1 in 
obesity, T2DM and MetSyn (Cooper & Stewart, 2009; Gathercole & Stewart, 2010; London & 
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Castonguay, 2009; Masuzaki & Flier, 2003; Morton, 2010; Staab & Maser, 2010; Tomlinson & 
Stewart, 2007; van Raalte et al., 2009; Wamil & Seckl, 2007).  
Initial studies in obese humans, that measured the ratio of cortisol to cortisone metabolites in 
urine as an indirect index of total body 11β-HSD activity, produced inconsistent results (such 
ratios, however, are inadequate as they may be influenced by other enzymes involved in 
cortisol metabolism). Recently, more trustworthy results from various more tissue-specific 
measures were obtained (Andrews et al., 2002; Andrews et al., 2003; Desbriere et al., 2006; 
Gathercole & Stewart, 2010; Karlsson et al., 2010; Morton, 2010; Paulmyer-Lacroix et al., 2002; 
Rask et al., 2001; Rask et al., 2002; Sandeep et al., 2005; Stewart & Tomlinson, 2009; R.  Stimson 
et al., 2011; Tomlinson et al., 2008; Valsamakis et al., 2004; Wamil & Seckl, 2007). After studies 
in men and women, representing a wide range of body compositions and insulin sensitivities 
(but without T2DM), 11β-HSD1 activity is found selectively increased in the abdominal 
subcutaneous AT (SAT) in obese humans (Rask et al., 2001; Rask et al., 2002; Sandeep et al., 
2005), to a similar degree as the increase in transgenic overexpressing mice (Andrews et al., 
2003), but impaired in the liver (Rask et al., 2001; Rask et al., 2002; Stewart et al., 1999). This 
decrease in hepatic tissue may represent a compensatory mechanism to preserve insulin 
sensitivity and to decrease hepatic glucose output (Gathercole & Stewart, 2010; Morton, 2010; 
Valsamakis et al., 2004; Wamil & Seckl, 2007). Increased adipose 11β-HSD1 activity results 
from increased 11β-HSD1 mRNA expression (Desbriere et al., 2006; Paulmyer-Lacroix et al., 
2002) in the abdominal SAT in adipocytes, and also in the VAT in both adipocytes and stroma 
(Paulmyer-Lacroix et al., 2002). Valsamakis et al. report a lack of inhibition of 11β-HSD1 
activity with increasing body mass index (BMI) in diabetic patients versus non-diabetic BMI- 
and age-matched controls (where the inhibition is closely associated with VAT mass), and 
suggest that a reduction in 11β-HSD1 activity might act as an autocrine protective mechanism 
to prevent increasing adiposity and increased hepatic glucose output with advancing obesity. 
This adaptive mechanism of reduced cortisol regeneration does not occur in obesity-associated 
T2DM and might contribute to the underlying pathogenesis of the disease (Gathercole & 
Stewart, 2010; Morton, 2010; Valsamakis et al., 2004; Wamil & Seckl, 2007). In contrast, in lean 
patients with T2DM (controlled by diet alone) a relatively small decrease in hepatic 11β-HSD1 
activity, and no change in gluteal SAT enzyme activity, has been reported, but only by one 
group (Andrews et al., 2002; Andrews et al., 2003). Abdominal SAT 11β-HSD1 expression is 
higher in obese women with impaired glucose tolerance than in obese women with normal 
glucose tolerance, despite AT (total and regional) being similar between the two groups, and 
positively correlated with glucose area under curve levels across an oral glucose tolerance 
testing (Tomlinson et al., 2008). Whole-body 11β-HSD1 activity is increased in obese men with 
T2DM, compared to healthy normal-weight control subjects, whereas liver 11β-HSD1 activity 
is sustained, unlike in euglycemic obesity (R.  Stimson et al., 2011). The evidences presented 
raise the hypothesis that hepatic 11β-HSD1 inhibition in obese people who develop impaired 
glucose tolerance may protect from progression to T2DM (Gathercole & Stewart, 2010; Morton, 
2010; Wamil & Seckl, 2007). Additionally, in line with this, myotubes established from obese 
T2DM subjects show an increased expression of 11β-HSD1 mRNA compared to healthy obese 
subjects (Abdallah et al., 2005). SAT 11β-HSD1 mRNA levels decrease during very low calorie 
diet (16 weeks) and anthropometric measurements and metabolic parameters are associated 
with 11β-HSD1 mRNA levels in obese subjects without the MetSyn (following the WHO 
definition). However, in obese subjects with the MetSyn these associations were lost or in the 
opposite direction. In another cohort, this difference is also observed in skeletal muscle (vastus 
lateralis) between subjects with T2DM or with normal glucose tolerance (Karlsson et al., 2010).  
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6.1. Findings of 11β-HSD1 biology from rodent models 
6.1.1 The aP2-HSD11B1 transgenic rodent model 
Transgenic mice with 2–3-fold overexpression of 11β-HSD1, comparable to that seen in 
obese humans, in white AT have been generated, exploiting the murine adipocyte fatty acid 
binding protein (aP2) promoter. These aP2-HSD11B1 transgenic mice have elevated 
corticosterone levels in the AT, but unaltered systemic plasma concentrations, and many 
features of the MetSyn: glucose intolerance and IR [exacerbated further by high-fat (HF) 
feeding], dyslipidemia, apparent leptin resistance, truncal obesity and hypertension 
associated with activation of the circulating renin-angiotensin system. 11β-HSD1 expression 
correlates strongly and positively with adipocyte size (London & Castonguay, 2009; 
Masuzaki & Flier, 2003; Masuzaki et al., 2001; Masuzaki et al., 2003; Morton, 2010; Staab & 
Maser, 2010; van Raalte et al., 2009; Wamil & Seckl, 2007). TNF- and leptin are elevated 
whereas resistin and insulin-sensitizing adiponectin are reduced. aP2-HSD11B1 transgenic 
mice are hyperphagic and obese, predominantly in the VAT. Expression of the GR-α is 
higher in VAT compared to SAT, while the expression of the transgene HSD11B1 is similar 
in all AT depots. The greater effects in VAT may reflect the higher GR and/or higher 
lipoprotein lipase in mesenteric AT. aP2-HSD11B1 transgenic mice have elevated 
corticosterone and free fatty acids (FFA) levels in the hepatic portal vein that drains blood 
from VAT to the liver (Masuzaki et al., 2001; Masuzaki et al., 2003; Morton, 2010; Wamil & 
Seckl, 2007). The aP2-HSD11B1 model shows that altered AT metabolism of GCs (similar to 
human MetSyn levels) could be the primary driver of many features of this disease 
(Masuzaki & Flier, 2003; Masuzaki et al., 2001; Masuzaki et al., 2003; Morton, 2010).  
6.1.2 The apolipoprotein E (apoE)-HSD11B1 transgenic rodent model 
To examine the impact of elevated liver GCs, mice overexpressing 11β-HSD1 selectively in 
that tissue under the control of the human apoE promoter have been generated. Transgenic 
lines with 2- and 5-fold-elevated 11β-HSD1 activity exhibit unaltered systemic 
corticosterone, modest IR (but lacking glucose intolerance), unaltered AT mass (lacking 
obesity or central adiposity), hepatic fat accumulation (mainly as triglycerides) and 
dyslipidemia (elevated circulating FFA and HF diet-induced dyslipidemic cholesterol 
lipoprotein profile), with increased hepatic lipid synthesis/flux associated with elevated 
hepatic LXR-α and PPAR-α expression as well as impaired hepatic lipid clearance. Increased 
expression of GC-inducible cholesterol 7α-hydroxylase present in apoE-HSD11B1 transgenic 
livers may drive increased bile acid synthesis, contributing to stimulation of LXR-α-
regulated pathways (and further potentiation of cholesterol 7α-hydroxylase expression) as 
well as PPAR-α. ApoE-HSD11B1 transgenic mice also have a marked, transgene-dose-
associated hypertension, paralleled by incrementally increased liver angiotensinogen 
expression. Elevated 11β-HSD1 hepatic expression may relate to the pathogenesis of specific 
fatty liver, insulin-resistant and hypertensive syndromes without obesity in humans as may 
occur in, possibly, the metabolically obese normal-weight individual (Paterson et al., 2004). 
6.1.3 The HSD11B1 knockout (KO) rodent model 
HSD11B1 KO mice have been generated, which are viable and healthy but unable to convert 
inert 11-dehydrocorticosterone to corticosterone. Despite compensatory adrenal hyperplasia 
and increased adrenal secretion of corticosterone, on fasting, HSD11B1 KO mice have 
attenuated activation of the hepatic gluconeogenic enzymes, presumably, because of relative 
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intra-hepatic GC deficiency. The HSD11B1 KO mice resist hyperglycemia provoked by 
obesity or stress (Kotelevtsev et al., 1997). HSD11B1 KO mice, fed ad lib, have markedly 
lower plasma triglyceride levels, driven by increased hepatic expression of enzymes of fat 
catabolism and PPAR-α. HSD11B1 KO mice also have increased plasma HDL-cholesterol, 
with elevated liver mRNA and serum levels of apoAI. Conversely, hepatic Aα-fibrinogen 
expression is decreased. Upon fasting, the normal elevation of hepatic PPAR-α mRNA is lost 
in HSD11B1 KO mice, consistent with attenuated GC induction. Despite this, crucial 
oxidative responses to fasting are maintained. Refeeding (4 h and/or 24 h) shows more 
rapid and/or marked induction of genes encoding lipogenic enzymes/transcription factors 
and a more rapid and/or marked suppression of genes for fat catabolism in HSD11B1 KO 
mice, implying increased liver insulin sensitivity. PPAR-α is suppressed by 4 h of refeeding 
(similarly in wild type and HSD11B1 KO mice), but PPAR-α levels are higher after 24 h of 
refeeding in HSD11B1 KO mice when compared to wild type mice, reestablishing the ad lib-
fed pattern. Concordant with this, 24 h refed HSD11B1 KO mice have higher plasma 
triglycerides than 24 h refed wild type mice and ad lib-fed HSD11B1 KO mice.  24 h Refed 
HSD11B1 KO mice have lower plasma glucose levels than 24 h refed wild type mice and ad 
lib-fed HSD11B1 KO mice. HSD11B1 KO mice also have improved glucose tolerance. 11β-
HSD1 deficiency may produce an improved lipid profile, hepatic insulin sensitization and a 
potentially atheroprotective phenotype (Morton et al., 2001). HSD11B1 KO mice on the 
control diet express, compared to wild-type mice, lower leptin, resistin and TNF- but 
higher PPAR-, adiponectin and uncoupling protein-2 (UCP-2) mRNA levels in epididymal 
AT, indicating insulin sensitization. On the control diet, in mesenteric VAT, PPAR- mRNA 
is elevated in HSD11B1 KO mice, though leptin, resistin, TNF-, adiponectin and UCP-2 
mRNA levels are unaltered, compared to wild-type mice. With HF feeding, the elevated 
PPAR-γ mRNA level in control-fed HSD11B1 KO mice is further increased selectively in 
VAT, what does not happen in the epididymal AT depot of HSD11B1 KO or wild-type mice. 
HSD11B1 KO mice also show a HF–mediated induction of UCP-2 selectively in VAT, which 
is greater than that observed in wild-type mice. Isolated adipocytes from HSD11B1 KO mice 
exhibit higher basal and insulin-stimulated glucose uptake. HSD11B1 KO mice also display 
reduced VAT accumulation upon HF feeding. HF-fed HSD11B1 KO mice rederived onto the 
C57BL/6J strain (obesity/T2DM/metabolic disease-susceptible) resist T2DM and weight 
gain despite consuming more calories. These data provided the first in vivo evidence that AT 
11β-HSD1 deficiency beneficially alters AT distribution and function (Morton et al., 2004), 
complementing the just above-described effects of hepatic 11β-HSD1 deficiency or data 
presented further bellow regarding 11β-HSD1 pharmacological inhibition. Since PPAR-γ 
ligands cause insulin sensitization and AT redistribution to the periphery, a mechanism for the 
beneficial AT redistribution is suggested, on the assumption that increased circulating FFA 
during HF feeding act as endogenous ligands for PPAR-γ receptors. Further, UCP-2 levels are 
higher in HSD11B1 KO mice AT, consistent with GC and PPAR-γ regulation. This higher 
PPAR-γ-responsive UCP-2 expression in HSD11B1 KO mice AT may drive increased energy 
dissipation within the adipocytes (Morton, 2010). Interestingly, when mice are fed a HF diet 
they preferentially gain weight in peripheral AT rather than in VAT what can be explained by 
an increased expression of PPAR-γ and UCP-2 in VAT (Morton, 2010; van Raalte et al., 2009; 
Wamil & Seckl, 2007).  
Mice overexpressing the cortisol inactivating enzyme specifically on the AT (aP2-HSD11B2 
mice) are phenotypically similar to HSD11B1 KO mice, exception only for food intake, what 
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6.1. Findings of 11β-HSD1 biology from rodent models 
6.1.1 The aP2-HSD11B1 transgenic rodent model 
Transgenic mice with 2–3-fold overexpression of 11β-HSD1, comparable to that seen in 
obese humans, in white AT have been generated, exploiting the murine adipocyte fatty acid 
binding protein (aP2) promoter. These aP2-HSD11B1 transgenic mice have elevated 
corticosterone levels in the AT, but unaltered systemic plasma concentrations, and many 
features of the MetSyn: glucose intolerance and IR [exacerbated further by high-fat (HF) 
feeding], dyslipidemia, apparent leptin resistance, truncal obesity and hypertension 
associated with activation of the circulating renin-angiotensin system. 11β-HSD1 expression 
correlates strongly and positively with adipocyte size (London & Castonguay, 2009; 
Masuzaki & Flier, 2003; Masuzaki et al., 2001; Masuzaki et al., 2003; Morton, 2010; Staab & 
Maser, 2010; van Raalte et al., 2009; Wamil & Seckl, 2007). TNF- and leptin are elevated 
whereas resistin and insulin-sensitizing adiponectin are reduced. aP2-HSD11B1 transgenic 
mice are hyperphagic and obese, predominantly in the VAT. Expression of the GR-α is 
higher in VAT compared to SAT, while the expression of the transgene HSD11B1 is similar 
in all AT depots. The greater effects in VAT may reflect the higher GR and/or higher 
lipoprotein lipase in mesenteric AT. aP2-HSD11B1 transgenic mice have elevated 
corticosterone and free fatty acids (FFA) levels in the hepatic portal vein that drains blood 
from VAT to the liver (Masuzaki et al., 2001; Masuzaki et al., 2003; Morton, 2010; Wamil & 
Seckl, 2007). The aP2-HSD11B1 model shows that altered AT metabolism of GCs (similar to 
human MetSyn levels) could be the primary driver of many features of this disease 
(Masuzaki & Flier, 2003; Masuzaki et al., 2001; Masuzaki et al., 2003; Morton, 2010).  
6.1.2 The apolipoprotein E (apoE)-HSD11B1 transgenic rodent model 
To examine the impact of elevated liver GCs, mice overexpressing 11β-HSD1 selectively in 
that tissue under the control of the human apoE promoter have been generated. Transgenic 
lines with 2- and 5-fold-elevated 11β-HSD1 activity exhibit unaltered systemic 
corticosterone, modest IR (but lacking glucose intolerance), unaltered AT mass (lacking 
obesity or central adiposity), hepatic fat accumulation (mainly as triglycerides) and 
dyslipidemia (elevated circulating FFA and HF diet-induced dyslipidemic cholesterol 
lipoprotein profile), with increased hepatic lipid synthesis/flux associated with elevated 
hepatic LXR-α and PPAR-α expression as well as impaired hepatic lipid clearance. Increased 
expression of GC-inducible cholesterol 7α-hydroxylase present in apoE-HSD11B1 transgenic 
livers may drive increased bile acid synthesis, contributing to stimulation of LXR-α-
regulated pathways (and further potentiation of cholesterol 7α-hydroxylase expression) as 
well as PPAR-α. ApoE-HSD11B1 transgenic mice also have a marked, transgene-dose-
associated hypertension, paralleled by incrementally increased liver angiotensinogen 
expression. Elevated 11β-HSD1 hepatic expression may relate to the pathogenesis of specific 
fatty liver, insulin-resistant and hypertensive syndromes without obesity in humans as may 
occur in, possibly, the metabolically obese normal-weight individual (Paterson et al., 2004). 
6.1.3 The HSD11B1 knockout (KO) rodent model 
HSD11B1 KO mice have been generated, which are viable and healthy but unable to convert 
inert 11-dehydrocorticosterone to corticosterone. Despite compensatory adrenal hyperplasia 
and increased adrenal secretion of corticosterone, on fasting, HSD11B1 KO mice have 
attenuated activation of the hepatic gluconeogenic enzymes, presumably, because of relative 
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intra-hepatic GC deficiency. The HSD11B1 KO mice resist hyperglycemia provoked by 
obesity or stress (Kotelevtsev et al., 1997). HSD11B1 KO mice, fed ad lib, have markedly 
lower plasma triglyceride levels, driven by increased hepatic expression of enzymes of fat 
catabolism and PPAR-α. HSD11B1 KO mice also have increased plasma HDL-cholesterol, 
with elevated liver mRNA and serum levels of apoAI. Conversely, hepatic Aα-fibrinogen 
expression is decreased. Upon fasting, the normal elevation of hepatic PPAR-α mRNA is lost 
in HSD11B1 KO mice, consistent with attenuated GC induction. Despite this, crucial 
oxidative responses to fasting are maintained. Refeeding (4 h and/or 24 h) shows more 
rapid and/or marked induction of genes encoding lipogenic enzymes/transcription factors 
and a more rapid and/or marked suppression of genes for fat catabolism in HSD11B1 KO 
mice, implying increased liver insulin sensitivity. PPAR-α is suppressed by 4 h of refeeding 
(similarly in wild type and HSD11B1 KO mice), but PPAR-α levels are higher after 24 h of 
refeeding in HSD11B1 KO mice when compared to wild type mice, reestablishing the ad lib-
fed pattern. Concordant with this, 24 h refed HSD11B1 KO mice have higher plasma 
triglycerides than 24 h refed wild type mice and ad lib-fed HSD11B1 KO mice.  24 h Refed 
HSD11B1 KO mice have lower plasma glucose levels than 24 h refed wild type mice and ad 
lib-fed HSD11B1 KO mice. HSD11B1 KO mice also have improved glucose tolerance. 11β-
HSD1 deficiency may produce an improved lipid profile, hepatic insulin sensitization and a 
potentially atheroprotective phenotype (Morton et al., 2001). HSD11B1 KO mice on the 
control diet express, compared to wild-type mice, lower leptin, resistin and TNF- but 
higher PPAR-, adiponectin and uncoupling protein-2 (UCP-2) mRNA levels in epididymal 
AT, indicating insulin sensitization. On the control diet, in mesenteric VAT, PPAR- mRNA 
is elevated in HSD11B1 KO mice, though leptin, resistin, TNF-, adiponectin and UCP-2 
mRNA levels are unaltered, compared to wild-type mice. With HF feeding, the elevated 
PPAR-γ mRNA level in control-fed HSD11B1 KO mice is further increased selectively in 
VAT, what does not happen in the epididymal AT depot of HSD11B1 KO or wild-type mice. 
HSD11B1 KO mice also show a HF–mediated induction of UCP-2 selectively in VAT, which 
is greater than that observed in wild-type mice. Isolated adipocytes from HSD11B1 KO mice 
exhibit higher basal and insulin-stimulated glucose uptake. HSD11B1 KO mice also display 
reduced VAT accumulation upon HF feeding. HF-fed HSD11B1 KO mice rederived onto the 
C57BL/6J strain (obesity/T2DM/metabolic disease-susceptible) resist T2DM and weight 
gain despite consuming more calories. These data provided the first in vivo evidence that AT 
11β-HSD1 deficiency beneficially alters AT distribution and function (Morton et al., 2004), 
complementing the just above-described effects of hepatic 11β-HSD1 deficiency or data 
presented further bellow regarding 11β-HSD1 pharmacological inhibition. Since PPAR-γ 
ligands cause insulin sensitization and AT redistribution to the periphery, a mechanism for the 
beneficial AT redistribution is suggested, on the assumption that increased circulating FFA 
during HF feeding act as endogenous ligands for PPAR-γ receptors. Further, UCP-2 levels are 
higher in HSD11B1 KO mice AT, consistent with GC and PPAR-γ regulation. This higher 
PPAR-γ-responsive UCP-2 expression in HSD11B1 KO mice AT may drive increased energy 
dissipation within the adipocytes (Morton, 2010). Interestingly, when mice are fed a HF diet 
they preferentially gain weight in peripheral AT rather than in VAT what can be explained by 
an increased expression of PPAR-γ and UCP-2 in VAT (Morton, 2010; van Raalte et al., 2009; 
Wamil & Seckl, 2007).  
Mice overexpressing the cortisol inactivating enzyme specifically on the AT (aP2-HSD11B2 
mice) are phenotypically similar to HSD11B1 KO mice, exception only for food intake, what 
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emphasizes the importance of AT as a target for enzyme inhibition (Wamil & Seckl, 2007). 
11β-HSD1 gene deficiency is associated with a number of improvements of adipose and 
hepatic functions, what highlights the importance of adipose and hepatic 11β-HSD1 in the 
development of metabolic disease.  
6.2 11β-HSD1 and T2DM/IR 
A role for 11β-HSD1 in exacerbating IR and T2DM has been proposed. Animals with 
targeted deletion of HSD11B1 manifest increased hepatic and adipose insulin sensitivity 
(Kotelevtsev et al., 1997; Morton et al., 2001; Morton et al., 2004), and when backcrossed onto 
the C57BL/6J strain appear to resist the development of IR in response to HF feeding 
(Morton et al., 2004). Additionally, specific 11β-HSD1 inhibitors improve insulin sensitivity 
(glycemic control and/or glucose and/or insulin levels) in animal models (associated or not 
with HF feeding) of hyperglycemia, obesity (by damage of feeding center or diet-induced), 
T2DM (also ob/ob) and combined T2DM, dyslipidemia and atherosclerosis (Alberts et al., 
2002; Alberts et al., 2003; Barf et al., 2002; Gathercole & Stewart, 2010; Hermanowski-
Vosatka et al., 2005; Morgan et al., 2009; Park et al., 2011; X. Zhang et al., 2009b). 
It is well known that excess GCs increase IR and can, in susceptible individuals, precipitate 
T2DM. In line with this, it has been suggested that the increased production of cortisol from 
VAT seen in obesity could drain through the portal circulation to the liver and pancreas 
contributing to IR (Cooper & Stewart, 2009; Masuzaki et al., 2001; Morton, 2010; R. Stimson et 
al., 2009; Walker & Andrew, 2006; Wamil & Seckl, 2007). This hypothesis was investigated in 
vivo in humans by Stimson et al. by quantifying, for the first time, selectively, the contributions 
of SAT, visceral tissues and liver to whole-body cortisol production by 11β-HSD1. Stimson et 
al. confirmed that splanchnic cortisol production is substantial, originating entirely from the 
11β-HSD1 activity in the liver. However, although release of cortisol by 11β-HSD1 into the 
portal vein, which drains a number of visceral organs, is not detected, a significant cortisol 
release into veins draining exclusively SAT has been found. So, cortisol release from SAT into 
the systemic circulation is unlikely to have effects in other organs because the feedback control 
by the HPA axis will adjust adrenal cortisol secretion to maintain circulating cortisol 
concentrations. Therefore, the most likely impact of this source of cortisol will be intracrine or 
paracrine in the local AT environment (R. Stimson et al., 2009). 
Skeletal muscle represents a key target tissue for insulin-stimulated glucose uptake, 
metabolism and utilization (Abdul-Ghani & DeFronzo, 2010; Benito, 2011; Van Cromphaut, 
2009). There are just a few studies regarding 11β-HSD1 in skeletal muscle from T2DM, 
although with non-consensual results (Cooper & Stewart, 2009). Whorwood et al. found, 
with kinetic analysis, that 11β-HSD1, in intact cultured human skeletal myoblasts (from both 
lean-moderately overweight and obese adult men, few with T2DM but without therapy), 
acts exclusively as a reductase and is down-regulated by insulin, which may maintain 
insulin sensitivity in skeletal muscle tissue by diminishing GC antagonism of insulin action 
(Whorwood et al., 2001). Cortisone reduces glucose uptake in myotubes established from 
obese T2DM men (treated either by diet alone or in combination with sulfonylurea or 
metformin, withdrawn one week before performing the biopsy), what could be mediated by 
an increased mRNA 11β-HSD1 expression (previously mentioned) emphasizing that the 
local conversion of inactive to active GCs may be important in IR pathogenesis (Abdallah et 
al., 2005). Accordingly, Zhang et al., in an animal model of T2DM (Wistar rats with HF 
feeding, combined with multiple low dose streptozotocin injection), report increased 11β-
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HSD1 mRNA and protein levels in skeletal muscle extracts of the diabetic animals versus the 
non-diabetic animals, what may be related to disturbances in insulin signaling pathway 
observed in the skeletal muscle (M. Zhang et al., 2009a). Jang et al. demonstrated that the 
activities of skeletal muscle 11β-HSD1 and 11β-HSD2 (in vastus lateralis biopsies) are 
altered in T2DM patients (treated by diet alone or oral hypoglycemic agents) versus healthy 
age- and sex-matched controls (altogether overweight and obese subjects): 11β-HSD1 
activity is reduced and 11β-HSD2 activity is higher in T2DM subjects (negative correlation 
between both enzyme activities; with similar mRNA levels in T2DM and control subjects for 
both enzymes), and, more importantly, 11β-HSD1 reductase activity is significantly lower in 
T2DM subjects whereas 11β-HSD1 dehydrogenase activity is significantly higher in the 
T2DM group (with very low levels of 11β-HSD1 dehydrogenase activity in both groups). 
Together these results may indicate a reduced intracellular cortisol generation, potentially 
conferring metabolic protection (Jang et al., 2007). In what regards the AT, Balachandran et 
al. demonstrated that insulin stimulates adipocyte 11β-HSD1 activity and expression both in 
vitro (in 3T3-L1 adipocytes) and in vivo (Wistar rat white AT) (Balachandran et al., 2008). 
Morgan et al. established a strong connection between a key player in insulin signaling, the 
insulin receptor substrate 1 (IRS1), and 11β-HSD1 in skeletal muscle: in KK/Ta Jcl mice (an 
hyperglycemic model) treated with A2, inducing selective 11β-HSD1 inhibition, skeletal 
muscle pSer307IRS1 decreases, pThr308Akt/PKB increases and lipogenic and lipolytic gene 
expression decreases (Morgan et al., 2009). 11β-HSD1 has also been proposed to have effects 
on insulin secretion itself. Davani et al. report 11β-HSD1 mRNA expression in human and 
ob/ob mice (non-insulin-dependent diabetes model) pancreatic β-cells, and also characterize 
the 11β-HSD1 activity in intact pancreatic rodent islets (where the reductive reaction 
prevails). In ob/ob mice islets, in the absence of carbenoxolone, 11-dehydrocorticosterone 
markedly inhibits insulin release, whereas a reversal of this effect is noted in the presence of 
carbenoxolone, indicating an important role of 11β-HSD1 in the regulation of insulin release 
(Davani et al., 2000). A more recent report describes a similar effect of dehydrocorticosterone 
on insulin release in human and murine pancreatic cells, but it appears that enzyme 
expression is absent in β-cells, with this effect being mediated indirectly through expression 
within α-cells. This α-cell expression additionally inhibits insulin-stimulated glucagon 
secretion (Cooper & Stewart, 2009; Swali et al., 2008). 
6.3 11β-HSD1 and hypertension 
GC hormones act on the cardiovascular system (Nussinovitch et al., 2010; Raff & Findling, 
2003; Walker et al., 2000; Wallerath et al., 1999). Cortisol and 11β-HSDs have been 
implicated in hypertension (Anagnostis et al., 2009; Andrews et al., 2003; Campino et al., 
2010; Cicala & Mantero, 2010; Edwards et al., 1988; Ferrari, 2010; Franks et al., 2004; 
Funder et al., 1988; Gathercole & Stewart, 2010; Y. Liu et al., 2008; Malavasi et al., 2010; 
Masuzaki et al., 2003; Millis, 2011; Monder et al., 1989; Morales et al., 2008; Mune et al., 
1995; Palermo et al., 2004; Paterson et al., 2004; Quinkler & Stewart, 2003; Raff & Findling, 
2003; S. Shah et al., 2011; Stewart et al., 1996; Walker & Andrew, 2006; Walker et al., 1993; 
Wallerath et al., 1999; White et al., 1997). 
The fact that 11β-HSD2 is important in protecting MR in the distal nephron from stimulation 
by GCs revealed its role in the regulation of arterial blood pressure. Pharmacological 
inhibition or genetic deficiency of 11β-HSD2 leads to the development of hypertension 
(Anagnostis et al., 2009; Andrews et al., 2003; Edwards et al., 1988; Ferrari, 2010; Funder et 
al., 1988; Gathercole & Stewart, 2010; Palermo et al., 2004; Walker et al., 1993; White et al., 
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emphasizes the importance of AT as a target for enzyme inhibition (Wamil & Seckl, 2007). 
11β-HSD1 gene deficiency is associated with a number of improvements of adipose and 
hepatic functions, what highlights the importance of adipose and hepatic 11β-HSD1 in the 
development of metabolic disease.  
6.2 11β-HSD1 and T2DM/IR 
A role for 11β-HSD1 in exacerbating IR and T2DM has been proposed. Animals with 
targeted deletion of HSD11B1 manifest increased hepatic and adipose insulin sensitivity 
(Kotelevtsev et al., 1997; Morton et al., 2001; Morton et al., 2004), and when backcrossed onto 
the C57BL/6J strain appear to resist the development of IR in response to HF feeding 
(Morton et al., 2004). Additionally, specific 11β-HSD1 inhibitors improve insulin sensitivity 
(glycemic control and/or glucose and/or insulin levels) in animal models (associated or not 
with HF feeding) of hyperglycemia, obesity (by damage of feeding center or diet-induced), 
T2DM (also ob/ob) and combined T2DM, dyslipidemia and atherosclerosis (Alberts et al., 
2002; Alberts et al., 2003; Barf et al., 2002; Gathercole & Stewart, 2010; Hermanowski-
Vosatka et al., 2005; Morgan et al., 2009; Park et al., 2011; X. Zhang et al., 2009b). 
It is well known that excess GCs increase IR and can, in susceptible individuals, precipitate 
T2DM. In line with this, it has been suggested that the increased production of cortisol from 
VAT seen in obesity could drain through the portal circulation to the liver and pancreas 
contributing to IR (Cooper & Stewart, 2009; Masuzaki et al., 2001; Morton, 2010; R. Stimson et 
al., 2009; Walker & Andrew, 2006; Wamil & Seckl, 2007). This hypothesis was investigated in 
vivo in humans by Stimson et al. by quantifying, for the first time, selectively, the contributions 
of SAT, visceral tissues and liver to whole-body cortisol production by 11β-HSD1. Stimson et 
al. confirmed that splanchnic cortisol production is substantial, originating entirely from the 
11β-HSD1 activity in the liver. However, although release of cortisol by 11β-HSD1 into the 
portal vein, which drains a number of visceral organs, is not detected, a significant cortisol 
release into veins draining exclusively SAT has been found. So, cortisol release from SAT into 
the systemic circulation is unlikely to have effects in other organs because the feedback control 
by the HPA axis will adjust adrenal cortisol secretion to maintain circulating cortisol 
concentrations. Therefore, the most likely impact of this source of cortisol will be intracrine or 
paracrine in the local AT environment (R. Stimson et al., 2009). 
Skeletal muscle represents a key target tissue for insulin-stimulated glucose uptake, 
metabolism and utilization (Abdul-Ghani & DeFronzo, 2010; Benito, 2011; Van Cromphaut, 
2009). There are just a few studies regarding 11β-HSD1 in skeletal muscle from T2DM, 
although with non-consensual results (Cooper & Stewart, 2009). Whorwood et al. found, 
with kinetic analysis, that 11β-HSD1, in intact cultured human skeletal myoblasts (from both 
lean-moderately overweight and obese adult men, few with T2DM but without therapy), 
acts exclusively as a reductase and is down-regulated by insulin, which may maintain 
insulin sensitivity in skeletal muscle tissue by diminishing GC antagonism of insulin action 
(Whorwood et al., 2001). Cortisone reduces glucose uptake in myotubes established from 
obese T2DM men (treated either by diet alone or in combination with sulfonylurea or 
metformin, withdrawn one week before performing the biopsy), what could be mediated by 
an increased mRNA 11β-HSD1 expression (previously mentioned) emphasizing that the 
local conversion of inactive to active GCs may be important in IR pathogenesis (Abdallah et 
al., 2005). Accordingly, Zhang et al., in an animal model of T2DM (Wistar rats with HF 
feeding, combined with multiple low dose streptozotocin injection), report increased 11β-
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HSD1 mRNA and protein levels in skeletal muscle extracts of the diabetic animals versus the 
non-diabetic animals, what may be related to disturbances in insulin signaling pathway 
observed in the skeletal muscle (M. Zhang et al., 2009a). Jang et al. demonstrated that the 
activities of skeletal muscle 11β-HSD1 and 11β-HSD2 (in vastus lateralis biopsies) are 
altered in T2DM patients (treated by diet alone or oral hypoglycemic agents) versus healthy 
age- and sex-matched controls (altogether overweight and obese subjects): 11β-HSD1 
activity is reduced and 11β-HSD2 activity is higher in T2DM subjects (negative correlation 
between both enzyme activities; with similar mRNA levels in T2DM and control subjects for 
both enzymes), and, more importantly, 11β-HSD1 reductase activity is significantly lower in 
T2DM subjects whereas 11β-HSD1 dehydrogenase activity is significantly higher in the 
T2DM group (with very low levels of 11β-HSD1 dehydrogenase activity in both groups). 
Together these results may indicate a reduced intracellular cortisol generation, potentially 
conferring metabolic protection (Jang et al., 2007). In what regards the AT, Balachandran et 
al. demonstrated that insulin stimulates adipocyte 11β-HSD1 activity and expression both in 
vitro (in 3T3-L1 adipocytes) and in vivo (Wistar rat white AT) (Balachandran et al., 2008). 
Morgan et al. established a strong connection between a key player in insulin signaling, the 
insulin receptor substrate 1 (IRS1), and 11β-HSD1 in skeletal muscle: in KK/Ta Jcl mice (an 
hyperglycemic model) treated with A2, inducing selective 11β-HSD1 inhibition, skeletal 
muscle pSer307IRS1 decreases, pThr308Akt/PKB increases and lipogenic and lipolytic gene 
expression decreases (Morgan et al., 2009). 11β-HSD1 has also been proposed to have effects 
on insulin secretion itself. Davani et al. report 11β-HSD1 mRNA expression in human and 
ob/ob mice (non-insulin-dependent diabetes model) pancreatic β-cells, and also characterize 
the 11β-HSD1 activity in intact pancreatic rodent islets (where the reductive reaction 
prevails). In ob/ob mice islets, in the absence of carbenoxolone, 11-dehydrocorticosterone 
markedly inhibits insulin release, whereas a reversal of this effect is noted in the presence of 
carbenoxolone, indicating an important role of 11β-HSD1 in the regulation of insulin release 
(Davani et al., 2000). A more recent report describes a similar effect of dehydrocorticosterone 
on insulin release in human and murine pancreatic cells, but it appears that enzyme 
expression is absent in β-cells, with this effect being mediated indirectly through expression 
within α-cells. This α-cell expression additionally inhibits insulin-stimulated glucagon 
secretion (Cooper & Stewart, 2009; Swali et al., 2008). 
6.3 11β-HSD1 and hypertension 
GC hormones act on the cardiovascular system (Nussinovitch et al., 2010; Raff & Findling, 
2003; Walker et al., 2000; Wallerath et al., 1999). Cortisol and 11β-HSDs have been 
implicated in hypertension (Anagnostis et al., 2009; Andrews et al., 2003; Campino et al., 
2010; Cicala & Mantero, 2010; Edwards et al., 1988; Ferrari, 2010; Franks et al., 2004; 
Funder et al., 1988; Gathercole & Stewart, 2010; Y. Liu et al., 2008; Malavasi et al., 2010; 
Masuzaki et al., 2003; Millis, 2011; Monder et al., 1989; Morales et al., 2008; Mune et al., 
1995; Palermo et al., 2004; Paterson et al., 2004; Quinkler & Stewart, 2003; Raff & Findling, 
2003; S. Shah et al., 2011; Stewart et al., 1996; Walker & Andrew, 2006; Walker et al., 1993; 
Wallerath et al., 1999; White et al., 1997). 
The fact that 11β-HSD2 is important in protecting MR in the distal nephron from stimulation 
by GCs revealed its role in the regulation of arterial blood pressure. Pharmacological 
inhibition or genetic deficiency of 11β-HSD2 leads to the development of hypertension 
(Anagnostis et al., 2009; Andrews et al., 2003; Edwards et al., 1988; Ferrari, 2010; Funder et 
al., 1988; Gathercole & Stewart, 2010; Palermo et al., 2004; Walker et al., 1993; White et al., 
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1997). HSD11B2 can be epigenetically regulated, what is also involved in hypertension 
development (Millis, 2011). In the same line, defects and polymorphisms in HSD11B2 have 
also been shown to play a role in human hypertension and cardiovascular disease [e.g. 
essential hypertension (Soro et al., 1995; Walker et al., 1993) and ‘salt-sensitive’ hypertension 
(Lovati et al., 1999)] (Bailey et al., 2008; Cooper & Stewart, 2009; Henschkowski et al., 2008). 
Campino et al. reported a high percentage of alterations in the cortisol metabolism at the 
pre-receptor level in hypertensive patients, previously misclassified as having essential 
hypertension, where 18% of the patients present reduced 11β-HSD2  activity or imbalance of 
11β-HSD1 activity in comparison to 11β-HSD2 (Campino et al., 2010). As referred above, 
hypertension is induced in mice genetically modified to overexpress 11β-HSD1 either in the 
liver or AT (Masuzaki et al., 2003; Paterson et al., 2004). HSD11B1 polymorphisms have been 
described, affecting enzyme expression and activity in vitro and/or in vivo, and/or being 
associated with hypertension (Franks et al., 2004; Malavasi et al., 2010; Morales et al., 2008). 
Variants of HSD11B1 were associated with the risk of hypertension in Pima Indians (Franks 
et al., 2004). Liu et al. showed that suppression of 11β-HSD1 expression in the renal medulla 
attenuates salt-induced hypertension in Dahl salt-sensitive rats (Y. Liu et al., 2008). Taking 
into consideration that diet is one important factor on MetSyn development, it is interesting 
to mention that in Dahl salt-sensitive hypertensive rats, fed a high-salt diet for 4 weeks, peri-
renal AT corticosterone concentration and 11β-HSD1 activity as well as GR, 11β-HSD1 and 
TNF-α expression increase when compared with Dahl salt-resistant rats fed the same diet 
(Usukura et al., 2009).  
6.4 11β-HSD1 and NAFLD 
NAFLD is being increasingly recognized as a common liver disorder that represents the 
hepatic manifestation of the MetSyn. NAFLD is more frequent among people with T2DM 
and obesity, and it is almost universal amongst T2DM patients who are morbidly obese 
(Bellentani et al., 2000; Fabbrini et al., 2010; Gupte et al., 2004; Konopelska et al., 2009; Ratziu 
et al., 2010; Wree et al., 2010). Non-alcoholic steatohepatitis (NASH) is the progressive form 
of liver injury that carries a risk of progressive fibrosis, cirrhosis and end-stage liver disease. 
There is strong evidence that IR and increased FFA are a major cause of NASH (Brunt, 2004; 
Konopelska et al., 2009; Ratziu et al., 2010; Scheen & Luyckx, 2002). Inflammation plays an 
important additional role with increased production of reactive oxygen species and pro-
inflammatory cytokines. In addition, several studies support a link between VAT and 
NASH (Kern et al., 2003; Konopelska et al., 2009; McCullough & Falck-Ytter, 1999). 
Konopelska et al., for the first time in patients with elevated liver enzymes (that after liver 
biopsies had histological diagnosis of normality, steatosis, NASH and other forms of 
hepatitis or cirrhosis), found no association between increased liver fat accumulation or 
different stages of liver inflammation and hepatic 11β-HSD1 expression, suggesting that, 
probably, there is no major role of this enzyme in the inflammatory process from fatty liver 
to NASH in humans (Konopelska et al., 2009). In contrast, as mentioned before, transgenic 
mice with hepatic overexpression of 11β-HSD1 develop fatty liver and dyslipidemia 
(Paterson et al., 2004). 11β-HSD1 expression correlated positively with H6PDH expression in 
the liver and negatively with waist-to-hip ratio in women (this being in accordance to 
obesity results we have mentioned previously). No evaluation of 11β-HSD1 and H6PDH 
protein or activity levels was done (Konopelska et al., 2009). 
Given all the above evidences, 11β-HSD1 has thus emerged as a major potential drug target 
for the treatment of obesity and its associated metabolic abnormalities.  
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7. 11β-HSD1 inhibition studies  
Several and distinct selective 11β-HSD1 inhibitors are being produced, developed and tested 
in vitro, ex vivo and in vivo, in normal animals, rodent models of metabolic alterations or 
disease (hyperglycemia, dyslipidemia, atherosclerosis, IR, T2DM, obesity, diet-induced 
obesity and/or MetSyn) and some of them already in humans, healthy or not (Alberts et al., 
2002; Alberts et al., 2003; Barf et al., 2002; Bhat et al., 2008; Bujalska et al., 2008a; Cho et al., 
2009; Cooper & Stewart, 2009; Coppola et al., 2005; Courtney et al., 2008; Feig et al., 2011; 
Gathercole & Stewart, 2010; Ge et al., 2010; Hale et al., 2008; Hale & Wang, 2008; 
Hermanowski-Vosatka et al., 2005; Hollis & Huber, 2011; Hughes et al., 2008; Hult et al., 
2006; Johansson et al., 2008; Julian et al., 2008; J. Liu et al., 2011; Morgan et al., 2009; Morgan 
& Tomlinson, 2010; Morton, 2010; Park et al., 2011; Rosenstock et al., 2010; S. Shah et al., 
2011; U. Shah et al., 2010; Siu et al., 2009; Stewart & Tomlinson, 2009; Tiwari, 2010; Tu et al., 
2008; van Raalte et al., 2009; Véniant et al., 2010; S. J. Wang et al., 2006; Webster et al., 2010; 
Yuan et al., 2007; X. Zhang et al., 2009b). Besides inhibition of 11β-HSD1 reductase activity, 
increase of 11β-HSD1 dehydrogenase (oxidase) activity, without inhibition of 11β-HSD2, 
may provide a better therapeutic strategy for T2DM, obesity and MetSyn (Ge et al., 2010). 
11β-HSD1 is also inhibited by natural compounds, such as an active ingredient of various 
Chinese herbs (emodin), derivatives or analogues of the licorice root, coffee extract,  
flavanone (and the monohydroxylated flavonoid 2′-hydroxyflavanone), endogenous 
steroids and their metabolites and bile acids (Andrews et al., 2003; Atanasov et al., 2006; 
Chalbot & Morfin, 2006; Classen-Houben et al., 2009; Diederich et al., 2000; Feng et al., 2010; 
Gathercole & Stewart, 2010; Hollis & Huber, 2011; Latif et al., 2005; Livingstone & Walker, 
2003; Maeda et al., 2010; Monder et al., 1989; Morris et al., 2004; Odermatt & Nashev, 2010; 
Sandeep et al., 2005; Schweizer et al., 2003; Su et al., 2007; Taylor et al., 2008; Tomlinson et 
al., 2007; van Raalte et al., 2009; Walker et al., 1995a; Wamil & Seckl, 2007). Glycyrrhetinic 
acid, the active pharmacological ingredient of the licorice root and some of its derivatives, as 
well as its steroidal synthetic analogue carbenoxolone (hemisuccinate derivative of 
glycyrrhetinic acid) are inhibitors of both 11β-HSD1 and 11β-HSD2 (the magnitude of the 
effect being dependent on in vitro versus in vivo environment, dose, administration mode, 
tissue and specie as well as compound structure) (Abdallah et al., 2005; Andrews et al., 2003; 
Classen-Houben et al., 2009; Gathercole & Stewart, 2010; Hollis & Huber, 2011; Jellinck et al., 
1993; Livingstone & Walker, 2003; Monder et al., 1989; Sandeep et al., 2005; Su et al., 2007; 
Taylor et al., 2008; Tomlinson et al., 2007; van Raalte et al., 2009; Walker et al., 1995a; Wamil 
& Seckl, 2007). Both 7-oxygenated steroids and 7-ketocholesterol modulate 11-HSD1 activity 
(Balázs et al., 2009; Odermatt & Nashev, 2010; Wamil et al., 2008; Wamil & Seckl, 2007). 
From all the bile salts tested in vitro and found to inhibit 11β-HSD1, Diederich et al. reported 
that chenodesoxycholic acid does not affect in vivo the activity of 11β-HSD1 when given in 
therapeutic doses to healthy men (Diederich et al., 2011).  
7.1 Human 11β-HSD1 inhibition studies  
In a study with carbenoxolone it is observed, in healthy non-diabetic men, a small (although 
significant) increase in whole body insulin sensitivity (Hollis & Huber, 2011; Walker et al., 
1995a). Walker et al. infered that carbenoxolone, by inhibiting hepatic 11β-HSD1 and reducing 
intra-hepatic cortisol concentration, increases hepatic insulin sensitivity and decreases hepatic 
glucose production (Walker et al., 1995b). Further developing their research on carbenoxolone 
11β-HSD1 inhibition, Walker et al. report decreased glucagon-stimulated glucose production 
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1997). HSD11B2 can be epigenetically regulated, what is also involved in hypertension 
development (Millis, 2011). In the same line, defects and polymorphisms in HSD11B2 have 
also been shown to play a role in human hypertension and cardiovascular disease [e.g. 
essential hypertension (Soro et al., 1995; Walker et al., 1993) and ‘salt-sensitive’ hypertension 
(Lovati et al., 1999)] (Bailey et al., 2008; Cooper & Stewart, 2009; Henschkowski et al., 2008). 
Campino et al. reported a high percentage of alterations in the cortisol metabolism at the 
pre-receptor level in hypertensive patients, previously misclassified as having essential 
hypertension, where 18% of the patients present reduced 11β-HSD2  activity or imbalance of 
11β-HSD1 activity in comparison to 11β-HSD2 (Campino et al., 2010). As referred above, 
hypertension is induced in mice genetically modified to overexpress 11β-HSD1 either in the 
liver or AT (Masuzaki et al., 2003; Paterson et al., 2004). HSD11B1 polymorphisms have been 
described, affecting enzyme expression and activity in vitro and/or in vivo, and/or being 
associated with hypertension (Franks et al., 2004; Malavasi et al., 2010; Morales et al., 2008). 
Variants of HSD11B1 were associated with the risk of hypertension in Pima Indians (Franks 
et al., 2004). Liu et al. showed that suppression of 11β-HSD1 expression in the renal medulla 
attenuates salt-induced hypertension in Dahl salt-sensitive rats (Y. Liu et al., 2008). Taking 
into consideration that diet is one important factor on MetSyn development, it is interesting 
to mention that in Dahl salt-sensitive hypertensive rats, fed a high-salt diet for 4 weeks, peri-
renal AT corticosterone concentration and 11β-HSD1 activity as well as GR, 11β-HSD1 and 
TNF-α expression increase when compared with Dahl salt-resistant rats fed the same diet 
(Usukura et al., 2009).  
6.4 11β-HSD1 and NAFLD 
NAFLD is being increasingly recognized as a common liver disorder that represents the 
hepatic manifestation of the MetSyn. NAFLD is more frequent among people with T2DM 
and obesity, and it is almost universal amongst T2DM patients who are morbidly obese 
(Bellentani et al., 2000; Fabbrini et al., 2010; Gupte et al., 2004; Konopelska et al., 2009; Ratziu 
et al., 2010; Wree et al., 2010). Non-alcoholic steatohepatitis (NASH) is the progressive form 
of liver injury that carries a risk of progressive fibrosis, cirrhosis and end-stage liver disease. 
There is strong evidence that IR and increased FFA are a major cause of NASH (Brunt, 2004; 
Konopelska et al., 2009; Ratziu et al., 2010; Scheen & Luyckx, 2002). Inflammation plays an 
important additional role with increased production of reactive oxygen species and pro-
inflammatory cytokines. In addition, several studies support a link between VAT and 
NASH (Kern et al., 2003; Konopelska et al., 2009; McCullough & Falck-Ytter, 1999). 
Konopelska et al., for the first time in patients with elevated liver enzymes (that after liver 
biopsies had histological diagnosis of normality, steatosis, NASH and other forms of 
hepatitis or cirrhosis), found no association between increased liver fat accumulation or 
different stages of liver inflammation and hepatic 11β-HSD1 expression, suggesting that, 
probably, there is no major role of this enzyme in the inflammatory process from fatty liver 
to NASH in humans (Konopelska et al., 2009). In contrast, as mentioned before, transgenic 
mice with hepatic overexpression of 11β-HSD1 develop fatty liver and dyslipidemia 
(Paterson et al., 2004). 11β-HSD1 expression correlated positively with H6PDH expression in 
the liver and negatively with waist-to-hip ratio in women (this being in accordance to 
obesity results we have mentioned previously). No evaluation of 11β-HSD1 and H6PDH 
protein or activity levels was done (Konopelska et al., 2009). 
Given all the above evidences, 11β-HSD1 has thus emerged as a major potential drug target 
for the treatment of obesity and its associated metabolic abnormalities.  
 
11-Hydroxysteroid Dehydrogenase Type 1 and the Metabolic Syndrome 
 
35 
7. 11β-HSD1 inhibition studies  
Several and distinct selective 11β-HSD1 inhibitors are being produced, developed and tested 
in vitro, ex vivo and in vivo, in normal animals, rodent models of metabolic alterations or 
disease (hyperglycemia, dyslipidemia, atherosclerosis, IR, T2DM, obesity, diet-induced 
obesity and/or MetSyn) and some of them already in humans, healthy or not (Alberts et al., 
2002; Alberts et al., 2003; Barf et al., 2002; Bhat et al., 2008; Bujalska et al., 2008a; Cho et al., 
2009; Cooper & Stewart, 2009; Coppola et al., 2005; Courtney et al., 2008; Feig et al., 2011; 
Gathercole & Stewart, 2010; Ge et al., 2010; Hale et al., 2008; Hale & Wang, 2008; 
Hermanowski-Vosatka et al., 2005; Hollis & Huber, 2011; Hughes et al., 2008; Hult et al., 
2006; Johansson et al., 2008; Julian et al., 2008; J. Liu et al., 2011; Morgan et al., 2009; Morgan 
& Tomlinson, 2010; Morton, 2010; Park et al., 2011; Rosenstock et al., 2010; S. Shah et al., 
2011; U. Shah et al., 2010; Siu et al., 2009; Stewart & Tomlinson, 2009; Tiwari, 2010; Tu et al., 
2008; van Raalte et al., 2009; Véniant et al., 2010; S. J. Wang et al., 2006; Webster et al., 2010; 
Yuan et al., 2007; X. Zhang et al., 2009b). Besides inhibition of 11β-HSD1 reductase activity, 
increase of 11β-HSD1 dehydrogenase (oxidase) activity, without inhibition of 11β-HSD2, 
may provide a better therapeutic strategy for T2DM, obesity and MetSyn (Ge et al., 2010). 
11β-HSD1 is also inhibited by natural compounds, such as an active ingredient of various 
Chinese herbs (emodin), derivatives or analogues of the licorice root, coffee extract,  
flavanone (and the monohydroxylated flavonoid 2′-hydroxyflavanone), endogenous 
steroids and their metabolites and bile acids (Andrews et al., 2003; Atanasov et al., 2006; 
Chalbot & Morfin, 2006; Classen-Houben et al., 2009; Diederich et al., 2000; Feng et al., 2010; 
Gathercole & Stewart, 2010; Hollis & Huber, 2011; Latif et al., 2005; Livingstone & Walker, 
2003; Maeda et al., 2010; Monder et al., 1989; Morris et al., 2004; Odermatt & Nashev, 2010; 
Sandeep et al., 2005; Schweizer et al., 2003; Su et al., 2007; Taylor et al., 2008; Tomlinson et 
al., 2007; van Raalte et al., 2009; Walker et al., 1995a; Wamil & Seckl, 2007). Glycyrrhetinic 
acid, the active pharmacological ingredient of the licorice root and some of its derivatives, as 
well as its steroidal synthetic analogue carbenoxolone (hemisuccinate derivative of 
glycyrrhetinic acid) are inhibitors of both 11β-HSD1 and 11β-HSD2 (the magnitude of the 
effect being dependent on in vitro versus in vivo environment, dose, administration mode, 
tissue and specie as well as compound structure) (Abdallah et al., 2005; Andrews et al., 2003; 
Classen-Houben et al., 2009; Gathercole & Stewart, 2010; Hollis & Huber, 2011; Jellinck et al., 
1993; Livingstone & Walker, 2003; Monder et al., 1989; Sandeep et al., 2005; Su et al., 2007; 
Taylor et al., 2008; Tomlinson et al., 2007; van Raalte et al., 2009; Walker et al., 1995a; Wamil 
& Seckl, 2007). Both 7-oxygenated steroids and 7-ketocholesterol modulate 11-HSD1 activity 
(Balázs et al., 2009; Odermatt & Nashev, 2010; Wamil et al., 2008; Wamil & Seckl, 2007). 
From all the bile salts tested in vitro and found to inhibit 11β-HSD1, Diederich et al. reported 
that chenodesoxycholic acid does not affect in vivo the activity of 11β-HSD1 when given in 
therapeutic doses to healthy men (Diederich et al., 2011).  
7.1 Human 11β-HSD1 inhibition studies  
In a study with carbenoxolone it is observed, in healthy non-diabetic men, a small (although 
significant) increase in whole body insulin sensitivity (Hollis & Huber, 2011; Walker et al., 
1995a). Walker et al. infered that carbenoxolone, by inhibiting hepatic 11β-HSD1 and reducing 
intra-hepatic cortisol concentration, increases hepatic insulin sensitivity and decreases hepatic 
glucose production (Walker et al., 1995b). Further developing their research on carbenoxolone 
11β-HSD1 inhibition, Walker et al. report decreased glucagon-stimulated glucose production 
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and glycogenolysis in T2DM men (non-obese normotensive, treated with diet alone), but not 
in healthy subjects, and decreased total cholesterol in healthy subjects, but not in T2DM 
patients. Carbenoxolone has no effect on gluconeogenesis, peripheral glucose uptake or 
insulin-mediated reduction of plasma FFA (Andrews et al., 2003). So, as just described, 
carbenoxolone enhances hepatic insulin sensitivity in healthy men and in non-obese 
normotensive T2DM. However, Sandeep et al. describe later, in non-diabetic obese men, a 
highly effective inhibition of whole-body 11-HSD turnover by carbenoxolone, but without 
inhibiting the conversion of cortisone to cortisol in SAT or modifying insulin sensitivity 
(Sandeep et al., 2005). Nevertheless, 11β-HSD1 inhibition in AT by carbenoxolone has been 
reported. After both a single dose and posterior 72 h of continuous treatment with 
carbenoxolone, in healthy male volunteers, Tomlinson et al. observe a decrease not only on 
serum cortisol generation, after oral administration of cortisone acetate (although only 
significantly for continuous treatment), but also on cortisol concentrations, after oral cortisone 
acetate, and glycerol concentrations, after oral prednisone, both within SAT interstitial fluid (in 
the latter location being indicative of inhibition of GC-mediated lipolysis) (Tomlinson et al., 
2007). It is important to mention that 11-HSD2 inhibition, with licorice or carbenoxolone, can 
lead to cortisol-dependent mineralocorticoid excess, with hypertension, sodium retention, 
hypokalemia and fluid retention (Andrews et al., 2003; Edwards et al., 1988; Ferrari, 2010; 
Gathercole & Stewart, 2010; Palermo et al., 2004; Stewart et al., 1990; Stewart et al., 1987). 11β-
HSD2 is expressed principally in the distal nephron, where it inactivates cortisol to cortisone 
and thereby protects MR from cortisol (Andrews et al., 2003; Edwards et al., 1988; Ferrari, 2010; 
Funder et al., 1988; Palermo et al., 2004). PF-915275 is a potent and selective 11β-HSD1 
inhibitor, without adverse side effects in a wide range of orally tested doses, that is selective 
for the human and primate enzymes (Bhat et al., 2008; Courtney et al., 2008). A modest 
pharmacodynamic effect of PF-915275 on 11β-HSD1 activity in the healthy human liver is 
reported, but experiments to assess its inhibitory effect in the AT have not been performed 
(Courtney et al., 2008; Hollis & Huber, 2011). So far, to our knowledge, there are no reports of 
PF-915275 activity in patients with T2DM or MetSyn (or any of the associated components). 
Bhat et al. showed, in normal cynomolgus monkeys, that PF-915275 dose-dependently inhibits 
11β-HSD1-mediated conversion of prednisone to prednisolone and reduces insulin levels 
(Bhat et al., 2008). Hollis et al. reviewed the clinical results obtained with the selective 11β-
HSD1 inhibitor INCB13739. In patients with T2DM inadequately controlled with metformin, 
INCB13739 treatment achieves significant reductions in hemoglobin A1c, fasting plasma 
glucose and HOMA-IR (homeostasis model assessment-IR), and improves hyperlipidemia and 
hypertriglyceridemia (when present). Adverse events (occurring in ≥ 3%: nasopharyngitis, 
headache, diarrhea, cough, nausea, arthralgia and upper respiratory tract infection) were 
similar across all treatment groups. Interestingly, those positive effects are observed primarily 
in subjects categorized as obese (BMI > 30 kg/m²) and not in subjects categorized as 
overweight (BMI ≤ 30 kg/m²), underscoring the likely importance of AT 11β-HSD1 activity to 
the cardiometabolic sequelae of obesity (Hollis & Huber, 2011; Rosenstock et al., 2010). Feig et 
al. showed that 11β-HSD1 selective inhibition with MK-0916 is generally well tolerated in 
patients with T2DM and MetSyn (NCEP ATP III-defined) (Feig et al., 2011; S. Shah et al., 2011). 
Although no significant improvement in fasting plasma glucose is observed with MK-0916 
compared to placebo, modest improvements in hemoglobin A1c, body weight and blood 
pressure are observed (Feig et al., 2011). These patients were only mildly hypertensive, with 
55% receiving ongoing anti-hypertensive therapy, and yet treatment with MK-0916 led to 
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reductions from baseline of 7.9 and 5.4 mmHg in systolic and diastolic blood pressure, 
respectively, relative to placebo (Feig et al., 2011; S. Shah et al., 2011). Further developing the 
research on 11β-HSD1 selective inhibition, Shah et al. reported that, in overweight-to-obese 
hypertensive patients, reduction in trough sitting diastolic blood pressure with MK-0736 is not 
statistically significant. Nonetheless, MK-0736 is well tolerated and appears to modestly 
improve other blood pressure endpoints as well as LDL-cholesterol and body weight. The 24 h 
ambulatory blood pressure measurements data (from the subset of patients who participated 
in ambulatory blood pressure measurements) suggest that MK-0736 has blood pressure-
lowering efficacy over a 24 h period not adequately represented by measuring sitting diastolic 
blood pressure and sitting systolic blood pressure, notably a greater blood pressure-lowering 
effect during daytime than during night-time (S. Shah et al., 2011). 11β-HSD1 inhibitors may 
improve a number of metabolic disturbances, unlike current available anti-diabetic 
compounds, that occur in obesity, T2DM and/or MetSyn patients, as seen from genetically 
engineered animal studies (Kotelevtsev et al., 1997; Morton et al., 2001; Morton et al., 2004) as 
well as from animal (Alberts et al., 2002; Alberts et al., 2003; Barf et al., 2002; Cooper & Stewart, 
2009; Feng et al., 2010; Gathercole & Stewart, 2010; Hermanowski-Vosatka et al., 2005; 
Johansson et al., 2008; J. Liu et al., 2011; Livingstone & Walker, 2003; Morgan et al., 2009; Park 
et al., 2011; Taylor et al., 2008; Véniant et al., 2010; S. J. Wang et al., 2006; X. Zhang et al., 2009b) 
and human 11β-HSD1 inhibition studies (Andrews et al., 2003; Courtney et al., 2008; Feig et al., 
2011; Gathercole & Stewart, 2010; Hollis & Huber, 2011; Morton, 2010; Rosenstock et al., 
2010; Sandeep et al., 2005; S. Shah et al., 2011; Tomlinson et al., 2007; van Raalte et al., 2009; 
Walker et al., 1995a; Wamil & Seckl, 2007). Taking this into account, pharmacological 
inhibition of 11β-HSD1 to lower intracellular cortisol concentrations in the liver and AT, 
without altering circulating cortisol concentrations or responses to stress, is an exciting 
potential therapy in those conditions and likely to be most effective in obese T2DM patients 
(Andrews et al., 2003; Courtney et al., 2008; Feig et al., 2011; Gathercole & Stewart, 2010; 
Hollis & Huber, 2011; Morton, 2010; Rosenstock et al., 2010; Sandeep et al., 2005; S. Shah et 
al., 2011; R.  Stimson et al., 2011; Tomlinson et al., 2007; van Raalte et al., 2009; Walker et al., 
1995a; Wamil & Seckl, 2007). 
8. Conclusion 
According to the rising prevalence of the MetSyn and the burden of its associated 
cardiometabolic complications, the study of the mechanisms of disease as well as of possible 
prophylactic and therapeutic approaches is becoming increasingly necessary. The 
recognition of the involvement of GCs and 11β-HSD1, as likely etiological factors, adds new 
avenues for MetSyn management. Lately, research focusing on 11β-HSD1 inhibition has 
shown promising results. The role of dietary patterns on MetSyn development and of 
dietary components on 11β-HSD1 modulation for the prevention and/or treatment of 
metabolic disorders is now starting to be unraveled and may be a worthwhile investigation. 
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Hollis & Huber, 2011; Morton, 2010; Rosenstock et al., 2010; Sandeep et al., 2005; S. Shah et 
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1. Introduction  
In the last 50 years the increase in the frequency of male reproductive abnormalities has 
been observed in human (Auger et al., 1995; Bergström et al., 1996; Carlsen et al., 1992; 
Skakkebaek et al., 2001; Thonneau et al., 2003). Epidemiological studies have shown 
increasing trends in the incidence of cryptorchidism (undescended testis) and hypospadias 
(abnormal location of the urethral opening) in several regions of Australia, Europe, and the 
United States (Acerini et al., 2009; Boisen et al., 2004; Källén et al., 1986; Nassar et al., 2007; 
Paulozzi, 1999; Toppari et al., 2001). Moreover, several reports indicated that semen quality 
have declined during last century (Auger et al., 1995; Carlsen et al., 1992; Swan et al., 2000; 
Sharpe & Irvine, 2004). Decreasing sperm concentration and percentage of motile 
spermatozoa, and increasing number of spermatozoa with morphological alterations were 
observed in European population between 1940 and 1990. For instance, it has been found 
that the prevalence of an abnormally low sperm count in young men reaches even 15–20% 
(Andersson et al., 2008; Jørgensen et al., 2006, 2011). In earlier study by Jørgensen et al. 
(2001) significant geographical variations in semen quality have been also described. 
Although, the reason for these regional differences is not fully elucidated, some data 
indicate that a correlation exists between impaired semen quality and exposure to pesticides 
used in agricultural areas (Swan et al., 2003). Interestingly, it has been noticed that in the 
industrial areas, where peoples are exposed to high levels of industrial chemicals, the birth 
sex ratio can be altered; in some region of Canada male birth sex ratio (i.e. number of male 
births per total number of births) have reached only 0.3 during the period 1990 – 2003 
(Mackenzie et al., 2005).  
In 2001 Skakkebaeck and co-workers have suggested that cryptorchidism, hypospadias, 
testicular cancer and oligozoospermia are interrelated disorders comprising a single 
syndrome, called the testicular dysgenesis syndrome (TDS) (Skakkebaeck et al., 2001; 
Skakkebaeck & Jørgensen, 2005). This idea arose from the observation that cryptorchidism 
and hypospadias are closely linked to testicular cancer, because in men with a history of one 
of these anomalies significantly increased risk of testicular cancer was described (Davenport 
et al., 1997; Dieckmann & Pichlmeier, 2004; Sharpe & Irvine, 2004). Moreover, 
oligozoospermia is frequently found in men, who develop testicular cancer (Møller & 
Skakkebaek, 1999). The disorders included in TDS are believed to result from disruption of 
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hormone synthesis or action during fetal development of reproductive system. Indeed, 
numerous experimental studies have demonstrated that prenatal exposure to some 
environmental chemicals may disrupt the endocrine system in males and thus interfere 
with hormone-dependent development (Delbès et al., 2006; Fisher, 2004a; Gray et al., 
2006). 
Male reproductive system anomalies have been also reported in wild living animals (Vos et 
al., 2000). In fish, sexual reversal, decreased sperm count and motility, and spermatogenesis 
impairment were noticed (Barnhoorn et al., 2004; Jobling et al., 2002; Vajda et al., 2008). 
Feminization and abnormal gonadal development were observed in reptiles and birds (De 
Solla et al., 1998, 2006; Fry, 1995; Guillette et al., 1994), whereas in mammals, such as 
panthers or polar bears cryptorchidism and reduced size of reproductive organs were found 
(Mansfield & Land, 2002; Sonne et al., 2006). An interesting example of the species in which 
environmental pollutants may be the cause of reproductive system abnormalities is Sitka 
Black-Tailed Deer. It was reported that in the population living in the Aliulik Peninsula of 
Kodiak Island extraordinary high percentage (75%) of the males exhibited cryptorchidism 
when compared with males living elsewhere on the Kodiak Archipelago, among which only 
12% were cryptorchid (Bubenik et al., 2001; Veeramachaneni et al., 2006a). Additionally, 
abnormal antlers and testicular neoplasia were frequently observed in cryptorchid deer 
from Aliulik Peninsula. The authors hypothesized that it was likely that testis and antler 
dysgenesis resulted from exposure of pregnant female (or alternatively, historic exposure of 
founders) to some estrogenic endocrine disrupting agent(s) present in the environment 
(Veeramachaneni et al., 2006a).  
Although the substances affecting endocrine system were studied from 1950’, the term 
“endocrine disruptor” was introduced in 1991 at Wingspread Conference, organized to 
evaluate the adverse effects observed in wildlife in the Great Lakes region in North America 
(Colborn & Clement, 1992; Colborn et al., 1993). According the World Health Organization 
(2006) endocrine disruptor (ED) is “an exogenous chemical substance or mixture that alters 
the function(s) of the endocrine system and thereby causes adverse effects to an organism, 
its progeny, or a (sub)population”. In 2009, The Endocrine Society presented the Scientific 
Statement in which endocrine disruptor was defined as “a compound, either natural or 
synthetic, which through environmental or inappropriate developmental exposure alters the 
hormonal and homeostatic systems that enable the organism to communicate with and 
respond to its environment” (Diamanti-Kandarakis et al., 2009). 
2. Role of androgens and estrogens in male reproductive tract development 
and function 
Androgens are steroid hormones that play a central role in the development and function of 
male reproductive system (Dohle et al., 2003). The principal androgens are testosterone and 
dihydrotestosterone (DHT). High amounts of testosterone are produced in the testes from 
early stages of fetal development until birth. During prenatal period testosterone is 
necessary for the differentiation of Wolffian duct into the epididymis, vas deferens and 
seminal vesicles. It is also involved in the process of testis descent. DHT, synthesized from 
testosterone by the action of 5α-reductase, mediates the masculinization of external genitalia 
and prostate. Studies by Welsh et al. (2008) revealed the existence of a fetal “masculinization 
programming window”, a period within which androgens action is necessary to ensure 
correct later development of the male reproductive system. Blockade of androgen action 
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only during this critical period by using androgen receptor antagonists (e.g., flutamide) 
suppresses development of the male accessory glands and disrupts testis descent leading to 
cryptorchidism (Macleod et al., 2010; Welsh et al., 2008). In rat masculinization programming 
window occurs at 15.5–18.5 gestational days, whereas in human it spans from 
approximately 8 to 14 weeks of gestation (Welsh et al., 2008). In neonates testosterone level 
is high for a short time, then its production decreases and is maintained at low level until 
puberty, when rising androgen level mediate growth and function of accessory sex glands, 
initiation of spermatogenesis and development of secondary male sex characteristics. In 
mature males androgen action is essential for the maintenance of male phenotype and 
fertility (Dohle et al., 2003).  
The discovery that aromatase (the enzyme converting androgens to estrogens) and estrogen 
receptors α and β (ERα and ER β) are expressed in male reproductive tract and studies on 
transgenic mouse models with inactivated estrogen receptor α (α ERKO) or aromatase genes 
(ArKO) led to the conclusion that not only androgens, but also estrogens are important for 
development and physiology of male reproductive system (Bilinska et al., 1997; Carreau et 
al., 2003; Levallet et al., 1998; Lubahn et al., 1993; Kuiper et al., 1996; Robertson et al., 1999). 
It was demonstrated that during fetal and neonatal life estrogens are involved in control of 
gametogenesis, promoting germ cell and seminiferous tubule development, and in the 
regulation of fetal Leydig cell steroidogenesis (Albrecht et al., 2009; Delbés et al., 2005; 
Vigueras-Villaseñor et al, 2006). Aromatase and ERs are transiently expressed in the 
hippocampus of newborn males, suggesting that estrogens are involved in brain 
masculinization (McEwen & Alves, 1999). In the reproductive system of adult males the role 
of ERs is associated with the maintenance of fluid reabsorption in the excurrent ducts of the 
testis (Hess, 2000; Hess et al., 1997). Data from studies on male mice with knockout of ERα 
suggested that long-term atrophy of the testes, observed in these animals, was caused by 
backpressure of the accumulating luminal fluids. Moreover, estrogens appear to have direct 
effects on the Leydig cell, controlling testosterone synthesis, and possibly on the 
seminiferous epithelium (Akingbemi et al., 2003; Hess, 2003). In male, estrogens play also a 
physiological role in non-reproductive tissues and organs such as bone and cardiovascular 
system (Oettel, 2002). 
Although endogenous estrogens are necessary for normal male fertility, excessive 
production of these hormones or exposure to exogenous estrogens during fetal or neonatal 
life could produce adverse outcomes, affecting reproductive system development and adult 
reproductive functions. Destructive effects of estrogen overexposure on the development of 
post-meiotic germ cells and testicular atrophy was observed in rodents and humans 
(Gancarczyk et al., 2004; Toyama et al., 2001; Williams et al., 2001). Moreover, 
cryptorchidism, spermatogenic arrest, Leydig cell hyperplasia, and decreased serum follicle-
stimulating hormone (FSH) and testosterone levels have been reported in the transgenic 
mouse model with aromatase overexpression (Fowler et al., 2000; Li et. al., 2001). 
3. Antiandrogens  
Antiandrogens are defined as chemicals that interfere with androgen action or production. 
The compounds shown to have antiandrogenic properties include pharmaceuticals (e.g., 
flutamide, ketoconazole) as well as environmental contaminants: pesticides (e.g., 
vinclozolin, linuron) and industrial chemicals (e.g., di(n-butyl) phthalate). 
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3.1 Flutamide as a model antiandrogen  
Flutamide, a pharmaceutical used in therapy of androgen-dependent prostate cancer, and its 
active metabolite hydroxyflutamide, are non-steroidal synthetic androgen receptor (AR) 
antagonists, which display pure antiandrogenic activity, without exerting agonistic or any 
other hormonal activity (Neri, 1989; Singh et al., 2000). Flutamide is regarded as a model 
antiandrogen and in experimental studies it is often used as a positive control in screening 
assays used for the identification of endocrine disruptors (O’Connor et al., 1998).  
In utero exposure to flutamide was shown to alter reproductive development and function in 
male rat offspring (Mikkila et al., 2006). Recently, it was reported that flutamide interferes 
with desert hedgehog (Dhh) signaling in the fetal testis, resulting in impaired fetal Leydig 
cell differentiation. Leydig cell dysfunction was reflected by suppressed levels of insulin-like 
factor 3 (Insl-3) and testosterone and reduced expression of steroidogenic enzymes, 
cytochrome P450scc and 3β-hydroxysteroid dehydrogenase (3β-HSD) (Brokken et al., 2009). 
Insufficient levels of testosterone and Insl-3 in the fetal testis could, in turn, prevent full 
masculinization. Decrease in gonad and accessory sex glands weight, cryptorchidism, 
testicular histological lesions and increased germ cell apoptosis have been reported in adult 
male rats exposed to flutamide during fetal period, indicating that flutamide exerts long-
term antiandrogenic effects (Omezzine et al., 2003).  
In our recent studies flutamide (50 mg/kg bw) was injected into pregnant gilts during 
gestational days 20–28 and 80–88, and into male piglets on postnatal days 2–10. We found 
no changes in testicular morphology of neonatal pigs in utero exposed to flutamide, 
whereas in prepubertal males some of the seminiferous tubules were altered, exhibiting 
reduced number of Sertoli cells and dilated lumina (Durlej et al., 2011; Kopera et al., 2010). 
Testes of adult pigs exposed to flutamide in utero exhibited moderate alterations of the 
spermatogenic process: seminiferous tubules showed degeneration of germ cells and their 
extensive sloughing into the lumen of the seminiferous tubules, however all generations 
of germ cells could be recognized in the seminiferous epithelium. Testes of neonatally 
exposed boars contained severely altered seminiferous tubules, exhibiting drastic increase 
in the number of apoptotic germ cells, hypospermatogenesis or spermatogenic arrest at 
the spermatocyte level. Alterations of normal histological structure were accompanied by 
decreased expression and/or disturbed localization of intercellular junction proteins, 
connexin 43, N-cadherin, β-catenin and ZO-1 in the seminiferous epithelium (Hejmej et 
al., 2011a; Kopera et al., 2011). Also interstitial tissue was adversely affected; Leydig cells 
displayed hyperplasia or hypertrophy, increased expression of aromatase and reduced 
expression of LH receptor. Dysfunction of Leydig cells led to disruption of androgen-
estrogen balance (Kotula-Balak et al., submitted for publication). These data suggest that 
in pigs flutamide acting during fetal, and especially, neonatal period can reprogram the 
development of testicular cells, leading to morphological and functional alterations of the 
testis at adulthood. 
Interestingly, flutamide exposure has also long-term effects on sperm morphology. Our data 
showed that in sperm derived from neonatally-treated boars either flattened head or 
abnormal sperm with altered shape of the acrosome and abnormal packaging of sperm 
chromatin were frequently observed. Prepuberal treatment with flutamide resulted in an 
increased number of sperm displaying abnormal midpiece or tail defects (Lydka et al., 
submitted for publication)  
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Several studies demonstrated the effects of short-term androgen blockage induced by the 
administration of flutamide to immature or mature males. In immature rats structure of 
interstitial tissue and seminiferous epithelium, and the expressions of steroidogenesis-
related genes, Cyp11a1 and StAR, were significantly affected by flutamide treatment (Vo et 
al., 2009). When administered to pubertal animals, flutamide accelerated testes maturation, 
causing degeneration and detachment of primary spermatocytes and round spermatids 
(Maschio et al., 2010). In adult males, germ-cell degeneration, alterations in ectoplasmic 
specialization between the Sertoli cell and spermatids, and premature detachment of 
spermatids, as well as increase in the relative volume of Leydig cells were observed 
(Anahara et al., 2008; Maschio et al., 2008). Moreover, our in vitro results showed that pig 
sperm incubated with hydroxyflutamide (50 and 100 μg/mL) displayed disorders in sperm 
phospholipid membrane, decreased oxidative capability of sperm mitochondria and 
decreased sperm membrane integrity (Lydka et al., submitted for publication)  
3.2 Environmental antiandrogens 
3.2.1 Pesticides: procymidone, vinclozolin, prochloraz, linuron and p,p’DDE 
Procymidone is used as a fungicide for the control of plant diseases. High quantities of this 
compound were found in rice, tomatoes and grapes (Gebara et al., 2011; US Environmental 
Protection Agency annual report, 1994). When administered to pregnant rats, the male pups 
displayed a reduced anogenital distance, nipple retention, hypospadias, cleft phallus, and 
reduced sex accessory gland size (Gray et al., 1999; Ostby et al., 1999). Moreover, in prostate 
and seminal vesicles fibrosis, cellular infiltration and epithelial hyperplasia were observed 
(Ostby et al., 1999). Chronic treatment of male rats with procymidone inhibited the negative 
feedback exerted by androgens on the hypothalamus and/or the pituitary, causing 
enhanced luteinizing hormone (LH) secretion and Leydig cell steroidogenesis, and in 
consequence, increased serum testosterone level (Hosokawa et al., 1993; Svechnikov et al., 
2005). Such a long-term hyperstimulation of Leydig cells induces Leydig cell tumors 
(Murakami et al., 1995). 
Vinclozolin is a dicarboximide fungicide used in the control of Botrytis cinerea, Sclerotinia 
sclerotiorum, and Moniliniam spp on vegetables, fruits and ornamental plants. Vinclozolin and 
its two active metabolites, M1 and M2, compete for androgen binding to AR and inhibit AR 
transactivation and androgen-dependent gene expression (Wong et al., 1995). 
Administration of vinclozolin to pregnant rats resulted in abnormalities of androgen-
regulated sexual differentiation in male offspring, including reduced anogenital distance, 
nipple retention, hypospadias, cryptorchidism, decreased sex accessory gland growth as 
well as in induction of prostate inflammation and reduced sperm production at adulthood 
(Cowin et al., 2010; Gray et al. 1994; 1999). Vinclozolin has also been implicated in epigenetic 
modifications of male reproductive tract via changes in DNA methyltransferase expression 
(Anway et al., 2008; Anway & Skinner, 2008). The most sensitive period of rat fetal 
development to the effects of vinclozolin was found to be gestational days 16-17, whereas 
less severe malformations were seen in males exposed during gestational days 14–15 and 
18–19 (Wolf et al. 2000). Peripubertal exposure resulted in delayed pubertal maturation, 
decreased sex accessory gland and epididymal growth concomitantly with increased serum 
levels of LH and testosterone (Monosson et al., 1999).  
Prochloraz is an imidazole fungicide widely used in gardening and agriculture which acts 
as both AR antagonist and inhibitor of fetal testosterone production. In addition to 
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Procymidone is used as a fungicide for the control of plant diseases. High quantities of this 
compound were found in rice, tomatoes and grapes (Gebara et al., 2011; US Environmental 
Protection Agency annual report, 1994). When administered to pregnant rats, the male pups 
displayed a reduced anogenital distance, nipple retention, hypospadias, cleft phallus, and 
reduced sex accessory gland size (Gray et al., 1999; Ostby et al., 1999). Moreover, in prostate 
and seminal vesicles fibrosis, cellular infiltration and epithelial hyperplasia were observed 
(Ostby et al., 1999). Chronic treatment of male rats with procymidone inhibited the negative 
feedback exerted by androgens on the hypothalamus and/or the pituitary, causing 
enhanced luteinizing hormone (LH) secretion and Leydig cell steroidogenesis, and in 
consequence, increased serum testosterone level (Hosokawa et al., 1993; Svechnikov et al., 
2005). Such a long-term hyperstimulation of Leydig cells induces Leydig cell tumors 
(Murakami et al., 1995). 
Vinclozolin is a dicarboximide fungicide used in the control of Botrytis cinerea, Sclerotinia 
sclerotiorum, and Moniliniam spp on vegetables, fruits and ornamental plants. Vinclozolin and 
its two active metabolites, M1 and M2, compete for androgen binding to AR and inhibit AR 
transactivation and androgen-dependent gene expression (Wong et al., 1995). 
Administration of vinclozolin to pregnant rats resulted in abnormalities of androgen-
regulated sexual differentiation in male offspring, including reduced anogenital distance, 
nipple retention, hypospadias, cryptorchidism, decreased sex accessory gland growth as 
well as in induction of prostate inflammation and reduced sperm production at adulthood 
(Cowin et al., 2010; Gray et al. 1994; 1999). Vinclozolin has also been implicated in epigenetic 
modifications of male reproductive tract via changes in DNA methyltransferase expression 
(Anway et al., 2008; Anway & Skinner, 2008). The most sensitive period of rat fetal 
development to the effects of vinclozolin was found to be gestational days 16-17, whereas 
less severe malformations were seen in males exposed during gestational days 14–15 and 
18–19 (Wolf et al. 2000). Peripubertal exposure resulted in delayed pubertal maturation, 
decreased sex accessory gland and epididymal growth concomitantly with increased serum 
levels of LH and testosterone (Monosson et al., 1999).  
Prochloraz is an imidazole fungicide widely used in gardening and agriculture which acts 
as both AR antagonist and inhibitor of fetal testosterone production. In addition to 
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antiandrogenic action, prochloraz antagonizes the estrogen receptor, agonizes the aryl 
hydrocarbon (Ah) receptor and suppresses aromatase activity (Andersen et al., 2002; 
Vinggaard et al., 2006). Gestational exposure significantly reduces testosterone production 
by inhibiting activity of cytochrome P450c17, decreases reproductive organ weights, 
increases nipple retention and induces malformations (e.g., hypospadias) in androgen-
dependent tissues of male offspring (Blystone et al. 2007; Laier et al., 2006; Noriega et al., 
2005; Vinggaard et al., 2005). 
Linuron is a herbicide employed to control of weeds in crops and potatoes (Gray et al., 
2006). It binds AR and inhibits dihydrotestosterone induced gene expression in vitro 
(Lambright et al., 2000). Fetal exposure to linuron resulted in epididymal and testicular 
abnormalities, reduced anogenital distance and nipple retention; however, in contrast to 
other AR antagonists, it does not induce hypospadias and cryptorchidism. Moreover, 
linuron was shown to decrease testosterone production by fetal Leydig cells (McIntyre et al., 
2000, 2002a, 2002b; Wilson et al., 2009). Thus its mechanism of action resembles those of 
phthalates (Gray et al., 2006). Interestingly, when administered to sexually immature and 
mature rats, linuron decreased weights of accessory sex organs, increased serum estradiol 
and LH levels, and produced Leydig cell tumors (Cook et al., 1993). 
p,p’-DDE (dichlorodiphenyldichloroethylene) is a metabolite of the persistent pesticide, 
DDT (dichlorodiphenyltrichloroethane). DTT is now banned in most countries, since in 
1960’ it was discovered that it has endocrine disrupting properties and causes birth defects 
in human and animals. However, it is still used in some regions to prevent malaria and 
other tropical diseases spread by insects (van den Berg et al., 2009). p,p’-DDE acts as AR 
antagonist both in vivo and in vitro (Kelce et al., 1995). Fetal treatment with this compound 
was shown to affect male development, leading to reduced anogenital distance, nipple 
retention and hypospadias (You et al., 1998). Recently, it was reported that p,p’-DDE 
induces testicular apoptosis in pubertal rats through the involvement of Fas/FasL, 
mitochondria and endoplasmic reticulum-mediated pathways (Shi et al., 2011).  
3.2.2 Phthalates  
The diesters of 1,2-benzenedicarboxylic acid, called phthalates, are widely used as 
plasticizers in the production of toys, medical devices, rainwear, food packaging, and 
certain cosmetics (Schettler, 2006). Di-n-butyl phthalate (DBP) and di(2-ethylhexyl) 
phthalate (DEHP) and their metabolites have been shown to cause antiandrogenic effects, 
however, without binding to AR (Frederiksen et al., 2007). Although, the exact mechanism 
of action is not yet fully elucidated, it was demonstrated that phthalates interfere with 
Leydig cell function, reducing the expression of most of genes involved in testosterone 
biosynthesis (Barlow et al., 2003). Fetal exposure to phthalates results in reduced anogenital 
distance, hypospadias, cryptorchidism, malformed epididymis, and nipple retention 
(Mylchreest et al., 1999, 2002; Mylchreest & Foster, 2000). At the histological level, 
multinucleated gonocytes, detachment of gonocytes from the seminiferous epithelium, 
Sertoli cell-only tubules and Leydig cell hyperplasia were found in the testes of males 
exposed to DEHP and DBP (Fisher et al., 2003; Mylchreest et al., 2002; Parks et al., 2000). 
Some of these alterations were permanent and affected testicular function in adulthood, 
resulting in low testosterone level and reduced sperm count. It is worth noting that 
histological changes induced in rat by in utero exposure to phthalates resemble those 
observed in patients with TDS (Fisher, 2004a). 
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4. Xenoestrogens  
Compounds with estrogenic activity, called xenoestrogens, comprise a broad range of 
synthetic chemicals (e.g., diethylstilbestrol, bisphenol-A, octylphenol, nonylphenol), 
naturally occurring phytoestrogens (e.g., genistein, resveratrol) and heavy metals (e.g., 
cadmium, lead, and boron). 
4.1 Diethylstilbestrol (DES) 
DES is synthetic potent non-steroidal estrogen used as a supplement in cattle and poultry 
feed and as a pharmaceutical (Rubin, 2007). DES was given to pregnant women to prevent 
miscarriages or premature deliveries from about 1940 to 1970. It was restricted in 1971 
because of increased risk of a rare reproductive tract cancer, vaginal clear cell 
adenocarcinoma, in daughters of women who had taken DES (Gill et al., 1979; Melnick et al., 
1987). Further studies have reported multiple adverse effects in males and females as a 
result of prenatal DES exposure. In males decreased fertility and anatomical malformations 
of reproductive organs such as cryptorchidism, epididymal cysts and prostatic squamous 
metaplasia were observed (Driscoll & Taylor, 1980; Marselos & Tomatis, 1992; Mittendorf, 
1995).  
Nowadays, experimental animals exposed to DES during fetal and neonatal development 
are useful models for studying mechanisms of endocrine disruption caused by exogenous 
estrogenic compounds (Diamanti-Kandarakis et al., 2009). In male mice exposed to DES 
during gestation, cryptorchidism, hypospadias, as well as underdeveloped epididymis, vas 
deferens and seminal vesicles were observed (McLachlan et al., 2001). Similarly, neonatal 
treatment of male rats with DES induced a wide range of reproductive abnormalities, 
including delay of testicular descent, retardation of pubertal spermatogenesis, reduction in 
testis weight, infertility, and gross morphological alterations in the rete testis, efferent ducts, 
epididymis and accessory sex glands (Atanassova et al., 1999, 2000; Fisher et al., 1999; 
McKinnell et al, 2001; Williams et al., 2001). Testes of adult rats neonatally exposed to DES 
displayed suppression of Leydig cell development and steroidogenesis, reduced Sertoli cell 
proliferation and spermatogenic impairment. It was shown that DES has both direct and 
pituitary-mediated effects on the developing testis, leading to decreased expression of AR 
and reduced FSH level (Sharpe et al., 1998, 2003). Studies on transgenic mouse models with 
inactivated ERs suggest that DES elicits its toxic effects in the male reproductive tract 
through an ERα-mediated mechanism (Prins et al., 2001). 
4.2 Environmental xenoestrogens 
4.2.1 Industrial xenoestrogens: bisphenol A and alkylphenols 
Bisphenol A (BPA) is one of the most important industrial chemicals, which worldwide 
production is over 500 000 tons per year. It is found mainly in plastic food containers, baby 
bottles, the resins lining food cans, dental sealants, cardboards, and as an additive in other 
plastics (Richter et al., 2007). BPA is structurally similar to DES and can act by binding to 
ERα and ERβ, and through other mechanisms, since some effects differ from those observed 
in response to activation of estrogen receptors. In vivo and in vitro experiments revealed that 
BPA mimics estrogen action, however it is also able to antagonize the activity of estradiol, 
acting as a selective estrogen receptor modulator (SERM) (Welshons et al., 2006). In high 
concentrations BPA can bind to AR and inhibit the androgen action (Lee et al., 2003). 
Although BPA is approximately 1000- to 2000-fold less potent than estradiol, exposure to 
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antiandrogenic action, prochloraz antagonizes the estrogen receptor, agonizes the aryl 
hydrocarbon (Ah) receptor and suppresses aromatase activity (Andersen et al., 2002; 
Vinggaard et al., 2006). Gestational exposure significantly reduces testosterone production 
by inhibiting activity of cytochrome P450c17, decreases reproductive organ weights, 
increases nipple retention and induces malformations (e.g., hypospadias) in androgen-
dependent tissues of male offspring (Blystone et al. 2007; Laier et al., 2006; Noriega et al., 
2005; Vinggaard et al., 2005). 
Linuron is a herbicide employed to control of weeds in crops and potatoes (Gray et al., 
2006). It binds AR and inhibits dihydrotestosterone induced gene expression in vitro 
(Lambright et al., 2000). Fetal exposure to linuron resulted in epididymal and testicular 
abnormalities, reduced anogenital distance and nipple retention; however, in contrast to 
other AR antagonists, it does not induce hypospadias and cryptorchidism. Moreover, 
linuron was shown to decrease testosterone production by fetal Leydig cells (McIntyre et al., 
2000, 2002a, 2002b; Wilson et al., 2009). Thus its mechanism of action resembles those of 
phthalates (Gray et al., 2006). Interestingly, when administered to sexually immature and 
mature rats, linuron decreased weights of accessory sex organs, increased serum estradiol 
and LH levels, and produced Leydig cell tumors (Cook et al., 1993). 
p,p’-DDE (dichlorodiphenyldichloroethylene) is a metabolite of the persistent pesticide, 
DDT (dichlorodiphenyltrichloroethane). DTT is now banned in most countries, since in 
1960’ it was discovered that it has endocrine disrupting properties and causes birth defects 
in human and animals. However, it is still used in some regions to prevent malaria and 
other tropical diseases spread by insects (van den Berg et al., 2009). p,p’-DDE acts as AR 
antagonist both in vivo and in vitro (Kelce et al., 1995). Fetal treatment with this compound 
was shown to affect male development, leading to reduced anogenital distance, nipple 
retention and hypospadias (You et al., 1998). Recently, it was reported that p,p’-DDE 
induces testicular apoptosis in pubertal rats through the involvement of Fas/FasL, 
mitochondria and endoplasmic reticulum-mediated pathways (Shi et al., 2011).  
3.2.2 Phthalates  
The diesters of 1,2-benzenedicarboxylic acid, called phthalates, are widely used as 
plasticizers in the production of toys, medical devices, rainwear, food packaging, and 
certain cosmetics (Schettler, 2006). Di-n-butyl phthalate (DBP) and di(2-ethylhexyl) 
phthalate (DEHP) and their metabolites have been shown to cause antiandrogenic effects, 
however, without binding to AR (Frederiksen et al., 2007). Although, the exact mechanism 
of action is not yet fully elucidated, it was demonstrated that phthalates interfere with 
Leydig cell function, reducing the expression of most of genes involved in testosterone 
biosynthesis (Barlow et al., 2003). Fetal exposure to phthalates results in reduced anogenital 
distance, hypospadias, cryptorchidism, malformed epididymis, and nipple retention 
(Mylchreest et al., 1999, 2002; Mylchreest & Foster, 2000). At the histological level, 
multinucleated gonocytes, detachment of gonocytes from the seminiferous epithelium, 
Sertoli cell-only tubules and Leydig cell hyperplasia were found in the testes of males 
exposed to DEHP and DBP (Fisher et al., 2003; Mylchreest et al., 2002; Parks et al., 2000). 
Some of these alterations were permanent and affected testicular function in adulthood, 
resulting in low testosterone level and reduced sperm count. It is worth noting that 
histological changes induced in rat by in utero exposure to phthalates resemble those 
observed in patients with TDS (Fisher, 2004a). 
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4. Xenoestrogens  
Compounds with estrogenic activity, called xenoestrogens, comprise a broad range of 
synthetic chemicals (e.g., diethylstilbestrol, bisphenol-A, octylphenol, nonylphenol), 
naturally occurring phytoestrogens (e.g., genistein, resveratrol) and heavy metals (e.g., 
cadmium, lead, and boron). 
4.1 Diethylstilbestrol (DES) 
DES is synthetic potent non-steroidal estrogen used as a supplement in cattle and poultry 
feed and as a pharmaceutical (Rubin, 2007). DES was given to pregnant women to prevent 
miscarriages or premature deliveries from about 1940 to 1970. It was restricted in 1971 
because of increased risk of a rare reproductive tract cancer, vaginal clear cell 
adenocarcinoma, in daughters of women who had taken DES (Gill et al., 1979; Melnick et al., 
1987). Further studies have reported multiple adverse effects in males and females as a 
result of prenatal DES exposure. In males decreased fertility and anatomical malformations 
of reproductive organs such as cryptorchidism, epididymal cysts and prostatic squamous 
metaplasia were observed (Driscoll & Taylor, 1980; Marselos & Tomatis, 1992; Mittendorf, 
1995).  
Nowadays, experimental animals exposed to DES during fetal and neonatal development 
are useful models for studying mechanisms of endocrine disruption caused by exogenous 
estrogenic compounds (Diamanti-Kandarakis et al., 2009). In male mice exposed to DES 
during gestation, cryptorchidism, hypospadias, as well as underdeveloped epididymis, vas 
deferens and seminal vesicles were observed (McLachlan et al., 2001). Similarly, neonatal 
treatment of male rats with DES induced a wide range of reproductive abnormalities, 
including delay of testicular descent, retardation of pubertal spermatogenesis, reduction in 
testis weight, infertility, and gross morphological alterations in the rete testis, efferent ducts, 
epididymis and accessory sex glands (Atanassova et al., 1999, 2000; Fisher et al., 1999; 
McKinnell et al, 2001; Williams et al., 2001). Testes of adult rats neonatally exposed to DES 
displayed suppression of Leydig cell development and steroidogenesis, reduced Sertoli cell 
proliferation and spermatogenic impairment. It was shown that DES has both direct and 
pituitary-mediated effects on the developing testis, leading to decreased expression of AR 
and reduced FSH level (Sharpe et al., 1998, 2003). Studies on transgenic mouse models with 
inactivated ERs suggest that DES elicits its toxic effects in the male reproductive tract 
through an ERα-mediated mechanism (Prins et al., 2001). 
4.2 Environmental xenoestrogens 
4.2.1 Industrial xenoestrogens: bisphenol A and alkylphenols 
Bisphenol A (BPA) is one of the most important industrial chemicals, which worldwide 
production is over 500 000 tons per year. It is found mainly in plastic food containers, baby 
bottles, the resins lining food cans, dental sealants, cardboards, and as an additive in other 
plastics (Richter et al., 2007). BPA is structurally similar to DES and can act by binding to 
ERα and ERβ, and through other mechanisms, since some effects differ from those observed 
in response to activation of estrogen receptors. In vivo and in vitro experiments revealed that 
BPA mimics estrogen action, however it is also able to antagonize the activity of estradiol, 
acting as a selective estrogen receptor modulator (SERM) (Welshons et al., 2006). In high 
concentrations BPA can bind to AR and inhibit the androgen action (Lee et al., 2003). 
Although BPA is approximately 1000- to 2000-fold less potent than estradiol, exposure to 
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environmentally relevant doses impacts the reproductive system development and function 
in male rodents (Richter et al., 2007). It was demonstrated that rodents exposed to BPA 
during fetal and/or neonatal life had decreased weights of the epididymis and seminal 
vesicles, but increased weights of the prostate and preputial glands, decreased epithelial 
height in the efferent ducts and decreased levels of testicular testosterone (Akingbemi et al., 
2004; Fisher et al., 1999; vom Saal et al., 1998). Alterations in ectoplasmic specialization 
between the Sertoli cell and spermatids, abnormalities in the acrosomal granule and nucleus 
of spermatids, reduced percentage of motile sperm, and increased incidence of sperm 
malformations were also observed (Aikawa et al., 2004; Toyama et al., 2004). Similar changes 
in the seminiferous epithelium and reduced fertility were found in adult males treated with 
BPA (Toyama et al., 2004). BPA was found to act directly on Leydig cell steroidogenesis, 
affecting the expression of cytochrome cytochrome P450 17α-hydroxylase/C17-20 lyase 
(P450c17) and aromatase enzymes and interfering with LH receptor-ligand binding 
(Akingbemi et al., 2004; Svechnikov et al., 2010). 
Alkylphenols, such as 4-nonylphenol and 4-tert-octylphenol, are used to manufacture the 
alkylphenol polyethoxylates, non-ionic surfactants used as detergents, plasticizers, 
emulsifiers and modifiers in paints, pesticides, textiles, and personal care products. 
Alkylphenols present in the environment, mainly in wastewater and rivers, derive from the 
release of unreacted alkylphenols during manufacturing as well as from degradation of the 
alkylphenol polyethoxylates in the environment (Blake et al., 2004; Staples et al., 2001). 
Currently, alkylphenols have been found in human urine and breast milk (Ademollo et al., 
2008; Calafat et al., 2008,). Octylphenol and nonylphenol has been reported to exhibit weak 
estrogenic activity as demonstrated by its ability to bind and activate the estrogen receptors 
(Kuiper et al., 1998; Lee, 1998; Safe et al., 2000). Although these chemicals are between 100 
and 10000-fold less estrogenic than 17β-estradiol, the widespread use of these compounds 
causes that they largely contribute to the environmental estrogen pool (Blake & Bookfor, 
1997).  
Maternal exposure to octylphenol was shown to affect the expression of genes essential for 
reproductive system development, such as steroidogenic factor-1 (SF-1) and steroidogenic 
enzymes in rat testes (Majdic et al., 1996, 1997). In the lamb, it was demonstrated to inhibit 
the secretion of FSH in the fetus with a concomitant decrease in testis size and Sertoli cell 
number at birth (Sweeney et al., 2000). In adult males exposed in utero or neonatally to 
alkylphenols abnormalities in reproductive organs histology, reduced weight of the testis, 
epididymis and prostate, reduced testosterone level as well as increased number of 
abnormal sperm and decreased sperm production were observed (Aydoğan & Barlas, 2006; 
Jie et al., 2010; Lee, 1998; Yoshida et al., 2001). These alterations may result from both 
modulation of the hypothalamus-pituitary axis and direct estrogenic action in reproductive 
tissues (Yoshida et al., 2001). Importantly, all these effects were observed only when 
relatively high doses (400 mg/kg bw) of alkylphenols were used (Atanassova et al., 2000; 
Sharpe et al., 2003). 
Administration of high doses of alkylphenols to adult males resulted in reduced size and 
function of the testis, epididymis and male accessory glands, decreased serum LH, FSH and 
testosterone concentrations, increased apoptosis of germ cells and reduced sperm count 
(Blake & Boockfor, 1997; Boockfor & Blake, 1997; Han et al., 2004; Gong & Han, 2006; Kim et 
al., 2007). However, reports on the effects of lower doses (<200 mg/kg bw) of octylphenol 
on male reproductive system are contradictory (Bian et al., 2006; Kim et al., 2007). 
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Recently, bank vole, a seasonally breeding rodent, was used to investigate the effects of 4-
tert-octylphenol on testes and seminal vesicles, depending on the length of exposure and 
reproductive status of animals. Adult bank vole males kept under long or short photoperiod 
were orally administered octylphenol (200 mg/kg bw) for 30 or 60 days. We found that 
treatment for 30 days had no effect on the reproductive organs, whereas treatment for 60 
days adversely influenced sperm morphology as well as weights and histological structure 
of the testes and seminal vesicles. In these tissues, expression of 3β-HSD and AR, and 
testosterone levels were decreased, concomitantly with increased expression of aromatase 
and ERα, and elevated estradiol levels, resulting in androgen-estrogen imbalance. These 
data indicate that long-term exposure to octylphenol is necessary to affect male reproductive 
organs histology and hormonal milieu. Furthermore, a subtle difference in the sensitivity to 
octylphenol between voles kept in different light conditions was noted (Hejmej et al., 2011b). 
In a further study negative effects of this compound on MA-10 Leydig cells in vitro have 
been reported. In cell cultures treated with different octylphenol concentrations, dose-
related changes in the cytoarchitecture of MA-10 cells, including cytoplasm vacuolization 
and altered size and distribution of lipid droplets, were visible. Moreover, it was shown that 
high doses attenuate 3β-HSD and AR expression, concomitantly with the reduction of 
progesterone synthesis. Based on this results it was hypothesized that octylphenol besides 
binding to ERs may use other potential routes of action such as effects on the AR (Kotula-
Balak et al., 2011). 
4.2.2 Phytoestrogens  
Phytoestrogens are plant compounds, structurally similar to 17β-estradiol and thus 
exhibiting estrogenic or antiestrogenic activity. There are four main classes of 
phytoestrogens: isoflavones (genistein, daidzein, biochanin A, naringenin), coumestans 
(coumestrol), lignans (matairesinol) and stilbene (resveratrol). Phytoestrogens are present in 
fruits, vegetables and leguminous plants, but the main source of these compounds in human 
diet are soy-based products, i. a. soy-based infant formula, that contain high concentration 
of genistein and daidzein (Reinli & Block, 1996; Setchell et al., 1997). It is believed that 
isoflavones exert beneficial effects in prevention of cancer, cardiovascular diseases and 
osteoporosis, however it was reported that they can adversely affect development and 
function of male and female reproductive function (Lee et al., 2004; Suthar et al., 2001). This 
may be of special concern in case of infants fed with soy formula milk. Although, 
phytoestrogens binding affinity to the estrogen receptors is 1000-10000-fold lower compared 
with the 17β-estradiol, in infants, which consume even 9 mg/kg/day of isoflavones, mainly 
genistein, blood concentrations of the isoflavones exceed 1000 times those of endogenous 
estradiol and are higher than the amount reported to produce hormonal effects in adult 
women (Henley & Korach et al., 2010; Schmitt et al., 2001; Setchell et al., 1997). Therefore in 
recent years multiple studies on animal models were undertaken to elucidate the 
mechanism of action and the consequences of exposure to genistein. In rodents dietary 
administration of genistein induced Leydig cell hyperplasia and decrease of testosterone 
level by down-regulation of the expression of steroidogenic enzymes (e.g., cytochrome 
P450scc) (Svechnikov et al., 2005). In vivo and in vitro data indicate that genistein is able to 
signal through both ERα and ERβ, depending on the specific tissue (Mueller et al., 2004). 
In recent years resveratrol, a stilbene found in grapes and wine, has been widely used to 
prevent cardiovascular diseases, since it was shown to inhibit oxidation of LDL cholesterol, 
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environmentally relevant doses impacts the reproductive system development and function 
in male rodents (Richter et al., 2007). It was demonstrated that rodents exposed to BPA 
during fetal and/or neonatal life had decreased weights of the epididymis and seminal 
vesicles, but increased weights of the prostate and preputial glands, decreased epithelial 
height in the efferent ducts and decreased levels of testicular testosterone (Akingbemi et al., 
2004; Fisher et al., 1999; vom Saal et al., 1998). Alterations in ectoplasmic specialization 
between the Sertoli cell and spermatids, abnormalities in the acrosomal granule and nucleus 
of spermatids, reduced percentage of motile sperm, and increased incidence of sperm 
malformations were also observed (Aikawa et al., 2004; Toyama et al., 2004). Similar changes 
in the seminiferous epithelium and reduced fertility were found in adult males treated with 
BPA (Toyama et al., 2004). BPA was found to act directly on Leydig cell steroidogenesis, 
affecting the expression of cytochrome cytochrome P450 17α-hydroxylase/C17-20 lyase 
(P450c17) and aromatase enzymes and interfering with LH receptor-ligand binding 
(Akingbemi et al., 2004; Svechnikov et al., 2010). 
Alkylphenols, such as 4-nonylphenol and 4-tert-octylphenol, are used to manufacture the 
alkylphenol polyethoxylates, non-ionic surfactants used as detergents, plasticizers, 
emulsifiers and modifiers in paints, pesticides, textiles, and personal care products. 
Alkylphenols present in the environment, mainly in wastewater and rivers, derive from the 
release of unreacted alkylphenols during manufacturing as well as from degradation of the 
alkylphenol polyethoxylates in the environment (Blake et al., 2004; Staples et al., 2001). 
Currently, alkylphenols have been found in human urine and breast milk (Ademollo et al., 
2008; Calafat et al., 2008,). Octylphenol and nonylphenol has been reported to exhibit weak 
estrogenic activity as demonstrated by its ability to bind and activate the estrogen receptors 
(Kuiper et al., 1998; Lee, 1998; Safe et al., 2000). Although these chemicals are between 100 
and 10000-fold less estrogenic than 17β-estradiol, the widespread use of these compounds 
causes that they largely contribute to the environmental estrogen pool (Blake & Bookfor, 
1997).  
Maternal exposure to octylphenol was shown to affect the expression of genes essential for 
reproductive system development, such as steroidogenic factor-1 (SF-1) and steroidogenic 
enzymes in rat testes (Majdic et al., 1996, 1997). In the lamb, it was demonstrated to inhibit 
the secretion of FSH in the fetus with a concomitant decrease in testis size and Sertoli cell 
number at birth (Sweeney et al., 2000). In adult males exposed in utero or neonatally to 
alkylphenols abnormalities in reproductive organs histology, reduced weight of the testis, 
epididymis and prostate, reduced testosterone level as well as increased number of 
abnormal sperm and decreased sperm production were observed (Aydoğan & Barlas, 2006; 
Jie et al., 2010; Lee, 1998; Yoshida et al., 2001). These alterations may result from both 
modulation of the hypothalamus-pituitary axis and direct estrogenic action in reproductive 
tissues (Yoshida et al., 2001). Importantly, all these effects were observed only when 
relatively high doses (400 mg/kg bw) of alkylphenols were used (Atanassova et al., 2000; 
Sharpe et al., 2003). 
Administration of high doses of alkylphenols to adult males resulted in reduced size and 
function of the testis, epididymis and male accessory glands, decreased serum LH, FSH and 
testosterone concentrations, increased apoptosis of germ cells and reduced sperm count 
(Blake & Boockfor, 1997; Boockfor & Blake, 1997; Han et al., 2004; Gong & Han, 2006; Kim et 
al., 2007). However, reports on the effects of lower doses (<200 mg/kg bw) of octylphenol 
on male reproductive system are contradictory (Bian et al., 2006; Kim et al., 2007). 
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Recently, bank vole, a seasonally breeding rodent, was used to investigate the effects of 4-
tert-octylphenol on testes and seminal vesicles, depending on the length of exposure and 
reproductive status of animals. Adult bank vole males kept under long or short photoperiod 
were orally administered octylphenol (200 mg/kg bw) for 30 or 60 days. We found that 
treatment for 30 days had no effect on the reproductive organs, whereas treatment for 60 
days adversely influenced sperm morphology as well as weights and histological structure 
of the testes and seminal vesicles. In these tissues, expression of 3β-HSD and AR, and 
testosterone levels were decreased, concomitantly with increased expression of aromatase 
and ERα, and elevated estradiol levels, resulting in androgen-estrogen imbalance. These 
data indicate that long-term exposure to octylphenol is necessary to affect male reproductive 
organs histology and hormonal milieu. Furthermore, a subtle difference in the sensitivity to 
octylphenol between voles kept in different light conditions was noted (Hejmej et al., 2011b). 
In a further study negative effects of this compound on MA-10 Leydig cells in vitro have 
been reported. In cell cultures treated with different octylphenol concentrations, dose-
related changes in the cytoarchitecture of MA-10 cells, including cytoplasm vacuolization 
and altered size and distribution of lipid droplets, were visible. Moreover, it was shown that 
high doses attenuate 3β-HSD and AR expression, concomitantly with the reduction of 
progesterone synthesis. Based on this results it was hypothesized that octylphenol besides 
binding to ERs may use other potential routes of action such as effects on the AR (Kotula-
Balak et al., 2011). 
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of genistein and daidzein (Reinli & Block, 1996; Setchell et al., 1997). It is believed that 
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platelets aggregation and synthesis of eikozanoids (Kris-Etherton et al., 2002). However, 
resveratrol appeared to have adverse effect on Leydig cell steroidogenesis through 
suppression of the expression of StAR and cytochrome P450c17 (Svechnikov et al., 2009).  
Estrogenic activity is also attributed to several other compounds derived from plants, for 
example lavender oil and tea tree oil, frequently used in cosmetics, such as lotions, gels, and 
creams. It is supposed that exposure to these chemicals may induce prepubertal 
gynecomastia in humans. In vitro experiments revealed that apart from estrogenic activity 
both lavender and tea tree oil possess antiandrogenic properties (Henley et al., 2007; Henley 
& Korach et al., 2010).  
Interestingly, based on the analysis of published data concerning correlations between 
exposure to different endocrine disruptors and decrease in sperm counts and increase in 
testicular cancer rate, Safe (2004) suggested that dietary phytoestrogens, rather than 
synthetic environmental endocrine disruptors may by involved in induction of reproductive 
tract disorders in human. 
4.2.3 Methoxychlor 
Methoxychlor was introduced in 1944 to substitute more persistent and more toxic 
insecticide, DDT. It is used on agricultural crops, livestock, animal feed, grain storage, home 
gardens, and on pets. Methoxychlor exhibits mixed estrogenic and antiandrogenic activity: 
the most active estrogenic metabolite is HPTE [2,2-bis-(p-hydroxyphenyl)-1, 1, 1-
trichloroethane], whereas other metabolites have antiandrogenic activity (Cummings, 1997; 
Dehal & Kupfer, 1994; Kelce & Wilson, 1997). HPTE has differential effects on ERs, being an 
ERα agonist and ERβ antagonist (Gaido et al., 1999, 2000). In cultured Leydig cells from 
immature and adult rats, HPTE was shown to inhibit both basal and hCG-stimulated 
testosterone production, and these effects were reported to be mediated through the ER 
(Murono & Derk, 2005). Recently, a direct inhibitory activity of methoxychlor and HPTE on 
3β-HSD and 17β-hydroxysteroid dehydrogenase (17β-HSD) was reported (Hu et al., 2011). 
Exposure to methoxychlor during gestation or neonatal period affected embryonic testis 
cellular composition, Sertoli and germ cell numbers, germ cell survival and epididymal 
sperm count, reducing spermatogenic potential of males (Chapin et al., 1997; Johnson et al., 
2002; Suzuki et al., 2004). In adult rat testis methoxychlor induced apoptosis via 
mitochondria- and FasL-mediated pathways (Vaithinathan et al., 2010). 
4.2.4 Heavy metals 
Numerous heavy metals (e.g., cadmium, lead, arsenic, boron, mercury, antimony, 
aluminum, cobalt, chromium, lithium) have been demonstrated to adversely affect the 
reproductive function of human and experimental animals. For example, cadmium, used in 
battery electrode production, galvanizing, plastics, alloys and paint pigments, has potent 
estrogen- and androgen-like activities in vivo and in vitro (Sikka et al., 2008; Takiguchi & 
Yoshihara, 2006). In mice exposed to cadmium during late gestation and puberty markedly 
reduced weights of testes, epididymides, prostate and seminal vesicles, and decreased 
testosterone levels were observed. Moreover, testicular expression of StAR and 
steroidogenic enzymes, such as cytochrome P450scc, 17α-HSD and 17β-HSD, was down-
regulated (Ji et al., 2010, 2011). In the seminiferous tubules, cadmium caused disruption of 
the blood-testis barrier and oxidative stress, leading to germ cell degeneration, seminiferous 
tubules vacuolization, and aberrant morphology and apoptosis of Sertoli cells (de Souza 
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Predes et al., 2010; Zhang et al., 2010). Epidemiological and animal studies have additionally 
demonstrated a carcinogenic effect of cadmium on the prostate (Nakamura et al., 2002).  
Lead, another metal widespread in the environment, has adverse reproductive effect on the 
testes and the hypothalamic-pituitary axis. In animal studies, lead has been shown to reduce 
serum testosterone and FSH levels, disrupt spermatogenesis and induce oxidative cellular 
damage in epididymis (Foster at al., 1998; Marchlewicz et al., 2004; Sokol et al., 1985). 
Clinical studies have associated exposure to lead with reduced libido, reduced sperm 
motility and sperm count, chromosomal damage, infertility, and changes in serum 
testosterone (Braunstein et al., 1978; Winder, 1989). 
5. Mechanisms of action  
Endocrine disruptors affect cellular processes by different modes of action. They can act by 
mimicking the action of naturally produced hormones, blocking their receptors in target 
cells or altering the synthesis or metabolism of hormones and hormone receptors. It is 
important to note, that many endocrine disruptors have more than one mechanism of action 
(e.g., methoxychlor) (Gaido et al., 2000). Some can be metabolized to hormonally active 
compounds, exhibiting different properties (e.g., DDT and its metabolite DDE) (Kelce et al., 
1995). Moreover, even compounds with the same supposed mechanism of action can induce 
different effects after exposure. It was also demonstrated that action of some xenoestrogens 
may be different in various tissues; thus they can act as SERMs (e.g., BPA, resveratrol, 
naringenin) (Gehm et al., 1997; Gould et al., 1998; Yoon et al., 2001).  
5.1 Interaction with hormone receptors  
Endocrine disruptors can bind to specific hormone receptors and act via agonistic or 
antagonistic mechanism. Numerous xenoestrogens (e.g., BPA, alkylphenols, genistein) 
activate estrogen receptors, interacting with their binding pockets (Lehraiki et al., 2011; 
Mueller, 2004; Singleton & Khan, 2003). It is possible due to structural similarities of these 
compounds to estradiol. The affinity of xenoestrogens to the estrogen receptor and/or their 
ability to initiate nuclear retention and transcriptional effects is usually lower than those of 
estradiol. It is worth noting, however, that weak activity via receptor-dependent pathway 
does not necessarily predict the potency of the chemical acting via another signaling 
pathway. Moreover, many xenoestrogenic compounds bioaccumulate in fat tissues, 
resulting in prolonged exposure (Watson et al., 2011). Several estrogenic chemicals, among 
others flavonoids and resveratrol, have been shown to interact not only with ERs, but also 
with aryl hydrocarbon receptor (AhR) (Revel et al., 2003; Van der Heiden, et al., 2009). 
Antiandrogens, such as flutamide, vinclozolin, prochloraz and linuron, repress AR-
mediated transcriptional activation, by competitive inhibition of endogenous androgens 
binding to their receptor (Gray et al., 1999; Lambright et al., 2000; Mohler et al., 2009; 
Noriega et al., 2005; Vinggaard et al., 2002). Binding of antiandrogen may result in a 
conformational change of ligand binding domain of AR appropriate for the interaction with 
co-repressors, instead of coactivators (Berrevoets et al., 2002; Hodgson et al., 2008). 
Besides classical intracellular steroid hormone receptors, several membrane steroid 
receptors, capable to mediating non-genomic steroid actions, have been described (Thomas 
& Dong, 2006; Watson et al., 2007). BPA has been shown to bind to membrane-bound form 
of ERα (mER) and a transmembrane G protein-coupled receptor 30 (GPR30) (Watson et al., 
2005). This GPCR-mediated non-genomic action included activation of cAMP-dependent 
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protein kinase and cGMP-dependent protein kinase pathways and a rapid phosphorylation 
of the transcription factor cAMP response-element-binding protein (CREB) (Bouskine et al., 
2009). Recent results revealed the possibility that BPA may have adverse effects on 
spermatogenesis via activation of extracellular signal-related kinases 1 and 2 (ERK1/2) 
(Izumi et al., 2011). Also alkylphenols and phytoestrogens appear to activate non-genomic 
pathways, signaling via calcium influx and activation of mitogen-activated protein kinases 
(MAP kinases) (Bulayeva & Watson, 2004; Wozniak et al., 2005). 
5.2 Alterations in synthesis, metabolism and transport of hormones or their receptors  
It was reported that some endocrine disruptors can interfere with steroid synthesis or 
metabolism, acting via non-receptor mediated mechanisms (Fisher, 2004b). Phthalates 
induce antiandrogenic effects, however they do not interact with the AR (Lehraiki et al., 
2009; Stroheker et al., 2005,). It was demonstrated that DBP and DEHP decrease fetal 
testosterone synthesis by reducing the expression of steroidogenic genes, such as Cyp17, 
Cyp11a and StAR (Barlow & Foster, 2003; Borch et al., 2006; Howdeshell et al., 2007; Parks et 
al., 2000). Phthalates were also shown to decrease the expression of Insl-3, a factor produced 
by fetal Leydig cells. Insl-3 is an important regulator of testicular descent and phthalate-
induced reduction of Insl-3 is consistent with the high incidence of cryptorchidism (Gray et 
al., 2006; Laguë & Tremblay, 2008; Wilson et al., 2004). In contrast to phthalates, in utero 
exposure to prochloraz decreases testosterone production by direct inhibition of the activity 
of steroidogenic enzymes without affecting the mRNA expression of these enzymes 
(Blystone et al., 2007; Wilson et al., 2008).  
As mentioned above, biosynthesis of estrogens is catalyzed by the enzyme aromatase. 
Various endocrine disruptors were reported to alter the expression or activity of aromatase, 
leading to testosterone-estradiol imbalance. Enhanced expression of aromatase was found in 
testes of males exposed to octylphenol and BPA (Hejmej et al., 2011b; Kim et al., 2010), 
whereas prochloraz reduced aromatase expression (Vinggaard et al., 2006). Estradiol level 
can also be influenced by inhibition of SULT 1A1 and 2E1 enzymes, which catalyze 
inactivation of estrogens by sulphation. It was shown that alkylphenols and phthalates, 
suppressing these enzymes, cause a rise in the levels of the free active endogenous estrogens 
(Waring & Harris, 2005).  
Some endocrine disruptors may additionally influence the expression levels of hormone 
receptors, shifting the balance between concentrations of endogenous ligand and its 
receptor. For instance, it was reported that exposure to DES (McKinnell et al., 2001; Williams 
et al., 2001) and octylphenol (Hejmej et al., 2011b; Kotula-Balak et al., 2011) results in up-
regulation of ERα and down-regulation of AR in male reproductive tissues.  
In case of steroid hormones, the level of bioavailable hormone is determined not only by the 
level of synthesis and metabolism, but also by concentration of steroid hormone-binding 
globulin (SHBG), protein involved in transport of steroids in the blood. Studies revealed 
that endocrine disruptors may influence SHBG level, altering the level of free, bioavailable 
hormone (Bagchi et al., 2009; Sikka & Wang, 2008).  
It should be mentioned, that xenoestrogens and antiandrogens affect reproductive functions 
not only acing directly on reproductive organs, but also disturbing hypothalamus-pituitary-
testicular axis. For example, in adult male rats exposed to BPA during pre- and early postnatal 
periods, LH serum levels showed no changes, whereas FSH and testosterone levels decreased 
significantly (Cardoso et al., 2011). Secretion of FSH was also reduced following prenatal 
octylphenol and vinclozolin exposure (Sweeney et al., 2000; Veeramachaneni et al., 2006b). 
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5.3 Epigenetic mechanisms  
Epigenetic modifications are regulators in numerous biological processes, including 
spermatogenesis. Key mechanism in establishing epigenetic change is DNA methylation, 
which usually suppresses expression of the gene. Several studies revealed that endocrine 
disrupting chemicals are implicated in epigenetic programming and DNA methylation 
(McLachlan, 2001; Skinner & Anway, 2005). Indeed, hypermethylation found in several genes 
in the sperm DNA (i. a. Mest, Snrpn, Peg1 and Peg3) was accompanied by the reduction of 
semen quality (Stouder & Paoloni-Giacobino, 2010). These changes may be heritable, if they 
occur during certain stages of development (Crews & McLachlan, 2006). It was demonstrated 
that methoxychlor and vinclozolin when administered during prenatal period interfere with 
testis development and lead to increased spermatogenic cell apoptosis and decreased fertility 
in the adult males. These spermatogenic defects were also evident in subsequent generations 
(Chang et al., 2006; Skinner & Anway, 2005). Also maternal exposure to BPA resulted in 
postnatal changes in DNA methylation status and altered expression of specific genes in 
offspring (Bernal & Jirtle, 2010; Kundakovic & Champagne, 2011). 
Taken together, estrogenic and antiandrogenic compounds act by multiple mechanisms of 
toxicity disrupting the interactions among the interconnected signaling pathways in 
reproductive tissues. Importantly, in the environment organisms are usually exposed to 
mixtures of multiple endocrine disruptors, which can produce cumulative effects, regardless 
of the mode of action of the individual mixture component (Gray et al., 2006). 
6. Conclusion  
Experimental studies clearly suggest that estrogenic and antiandrogenic compounds could 
cause alterations of sexual differentiation and impairment of male reproductive functions. 
Although the process of spermatogenesis is directly vulnerable to exposure to endocrine 
disrupting agents only in sexually mature males, above-mentioned data imply that exposure 
during the period of reproductive system development may have subsequent impact on the 
reproductive functions in adulthood. Fetal and neonatal exposures might result in the 
reprogramming of the developmental process of testicular cells, leading to their irreversible 
dysfunction. In contrast, adverse effects on the process of spermatogenesis in adulthood can 
be reversible (Sharpe, 2010; West et al., 2005). It is likely, therefore, that fetal and neonatal 
periods are of critical importance, when considering the role of hormonally active chemicals 
in male reproductive functions. 
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Relationship Between Steroid Hormones 
 and Helicobacter pylori 
Hirofumi Shimomura 
Jichi Medical University 
Japan 
1. Introduction 
Helicobacter pylori is a Gram-negative microaerobic curved-rod possessing polar flagella as 
the motility organ. This bacterium colonizes human gastric epithelium and causes chronic 
gastritis and peptic ulcers (Graham, 1991; Warren & Marshall, 1983; Wyatt & Dixon, 1988). 
Via longer periods of colonization in the human stomach, it also contributes to the 
development of gastric cancer and marginal zone B-cell lymphoma (Forman, Eurogast 
Study Group, 1993; Wotherspoon et al., 1991). Approximately half of population in the 
world is infected with Helicobacter pylori, and the majority of infected persons develop 
atrophic gastritis with or without symptoms. Among Helicobacter pylori-infected individuals, 
about 10% persons develop gastric and duodenal ulcers, 1% to 3% persons develop gastric 
adenocarcinoma, and 0.1% or less person develops gastric mucosa-associated lymphoid 
tissue (MALT) lymphoma (Fukase et al., 2008; Peek & Blaser, 2002; Peek & Crabtree, 2006; 
Stolte et al., 2002; Uemura et al., 2001). 
The bacterial species belonging to the genus Helicobacter have a unique feature of free-
cholesterol (FC) assimilation into the membrane lipid compositions (Haque et al., 1995, 
1996). Helicobacter pylori aggressively absorbs free-cholesterol supplemented to a medium, or 
extracts free-cholesterol from the lipid raft of epithelial cell membrane when the organism 
adhered onto the epithelial cell surface (Wunder et al., 2006). The free-cholesterol 
assimilated into the Helicobacter pylori membranes is glucosylated via the enzymatic action, 
and the organism utilizes as the membrane lipid components both free-cholesterol itself and 
the glucosylated cholesterols. Previous study by our group has identified the following 
three types of glucosyl cholesterols in the membrane lipid compositions of Helicobacter pylori 
(Hirai et al., 1995): cholesteryl--D-glucopyranoside (CGL), cholesteryl-6-O-tetradecanoyl--
D-glucopyranoside (CAG), and cholesteryl-6-O-phosphatidyl--D-glucopyranoside (CPG). 
One of the enzymes involved in the biosynthesis of glucosyl cholesterols is HP0421 protein, 
a cholesterol -glucosyltransferase encoded by HP0421 gene in Helicobacter pylori (Lebrun et 
al., 2006). The HP0421 protein adopts as the glucose source a uridine diphosphate-glucose 
(UDP-Glc) and catalyzes the dehydration condensation reaction between a 1-hydroxyl 
(OH) group of D-glucose (Glc) molecule and a 3-OH group of free-cholesterol (FC) 
molecule, and thereby CGL is synthesized. The other enzymes involved in the biosynthesis 
of CAG and CPG have still not been identified (Fig. 1). 
Though it is almost special cases that bacterial species produce glucosyl sterols, plants and 
fungi universally produce various glucosyl sterols such as glucosyl sitosterol and glucosyl 
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(Hirai et al., 1995): cholesteryl--D-glucopyranoside (CGL), cholesteryl-6-O-tetradecanoyl--
D-glucopyranoside (CAG), and cholesteryl-6-O-phosphatidyl--D-glucopyranoside (CPG). 
One of the enzymes involved in the biosynthesis of glucosyl cholesterols is HP0421 protein, 
a cholesterol -glucosyltransferase encoded by HP0421 gene in Helicobacter pylori (Lebrun et 
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Though it is almost special cases that bacterial species produce glucosyl sterols, plants and 
fungi universally produce various glucosyl sterols such as glucosyl sitosterol and glucosyl 
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ergosterol (Kim et al., 2002; Oku et al., 2003; Peng et al., 2002; Warnecke et al., 1994, 1997, 
1999). As with Helicobacter pylori, the bacterial species that produce glucosyl cholesterol have 
been only reported in Borrelia hermsi, Acholeplasma axanthum, Spiroplasma spp., and 
Mycoplasma gallinarum (Livermore et al., 1978; Mayberry & Smith, 1983; Patel et al., 1978; 
Smith, 1971). Recent studies have shown that Borrelia burgdorferi, Borrelia garinii, and Borrelia 
afzelii possess the galactosyl cholesterol that binds to the cholesterol a D-galactose as the 
sugar molecule in place of a D-glucose (Ben-Menachem et al., 2003; Schröder et al., 2003; 
Stübs et al., 2009). Plants and fungi carry out the biosynthesis of sterols by themselves, and 
thereafter attach a D-glucose molecule to the sterols biosynthesized via the catalytic action 
of sterol -glucosyltransferase. In contrast, bacterial species including Helicobacter pylori do 
not have the anabolic pathway for cholesterol. Therefore, Helicobacter pylori must absorb 
free-cholesterol from the outside environments to biosynthesize glucosyl cholesterols. In 
addition, there is the structural difference between glucosyl cholesterols of Helicobacter pylori 
and the other glucosyl sterols. The D-glucose molecule in glucosyl cholesterols of 
Helicobacter pylori is attached to the cholesterol molecule with -configuration, whereas the 
D-glucose molecule of phytogenic and fungal glucosyl sterols is attached to the sterol 
molecule with -configuration. This structural difference is resulting from the enzymatic 
action catalyzing the binding of D-glucose into the sterol. In sum, the HP0421 protein of 
Helicobacter pylori catalyzes the -glucosidic linkage between the 1-OH group of D-glucose 
molecule and the 3-OH group of free-cholesterol molecule, whereas the sterol -
glucosyltransferase of plants and fungi catalyzes the -glucosidic linkage between the 1-
OH group of D-glucose molecule and the 3-OH group of free-sterol molecule. 
 
 
Fig. 1. The free-cholesterol (FC) assimilation of Helicobacter pylori 
For many years, the biological significance of cholesterol glucosylation in Helicobacter pylori 
remained to be clarified. Recently, it has been, however, elucidated that Helicobacter pylori 
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induces the glucosylation of free-cholesterol absorbed into the membranes to evade the host 
immune systems (Wunder et al., 2006). The HP0421 gene-knockout Helicobacter pylori mutant, 
which lacks the capability to biosynthesize the glucosyl cholesterols and retains free-
cholesterol without glucosylation, easily succumbs to the phagocytosis of macrophages, and 
strongly induces the activation of antigen-specific T cells, compared to the wild type 
Helicobacter pylori. In addition, when the HP0421 gene-knockout mutant is inoculated into the 
mouse via oral administration, the organism is promptly excluded from the murine gastric 
epithelium. The abnormal wild type Helicobacter pylori, which fails to induce the biosynthesis 
of enough amount glucosyl cholesterols by artificial insertion of excessive free-cholesterol into 
the membranes, also succumbs to the phagocytosis of macrophages and induces the activation 
of antigen-specific T cells, to similar to the cases of HP0421 gene-knockout mutant. In contrast, 
the normal wild type Helicobacter pylori and the HP0421 gene-reconstructed organism resist the 
phagocytosis of macrophages, control the induction of antigen-specific T cell activation, and 
colonize longer periods onto the gastric epithelium of mouse. These findings indicate that the 
glucosylation of free-cholesterol absorbed into the membranes of Helicobacter pylori plays an 
important role in survival and colonization of the organism in host. 
However, it remains to be clarified about why Helicobacter pylori aggressively absorbs 
exogenous free-cholesterol into the membranes. If Helicobacter pylori, as with the general 
bacterial species, did not absorb free-cholesterol into the membranes, the organism will not 
need to glucosylate it. In addition, free-cholesterol is rather harmful for the survival of 
Helicobacter pylori, because the organism possessing free-cholesterol without glucosylation 
strongly activates the macrophages and the antigen-specific T cells, and is eradicated from the 
gastric epithelium by inducing the host immune responses. Moreover, whether the free-
cholesterol is the only sterol absorbed into the membranes of Helicobacter pylori is also 
unsolved. Our group, thus, assumed that the free-cholesterol (or steroid) absorption in 
Helicobacter pylori has other some physiological role to maintain the viability of the organism. 
To elucidate these unsolved points, our group has initiated the investigations as to the 
capability of Helicobacter pylori to use steroid hormones. Steroid hormones, such as sex 
hormones and corticoids, are typical sterol analogues that are derived from free-cholesterol 
in mammals. A number of investigations have demonstrated that the enzymes involved in 
the biosynthesis and the activation of sex hormones are also expressed in human stomach 
tissue (Javitt et al., 2001; Miki et al., 2002; Takeyama et al., 2000; Turgeon et al., 2001). In 
addition, the expression of sex hormone receptors has been found in gastric cancer 
(Kominea et al., 2004; Matsuyama et al., 2002; Takano et al., 2002). These studies indirectly 
indicate that sex hormones exist in the human stomach environment. We know that 
Helicobacter pylori colonizes the human stomach. In sum, there is possibility that Helicobacter 
pylori has contact with sex hormones in the human stomach. No earlier studies, however, 
have investigated the assimilation of sex hormones in Helicobacter pylori, and/or the 
influence of sex hormones on the viability of the organism. 
Based on the findings from our current basal research, this chapter summarizes the 
capability of Helicobacter pylori to assimilate various sex hormones, and the bactericidal 
activity of certain sex hormones targeting selectively the Helicobacter pylori. 
2. The 3-OH steroids and Helicobacter pylori 
Of the steroid hormones including steroid pre-hormone, pregnenolone (PN), 
dehydroepiandrosterone (DEA), and epiandrosterone (EA) possess a hydroxyl group (3-
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strongly activates the macrophages and the antigen-specific T cells, and is eradicated from the 
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cholesterol is the only sterol absorbed into the membranes of Helicobacter pylori is also 
unsolved. Our group, thus, assumed that the free-cholesterol (or steroid) absorption in 
Helicobacter pylori has other some physiological role to maintain the viability of the organism. 
To elucidate these unsolved points, our group has initiated the investigations as to the 
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in mammals. A number of investigations have demonstrated that the enzymes involved in 
the biosynthesis and the activation of sex hormones are also expressed in human stomach 
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addition, the expression of sex hormone receptors has been found in gastric cancer 
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indicate that sex hormones exist in the human stomach environment. We know that 
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Based on the findings from our current basal research, this chapter summarizes the 
capability of Helicobacter pylori to assimilate various sex hormones, and the bactericidal 
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2. The 3-OH steroids and Helicobacter pylori 
Of the steroid hormones including steroid pre-hormone, pregnenolone (PN), 
dehydroepiandrosterone (DEA), and epiandrosterone (EA) possess a hydroxyl group (3-
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OH) with -configuration at the carbon-3 position of steroid framework, as with free-
cholesterol (FC). First of all, our group has, therefore, examined the capability of Helicobacter 
pylori to assimilate the 3-OH steroid hormones. After Helicobacter pylori (105 CFU, colony-
forming unit/ml) was cultured for 24 hours with pregnenolone (50 µM concentration), 
dehydroepiandrosterone (50 µM concentration), or epiandrosterone (50 µM concentration) 
in a serum-free medium (10 ml) with continuous shaking under microaerobic conditions (an 
atmosphere of 5% O2, 10% CO2, and 85% N2 at 37C), the membrane lipids of the organisms 
were purified via the Folch method (Folch et al., 1957) and analyzed by thin-layer 
chromatography (TLC). This paragraph summarizes the assimilation of 3-OH steroid 
hormones in Helicobacter pylori. 
2.1 Pregnenolone and Helicobacter pylori 
Though the structure at the carbon-17 position of pregnenolone framework differs from that 
at the same carbon position of free-cholesterol framework, the membranes of Helicobacter 
pylori aggressively absorbed the exogenous pregnenolone, and the organism induced the 
glucosylation of this 3-OH steroid pre-hormone: the TLC analysis detected the three spots 
of glucosyl pregnenolones equivalent to the three spots of glucosyl cholesterols (CGL, CAG 
and CPG) in the membrane lipid compositions of Helicobacter pylori (Hosoda et al., 2009). 
The recombinant HP0421 protein expressed in Escherichia coli has been shown to catalyze -
glucosylation of various phytogenic and fungal sterols (Lebrun et al., 2006). Moreover, 
Helicobacter pylori lacks the gene that encodes sterol -glucosyltransferase in plants and 
fungi. Therefore, the glucosyl pregnenolones detected in the membrane lipid compositions 
of Helicobacter pylori are easily guessed to be all -glucosyl pregnenolones. As with free-
cholesterol (FC), the functional group to which a D-glucose molecule can be attached via the 
catalytic action of HP0421 protein is the only 3-OH group in the pregnenolone (PN) 
framework (Fig. 2). The spot of glucosyl pregnenolone corresponding to the CGL spot 
detected in the TLC analysis must, in sum, be a 3-(-D-glucosyl)-pregnenolone. In 
addition, the spot of glucosyl pregnenolone corresponding to the CAG spot is guessed to be 
a 3-(6-O-tetradecanoyl--D-glucosyl)-pregnenolone, and the spot of glucosyl pregnenolone 
corresponding to the CPG spot is guessed to be a 3-(6-O-phosphatidyl--D-glucosyl)-
pregnenolone. 
2.2 Dehydroepiandrosterone and Helicobacter pylori 
As with pregnenolone, the structure at the carbon-17 position of dehydroepiandrosterone 
framework also differs from that at the same carbon position of free-cholesterol framework. 
Helicobacter pylori, however, absorbed the exogenous dehydroepiandrosterone into the 
membranes and induced the glucosylation of this androgen. Though the TLC analysis 
detected the three spots of glucosyl dehydroepiandrosterones, the detection level of the 
glucosyl dehydroepiandrosterone corresponding to the CGL was remarkably lower than the 
detection levels of the other glucosyl dehydroepiandrosterones corresponding to the CAG 
and CPG. 
Our previous study has demonstrated that the detection level of CGL, a basic structure of 
glucosyl cholesterols, in the membrane lipid compositions of Helicobacter pylori undergoing 
the long-term cultures reduces via the conversion to both CAG and CPG that are produced 
by modifying the CGL molecule with an acyl group and a phosphatidyl group, respectively, 
and thereby the detection levels of CAG and CPG increase in the membrane lipid 
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compositions of organism (Shimomura et al., 2004). Our findings as to the assimilation of 
this androgen, in sum, suggest that Helicobacter pylori promptly converts the 3-(-D-
glucosyl)-dehydroepiandrosterone, which is a fundamental structure of the glucosyl de- 
hydroepiandrosterones, to those modified by an acyl group or a phosphatidyl group. 
However, the transferases that attach an acyl group or a phosphatidyl group to the CGL 
molecule have still not been identified in Helicobacter pylori. Investigations into the CGL 
acyltransferase and CGL phosphatidyltransferase will be, therefore, required to elucidate 
the anabolic pathway in glucosyl cholesterols and glucosyl steroid hormones. 
2.3 Epiandrosterone and Helicobacter pylori 
The only structural difference between dehydroepiandrosterone and epiandrosterone is in 
the part of double bond between the carbon-5 position and the carbon-6 position in the 
steroid molecule: dehydroepiandrosterone has the double bond between those carbon 
positions, while epiandrosterone lacks its double bond. The TLC analysis detected the three 
spots of glucosyl epiandrosterones in the membrane lipid compositions into which 
Helicobacter pylori assimilated this androgen, but the detection level of the glucosyl 
epiandrosterone corresponding to the CGL was remarkably lower than the detection levels 
of the other glucosyl epiandrosterones corresponding to the CAG and CPG, as with the case 
of dehydroepiandrosterone. These results also suggest that Helicobacter pylori promptly 




Fig. 2. The 3-OH: a crucial conformation for steroid glucosylation by Helicobacter pylori 
These findings from our recent study show that Helicobacter pylori glucosylates not only free-
cholesterol, but also various 3-OH steroid hormones. The only common structure among 
pregnenolone (PN), dehydroepiandrosterone (DEA), epiandrosterone (EA), and free-
cholesterol (FC) is a 3-OH group in the steroid framework (Fig. 2). This, thus, indicates that 
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the 3-OH of steroids is a crucial conformation required for the steroid glucosylation by 
Helicobacter pylori. Further conformation analyses will be required to identify the chemical 
structures of glucosyl steroid hormones in more detail. 
Our group has demonstrated the first report to describe the capability of Helicobacter pylori 
to glucosylate steroid hormones (Hosoda et al., 2009). In addition, no earlier studies have 
reported that the glucosyl sex hormones were detected in eukaryotes, prokaryotes, and/or 
environments. Further investigations will be necessary to analyze the hormonal actions or 
biological activities of these glucosyl sex hormones produced by Helicobacter pylori. 
3. The 3-OH steroids and Helicobacter pylori 
The three female hormones, namely, estrone (E1), estradiol (E2), and estriol (E3) possess a 
flat hydroxyl group (3-OH) at the carbon-3 position of the steroid framework. Our recent 
studies have revealed that these 3-OH steroid hormones have the different influences on the 
viability of Helicobacter pylori. This paragraph describes the relationship between the 3-OH 
steroid hormones and Helicobacter pylori. 
3.1 Estrone and Helicobacter pylori 
When Helicobacter pylori (105 CFU/ml) was cultured for 24 hours with estrone at the 50 µM 
concentration in a serum-free medium (10 ml) with continuous shaking under microaerobic 
conditions, the membranes of organism efficiently absorbed the estrone (Hosoda et al., 
2009). These findings indicate that Helicobacter pylori aggressively uses as the membrane 
lipid components not only 3-OH steroids (including free-cholesterol), but also 3-OH steroid 
estrone. However, the organism has failed to induce the glucosylation of estrone absorbed 
into the membranes. In combination with the results of glucosylation observed in the 3-OH 
steroid hormones, they strongly indicate that Helicobacter pylori recognizes only the 3-OH 
conformation of steroid molecule and glucosylates only the 3-OH steroids with or without 
the other structural differences. 
3.2 Estradiol and Helicobacter pylori 
Our group has recently clarified the inhibitory effect of estradiol on the growth of 
Helicobacter pylori. When Helicobacter pylori (105 CFU/ml) was cultured for 24 hours with 
estradiol at the 50 and 100 µM concentrations in a serum-free medium (3 ml) with 
continuous shaking under microaerobic conditions, the estradiol at these concentrations 
made the division and proliferation of Helicobacter pylori stagnate: the levels of colony-
forming unit (CFU), which indicates the number of living bacterial cells in the meaning of 
the wide sense, at that time maintained the baseline CFU level (105 CFU/ml) immediately 
after the culture initiation (Hosoda et al., 2011). Estradiol has been, in sum, found to exhibit 
the bacteriostatic action to Helicobacter pylori. This estrogen seems to act to Helicobacter pylori 
by attaching to the cell surface of the organism, since it is contained in the membrane lipids 
purified from the Helicobacter pylori incubated in the presence of estradiol. Incidentally, 
estrone has no influence on the growth of Helicobacter pylori, and the proliferation capability 
of the organism even in the presence of estrone at the 100 µM concentration is comparable to 
that of the organism in the absence of its estrogen. 
Earlier investigations (including our own) have shown that Helicobacter pylori 
morphologically converts from a bacillary form to a coccoid form when the organism 
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exposed to various stresses such as excessive oxygen, alkaline pH, or long-term culture 
(Benaïssa et al., 1996; Catrenich & Makin, 1991; Donelli et al., 1998; Shimomura et al., 2004). 
For many years, there is a controversy as to whether the coccoid-converted Helicobacter pylori 
cells are maintaining a viable state. Cells that had changed to a coccoid form lack the ability 
to form colonies on an agar plate, which it makes very difficult to accurately determine the 
CFU in coccoid-converted Helicobacter pylori. Our group has, therefore, examined whether 
estradiol confers the bacteriostatic action to Helicobacter pylori by promoting the induction of 
coccoid-conversion in the bacterial cells. Though the cell morphologies of Helicobacter pylori 
were observed with a differential interference microscope after the organisms (105 CFU/ml) 
were incubated for 24 hours with estradiol at the 100 µM concentration in a serum-free 
medium (3 ml) with continuous shaking under microaerobic conditions, the coccoid 
Helicobacter pylori cells were unobserved. This indicates that estradiol inhibits the 
proliferation of Helicobacter pylori via a certain bacteriostatic mechanism but not the 
induction of coccoid-conversion against the bacterial cells. 
Epidemiological studies and animal models have suggested that female hormones, 
particularly estrogens, play a protective role in gastric cancer (Campbell-Thompson et al., 
1999; Freedman et al., 2007; Furukawa et al., 1982; Ketkar et al., 1978; Sipponen & Correa, 
2002). Helicobacter pylori infection is also one of the risk factors in developing of gastric 
cancer in humans. Recent study by others has demonstrated that estradiol somehow 
protects against the development of Helicobacter pylori-induced gastric cancer in a mouse 
model (Ohtani et al., 2007). The bacteriostatic action of estradiol may play some role in 
mechanisms preventing the development of Helicobacter pylori-induced gastric cancer. 
Further investigations will be necessary to elucidate the relationship between estradiol and 
Helicobacter pylori in vivo. 
3.3 Estriol and Helicobacter pylori 
When Helicobacter pylori (105 CFU/ml) was cultured for 24 hours with estriol at the 50 and 
100 µM concentrations in a serum-free medium (10 ml) with continuous shaking under 
microaerobic conditions, estriol had no influence on the growth of Helicobacter pylori, and the 
CFU levels of the organism cultured in the presence of estriol (both 50 µM and 100 µM) were 
comparable to the control CFU level (108 CFU/ml) of the organism cultured in the absence 
of estriol. In addition, this estrogen was undetectable in the membrane lipid compositions of 
the organism in the TLC analysis. Helicobacter pylori has, thus, failed to use as the membrane 
lipid component estriol. 
4. Membrane distribution of steroids assimilated by Helicobacter pylori 
In general, Gram-negative bacteria including Helicobacter pylori have two membranes that are 
composed of the phospholipid bilayer, namely an inner membrane and an outer membrane. 
The phospholipid components constituting both the inner and outer membranes are 
phosphatidylethanolamine, phosphatidylglycerol and cardiolipin. The outside lipid layer of 
the outer membrane also contains as the major glycolipid component a lipopolysaccharide 
(LPS) (Rietschel et al., 1994). LPS is composed of an O-polysaccharide chain, an outer core 
saccharide, an inner core saccharide, and a lipid A regions. The lipid A is composed of two 
phosphorylated glucosamine molecules linked by  (16)-glycosidic bond and plural fatty 
acid molecules (5 to 7 molecules) attached to the glucosamine molecules, and is buried in the 
outside lipid layer of the outer membrane. Meanwhile, the O-polysaccharide chain region has 
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the 3-OH of steroids is a crucial conformation required for the steroid glucosylation by 
Helicobacter pylori. Further conformation analyses will be required to identify the chemical 
structures of glucosyl steroid hormones in more detail. 
Our group has demonstrated the first report to describe the capability of Helicobacter pylori 
to glucosylate steroid hormones (Hosoda et al., 2009). In addition, no earlier studies have 
reported that the glucosyl sex hormones were detected in eukaryotes, prokaryotes, and/or 
environments. Further investigations will be necessary to analyze the hormonal actions or 
biological activities of these glucosyl sex hormones produced by Helicobacter pylori. 
3. The 3-OH steroids and Helicobacter pylori 
The three female hormones, namely, estrone (E1), estradiol (E2), and estriol (E3) possess a 
flat hydroxyl group (3-OH) at the carbon-3 position of the steroid framework. Our recent 
studies have revealed that these 3-OH steroid hormones have the different influences on the 
viability of Helicobacter pylori. This paragraph describes the relationship between the 3-OH 
steroid hormones and Helicobacter pylori. 
3.1 Estrone and Helicobacter pylori 
When Helicobacter pylori (105 CFU/ml) was cultured for 24 hours with estrone at the 50 µM 
concentration in a serum-free medium (10 ml) with continuous shaking under microaerobic 
conditions, the membranes of organism efficiently absorbed the estrone (Hosoda et al., 
2009). These findings indicate that Helicobacter pylori aggressively uses as the membrane 
lipid components not only 3-OH steroids (including free-cholesterol), but also 3-OH steroid 
estrone. However, the organism has failed to induce the glucosylation of estrone absorbed 
into the membranes. In combination with the results of glucosylation observed in the 3-OH 
steroid hormones, they strongly indicate that Helicobacter pylori recognizes only the 3-OH 
conformation of steroid molecule and glucosylates only the 3-OH steroids with or without 
the other structural differences. 
3.2 Estradiol and Helicobacter pylori 
Our group has recently clarified the inhibitory effect of estradiol on the growth of 
Helicobacter pylori. When Helicobacter pylori (105 CFU/ml) was cultured for 24 hours with 
estradiol at the 50 and 100 µM concentrations in a serum-free medium (3 ml) with 
continuous shaking under microaerobic conditions, the estradiol at these concentrations 
made the division and proliferation of Helicobacter pylori stagnate: the levels of colony-
forming unit (CFU), which indicates the number of living bacterial cells in the meaning of 
the wide sense, at that time maintained the baseline CFU level (105 CFU/ml) immediately 
after the culture initiation (Hosoda et al., 2011). Estradiol has been, in sum, found to exhibit 
the bacteriostatic action to Helicobacter pylori. This estrogen seems to act to Helicobacter pylori 
by attaching to the cell surface of the organism, since it is contained in the membrane lipids 
purified from the Helicobacter pylori incubated in the presence of estradiol. Incidentally, 
estrone has no influence on the growth of Helicobacter pylori, and the proliferation capability 
of the organism even in the presence of estrone at the 100 µM concentration is comparable to 
that of the organism in the absence of its estrogen. 
Earlier investigations (including our own) have shown that Helicobacter pylori 
morphologically converts from a bacillary form to a coccoid form when the organism 
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exposed to various stresses such as excessive oxygen, alkaline pH, or long-term culture 
(Benaïssa et al., 1996; Catrenich & Makin, 1991; Donelli et al., 1998; Shimomura et al., 2004). 
For many years, there is a controversy as to whether the coccoid-converted Helicobacter pylori 
cells are maintaining a viable state. Cells that had changed to a coccoid form lack the ability 
to form colonies on an agar plate, which it makes very difficult to accurately determine the 
CFU in coccoid-converted Helicobacter pylori. Our group has, therefore, examined whether 
estradiol confers the bacteriostatic action to Helicobacter pylori by promoting the induction of 
coccoid-conversion in the bacterial cells. Though the cell morphologies of Helicobacter pylori 
were observed with a differential interference microscope after the organisms (105 CFU/ml) 
were incubated for 24 hours with estradiol at the 100 µM concentration in a serum-free 
medium (3 ml) with continuous shaking under microaerobic conditions, the coccoid 
Helicobacter pylori cells were unobserved. This indicates that estradiol inhibits the 
proliferation of Helicobacter pylori via a certain bacteriostatic mechanism but not the 
induction of coccoid-conversion against the bacterial cells. 
Epidemiological studies and animal models have suggested that female hormones, 
particularly estrogens, play a protective role in gastric cancer (Campbell-Thompson et al., 
1999; Freedman et al., 2007; Furukawa et al., 1982; Ketkar et al., 1978; Sipponen & Correa, 
2002). Helicobacter pylori infection is also one of the risk factors in developing of gastric 
cancer in humans. Recent study by others has demonstrated that estradiol somehow 
protects against the development of Helicobacter pylori-induced gastric cancer in a mouse 
model (Ohtani et al., 2007). The bacteriostatic action of estradiol may play some role in 
mechanisms preventing the development of Helicobacter pylori-induced gastric cancer. 
Further investigations will be necessary to elucidate the relationship between estradiol and 
Helicobacter pylori in vivo. 
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When Helicobacter pylori (105 CFU/ml) was cultured for 24 hours with estriol at the 50 and 
100 µM concentrations in a serum-free medium (10 ml) with continuous shaking under 
microaerobic conditions, estriol had no influence on the growth of Helicobacter pylori, and the 
CFU levels of the organism cultured in the presence of estriol (both 50 µM and 100 µM) were 
comparable to the control CFU level (108 CFU/ml) of the organism cultured in the absence 
of estriol. In addition, this estrogen was undetectable in the membrane lipid compositions of 
the organism in the TLC analysis. Helicobacter pylori has, thus, failed to use as the membrane 
lipid component estriol. 
4. Membrane distribution of steroids assimilated by Helicobacter pylori 
In general, Gram-negative bacteria including Helicobacter pylori have two membranes that are 
composed of the phospholipid bilayer, namely an inner membrane and an outer membrane. 
The phospholipid components constituting both the inner and outer membranes are 
phosphatidylethanolamine, phosphatidylglycerol and cardiolipin. The outside lipid layer of 
the outer membrane also contains as the major glycolipid component a lipopolysaccharide 
(LPS) (Rietschel et al., 1994). LPS is composed of an O-polysaccharide chain, an outer core 
saccharide, an inner core saccharide, and a lipid A regions. The lipid A is composed of two 
phosphorylated glucosamine molecules linked by  (16)-glycosidic bond and plural fatty 
acid molecules (5 to 7 molecules) attached to the glucosamine molecules, and is buried in the 
outside lipid layer of the outer membrane. Meanwhile, the O-polysaccharide chain region has 
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direct contact with the outside of the bacterial cells and maintains the membrane permeability 
against exogenous lipophilic compounds. The outer core saccharide and the inner core 
saccharide regions are located between O-polysaccharide chain region and lipid A region. 
In addition to LPS, Helicobacter pylori retains the glucosyl cholesterols (CGL, CAG and CPG) 
as another glycolipid components into the membranes when the organism assimilated 
exogenous free-cholesterol. Our previous study has demonstrated that the percentage of 
total glucosyl cholesterols is greater than 20% in the total lipids (except for LPS) composing 
the Helicobacter pylori membranes (Shimomura et al., 2004). Glycerophospholipids, such as 
phosphatidylethanolamine and phosphatidylglycerol, have been known in Gram-negative 
bacteria to be in both the inner membrane and the outer membrane. No earlier reports have, 
however, investigated the localization of glucosyl cholesterols (CGL, CAG and CPG) in 
Helicobacter pylori membranes. 
To elucidate the membrane distribution of glucosyl cholesterols in Helicobacter pylori, we 
have divided the two membranes into the inner membrane fraction and the outer membrane 
fraction via sucrose-gradient centrifugation method, purified the lipids from each 
membrane fraction by the Folch method, and analyzed the lipid compositions obtained from 
these membrane fractions by thin-layer chromatography (TLC) (Shimomura et al., 2009). 
The TLC analysis detected the spot of free-cholesterol itself at a similar density in both the 
inner membrane fraction and the outer membrane fraction obtained from Helicobacter pylori 
ingested free-cholesterol from the medium. In contrast, the glucosyl cholesterols (CGL, CAG 
and CPG) produced via the absorption of free-cholesterol were detected at clearly higher 
levels in the outer membrane fraction than in the inner membrane fraction. In sum, the 
steroid itself was distributed into both the inner membrane and the outer membrane, 
whereas the glucosyl steroids were distributed into the outer membrane rather than into the 
inner membrane. We have also fractionated the inner membrane and the outer membrane of 
Helicobacter pylori that was cultured in the presence of estrone, and analyzed the lipids 
purified from each membrane fraction by TLC. As with the free-cholesterol itself, the spot of 
estrone absorbed by Helicobacter pylori was also detected at a similar density in both the 
outer and inner membrane fractions. 
These findings indicate that Helicobacter pylori assimilates exogenous steroids into the outer 
and inner membranes and uses the glucosylated steroids as major lipid components 
constituting the outer membrane. This membrane distribution of steroids also suggests a 
possibility that Helicobacter pylori possesses a certain membrane transport system for the ste- 
roids: the steroids absorbed into Helicobacter pylori are shifted from the outer membrane to 
the inner membrane, and thereafter, the steroids glucosylated in the inner membrane are 
transported to the outer membrane. There is, however, no evidence that HP0421 protein 
catalyzing the -glucosylation of steroids is distributed into the inner membrane of 
Helicobacter pylori. Therefore, it is important to ascertain the localization of HP0421 protein in 
the Helicobacter pylori membranes. In addition, further investigations will be necessary to 
clarify whether Helicobacter pylori possesses such a steroidal membrane transport system. 
5. The physiological role of steroid assimilation in Helicobacter pylori 
Though Helicobacter pylori aggressively assimilates various exogenous steroids into the 
membrane lipid compositions, the organism divides and proliferates even in the absence of 
steroids as well as the other bacterial species that have no ability to assimilate the exogenous 
steroids into the membranes. Our recent study has elucidated why Helicobacter pylori 
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physiologically requires steroids to survive (Shimomura et al., 2009). This paragraph describes 
an importance of steroid assimilation in maintaining the viability of Helicobacter pylori. 
Phosphatidylcholine, the most prevalent phospholipid in mammals, is much higher in 
concentration than free-cholesterol in the blood plasma of humans; phosphatidylcholine 
exists at a concentration of approximately 144 mg/dl, whereas free-cholesterol exists at a 
concentration of approximately 60 mg/dl. The fundamental chemical structure of phospha- 
tidylcholine is 1,2-diacyl-sn-glycero-3-phosphocholine (Fig. 3). In general, the carbon-1 (C1) 
position in the glycerol backbone of phosphatidylcholine carries a saturated fatty acid such 
as palmitic acid (C16:0) or stearic acid (C18:0), whereas the carbon-2 (C2) position in the 
glycerol backbone carries an unsaturated fatty acid such as oleic acid (C18:1), linoleic acid 
(C18:2), or arachidonic acid (C20:4). Lyso-phosphatidylcholine (LPC) is a monoacyl-type 
phosphatidylcholine and generally lacks an unsaturated fatty acid at the carbon-2 (C2) 
position of the glycerol backbone. A number of investigations have demonstrated that 
unsaturated fatty acids and lyso-phosphatidylcholines have the potential to kill various micro- 
organisms including Helicobacter pylori (Bruyn et al., 1996; Conley & Kabara, 1973; Constance et 
al., 1992; Kabara et al., 1972; Kanai & Kondo, 1979; Kanetsuna, 1985; Knapp & Melly, 1986; 
Kondo & Kanai, 1985; Nieman, 1954; Steel et al., 2002; Thompson et al., 1994). Thus, these 
individual lipophilic compounds constituting phosphatidylcholine act as antimicrobial agents 
against the various microorganisms. It remains unclear, however, whether the 
phosphatidylcholine itself also confers an antimicrobial action against the microorganisms. 
 
 
Fig. 3. The fundamental chemical structure of phosphatidylcholine 
A previous study by others has shown that the concentration of phosphatidylcholine is 124.8 
± 62.6 µM in gastric juice from eight healthy volunteers (Berstad et al., 1992). We know that 
Helicobacter pylori colonizes the human gastric epithelium. In sum, this study indicates that 
Helicobacter pylori is surrounded by phosphatidylcholine in vivo. If phosphatidylcholine itself 
affects the survival of Helicobacter pylori that has failed to assimilate exogenous steroids such 
as free-cholesterol or steroid hormones, it may explain the importance of steroid 
assimilation in the organism. We have, therefore, investigated the antibacterial activity of 
phosphatidylcholine itself against Helicobacter pylori (Shimomura et al., 2009). 
5.1 Antibacterial effects of phosphatidylcholine variants on the steroid-free 
Helicobacter pylori 
When the steroid-free Helicobacter pylori (107 CFU/ml) that has no steroid in the membrane 
lipid compositions was incubated for 24 hours with various phosphatidylcholine variants 
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direct contact with the outside of the bacterial cells and maintains the membrane permeability 
against exogenous lipophilic compounds. The outer core saccharide and the inner core 
saccharide regions are located between O-polysaccharide chain region and lipid A region. 
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total glucosyl cholesterols is greater than 20% in the total lipids (except for LPS) composing 
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membrane fraction by the Folch method, and analyzed the lipid compositions obtained from 
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ingested free-cholesterol from the medium. In contrast, the glucosyl cholesterols (CGL, CAG 
and CPG) produced via the absorption of free-cholesterol were detected at clearly higher 
levels in the outer membrane fraction than in the inner membrane fraction. In sum, the 
steroid itself was distributed into both the inner membrane and the outer membrane, 
whereas the glucosyl steroids were distributed into the outer membrane rather than into the 
inner membrane. We have also fractionated the inner membrane and the outer membrane of 
Helicobacter pylori that was cultured in the presence of estrone, and analyzed the lipids 
purified from each membrane fraction by TLC. As with the free-cholesterol itself, the spot of 
estrone absorbed by Helicobacter pylori was also detected at a similar density in both the 
outer and inner membrane fractions. 
These findings indicate that Helicobacter pylori assimilates exogenous steroids into the outer 
and inner membranes and uses the glucosylated steroids as major lipid components 
constituting the outer membrane. This membrane distribution of steroids also suggests a 
possibility that Helicobacter pylori possesses a certain membrane transport system for the ste- 
roids: the steroids absorbed into Helicobacter pylori are shifted from the outer membrane to 
the inner membrane, and thereafter, the steroids glucosylated in the inner membrane are 
transported to the outer membrane. There is, however, no evidence that HP0421 protein 
catalyzing the -glucosylation of steroids is distributed into the inner membrane of 
Helicobacter pylori. Therefore, it is important to ascertain the localization of HP0421 protein in 
the Helicobacter pylori membranes. In addition, further investigations will be necessary to 
clarify whether Helicobacter pylori possesses such a steroidal membrane transport system. 
5. The physiological role of steroid assimilation in Helicobacter pylori 
Though Helicobacter pylori aggressively assimilates various exogenous steroids into the 
membrane lipid compositions, the organism divides and proliferates even in the absence of 
steroids as well as the other bacterial species that have no ability to assimilate the exogenous 
steroids into the membranes. Our recent study has elucidated why Helicobacter pylori 
 
Relationship Between Steroid Hormones and Helicobacter pylori 
 
93 
physiologically requires steroids to survive (Shimomura et al., 2009). This paragraph describes 
an importance of steroid assimilation in maintaining the viability of Helicobacter pylori. 
Phosphatidylcholine, the most prevalent phospholipid in mammals, is much higher in 
concentration than free-cholesterol in the blood plasma of humans; phosphatidylcholine 
exists at a concentration of approximately 144 mg/dl, whereas free-cholesterol exists at a 
concentration of approximately 60 mg/dl. The fundamental chemical structure of phospha- 
tidylcholine is 1,2-diacyl-sn-glycero-3-phosphocholine (Fig. 3). In general, the carbon-1 (C1) 
position in the glycerol backbone of phosphatidylcholine carries a saturated fatty acid such 
as palmitic acid (C16:0) or stearic acid (C18:0), whereas the carbon-2 (C2) position in the 
glycerol backbone carries an unsaturated fatty acid such as oleic acid (C18:1), linoleic acid 
(C18:2), or arachidonic acid (C20:4). Lyso-phosphatidylcholine (LPC) is a monoacyl-type 
phosphatidylcholine and generally lacks an unsaturated fatty acid at the carbon-2 (C2) 
position of the glycerol backbone. A number of investigations have demonstrated that 
unsaturated fatty acids and lyso-phosphatidylcholines have the potential to kill various micro- 
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al., 1992; Kabara et al., 1972; Kanai & Kondo, 1979; Kanetsuna, 1985; Knapp & Melly, 1986; 
Kondo & Kanai, 1985; Nieman, 1954; Steel et al., 2002; Thompson et al., 1994). Thus, these 
individual lipophilic compounds constituting phosphatidylcholine act as antimicrobial agents 
against the various microorganisms. It remains unclear, however, whether the 
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Fig. 3. The fundamental chemical structure of phosphatidylcholine 
A previous study by others has shown that the concentration of phosphatidylcholine is 124.8 
± 62.6 µM in gastric juice from eight healthy volunteers (Berstad et al., 1992). We know that 
Helicobacter pylori colonizes the human gastric epithelium. In sum, this study indicates that 
Helicobacter pylori is surrounded by phosphatidylcholine in vivo. If phosphatidylcholine itself 
affects the survival of Helicobacter pylori that has failed to assimilate exogenous steroids such 
as free-cholesterol or steroid hormones, it may explain the importance of steroid 
assimilation in the organism. We have, therefore, investigated the antibacterial activity of 
phosphatidylcholine itself against Helicobacter pylori (Shimomura et al., 2009). 
5.1 Antibacterial effects of phosphatidylcholine variants on the steroid-free 
Helicobacter pylori 
When the steroid-free Helicobacter pylori (107 CFU/ml) that has no steroid in the membrane 
lipid compositions was incubated for 24 hours with various phosphatidylcholine variants 
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carrying different fatty acid molecules at the carbon-2 position of the glycerol backbone in a 
serum-free medium (3 ml) with continuous shaking under microaerobic conditions, the 
phosphatidylcholine variants attaching either a linoleic acid (C18:2) molecule or an 
arachidonic acid (C20:4) molecule to the carbon-2 (C2) position in the glycerol backbone 
conferred an antibacterial action fatal to the steroid-free Helicobacter pylori. In contrast, the 
phosphatidylcholine variants attaching either an oleic acid (C18:1) molecule or a palmitic acid 
(C16:0) molecule to the carbon-2 (C2) position in the glycerol backbone had no influence on 
the viability of Helicobacter pylori. 
To ascertain the antibacterial potencies of phosphatidylcholine-themselves, we have also 
investigated the antibacterial activity of compositional constituents of the two 
phosphatidylcholines that exhibited the anti-Helicobacter pylori action, a linoleic acid (C18:2), 
an arachidonic acid (C20:4), and a LPC (1-palmitoyl-sn-glycero-3-phosphocholine). When the 
steroid-free Helicobacter pylori (107 CFU/ml) was incubated for 24 hours with linoleic acid (10 
µg/ml), arachidonic acid (10 µg/ml), or LPC (10 µg/ml) in the serum-free medium (3 ml) 
containing a 0.2% dMCD (2,6-di-O-methyl--cyclodextrin) with continuous shaking under 
microaerobic conditions, the two fatty acids and LPC had no influence on the viability of the 
steroid-free organism. The dMCD has, thus, completely counteracted the antibacterial 
action of these lipophilic compounds against the steroid-free Helicobacter pylori. Incidentally, 
the linoleic acid (10 µg/ml), arachidonic acid (10 µg/ml), and LPC (10 µg/ml) in the absence 
of dMCD confer the antibacterial action fatal to the steroid-free Helicobacter pylori. 
Intriguingly, the dMCD had no influence on the anti-Helicobacter pylori action of the 
phosphatidylcholine variants carrying either a linoleic acid molecule or an arachidonic acid 
molecule at the carbon-2 position of the glycerol backbone, and these two 
phosphatidylcholine variants (concentrations ranging from 10 µg/ml to 100 µg/ml) 
conferred the bactericidal action to the steroid-free Helicobacter pylori even in the presence of 
the 0.2% dMCD, as with had being done in the absence of dMCD. 
The dMCD is a cyclic oligomer consisting of seven 2,6-di-O-methyl--D-glucose molecules 
linked by 4)-glycosidic bonds and has the ability to solubilize lipophilic compounds 
through the formation of molecular inclusion complexes (Ohtani et al., 1989). To examine 
whether dMCD inhibits the adsorption of unsaturated fatty acids, or phospha- 
tidylcholines onto the steroid-free Helicobacter pylori cells, we carried out the following 
experiments. The heat-killed Helicobacter pylori cells that have no steroid in the membranes 
were incubated for 24 hours with a linoleic acid (100 µg/ml), an arachidonic acid (100 
µg/ml), or phosphatidylcholine variants (100 µg/ml), to which either a linoleic acid 
molecule or an arachidonic acid molecule is attached as the acyl group, in the serum-free 
medium containing a 0.2% dMCD with continuous shaking at 37C, and thereafter the 
membrane lipids were purified from the heat-killed cells recovered via the Folch method 
and analyzed by TLC. The membrane lipids obtained from the heat-killed cells incubated in 
the absence of dMCD contained tremendous amounts of linoleic acid and arachidonic acid, 
whereas the membrane lipids obtained from the heat-killed cells incubated in the presence 
of dMCD (0.2%) contained negligible amounts of those fatty acids. Surprisingly, the 
phosphatidylcholines contained in the membrane lipids of the heat-killed cells incubated in 
the presence of dMCD (0.2%) were larger amount than those contained in the membrane 
lipids of the heat-killed cells incubated in the absence of dMCD. In sum, dMCD has 
inhibited the binding of the unsaturated fatty acids to the membranes of Helicobacter pylori 
but promoted the binding of the phosphatidylcholines to the membranes of the organism. 
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These results indicate that dMCD obstructs the hydrophobic interaction between the 
unsaturated fatty acids and the Helicobacter pylori membranes by solubilizing those fatty 
acids, and thereby protects the organism from the bactericidal action of the unsaturated 
fatty acids, and probably LPC (Fig. 4). It is unclear why dMCD promotes the adsorption of 
the two phosphatidylcholines onto the Helicobacter pylori membranes. These findings, 
however, indicate that the anti-Helicobacter pylori action originates in the potencies of 
phosphatidylcholine-themselves and that the unsaturated fatty acids (linoleic acid and 
arachidonic acid), and the LPC (1-palmitoyl-sn-glycero-3-phosphocholine), which result 
from the hydrolysis of the phosphatidylcholines, do not contribute to this action. We have, 
thus, elucidated the bactericidal activity of phosphatidylcholine (PC) variants carrying 
either a linoleic acid molecule or an arachidonic acid molecule at the carbon-2 position of the 
glycerol backbone against the steroid-free Helicobacter pylori. 
 
 
Fig. 4. The role of 2,6-di-O-methyl--cyclodextrin (dMCD) on the anti-Helicobacter pylori 
action of lipophilic compounds 
5.2 Bacteriolysis in the steroid-free Helicobacter pylori caused by the cell adsorption 
of phosphatidylcholines 
To examine the antibacterial mechanism of phosphatidylcholine variants carrying either a 
linoleic acid molecule or an arachidonic acid molecule at the carbon-2 position of the 
glycerol backbone, we performed the following experiments. After the steroid-free 
Helicobacter pylori (108 CFU/ml) was incubated for 8 hours with each phosphatidylcholine 
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carrying different fatty acid molecules at the carbon-2 position of the glycerol backbone in a 
serum-free medium (3 ml) with continuous shaking under microaerobic conditions, the 
phosphatidylcholine variants attaching either a linoleic acid (C18:2) molecule or an 
arachidonic acid (C20:4) molecule to the carbon-2 (C2) position in the glycerol backbone 
conferred an antibacterial action fatal to the steroid-free Helicobacter pylori. In contrast, the 
phosphatidylcholine variants attaching either an oleic acid (C18:1) molecule or a palmitic acid 
(C16:0) molecule to the carbon-2 (C2) position in the glycerol backbone had no influence on 
the viability of Helicobacter pylori. 
To ascertain the antibacterial potencies of phosphatidylcholine-themselves, we have also 
investigated the antibacterial activity of compositional constituents of the two 
phosphatidylcholines that exhibited the anti-Helicobacter pylori action, a linoleic acid (C18:2), 
an arachidonic acid (C20:4), and a LPC (1-palmitoyl-sn-glycero-3-phosphocholine). When the 
steroid-free Helicobacter pylori (107 CFU/ml) was incubated for 24 hours with linoleic acid (10 
µg/ml), arachidonic acid (10 µg/ml), or LPC (10 µg/ml) in the serum-free medium (3 ml) 
containing a 0.2% dMCD (2,6-di-O-methyl--cyclodextrin) with continuous shaking under 
microaerobic conditions, the two fatty acids and LPC had no influence on the viability of the 
steroid-free organism. The dMCD has, thus, completely counteracted the antibacterial 
action of these lipophilic compounds against the steroid-free Helicobacter pylori. Incidentally, 
the linoleic acid (10 µg/ml), arachidonic acid (10 µg/ml), and LPC (10 µg/ml) in the absence 
of dMCD confer the antibacterial action fatal to the steroid-free Helicobacter pylori. 
Intriguingly, the dMCD had no influence on the anti-Helicobacter pylori action of the 
phosphatidylcholine variants carrying either a linoleic acid molecule or an arachidonic acid 
molecule at the carbon-2 position of the glycerol backbone, and these two 
phosphatidylcholine variants (concentrations ranging from 10 µg/ml to 100 µg/ml) 
conferred the bactericidal action to the steroid-free Helicobacter pylori even in the presence of 
the 0.2% dMCD, as with had being done in the absence of dMCD. 
The dMCD is a cyclic oligomer consisting of seven 2,6-di-O-methyl--D-glucose molecules 
linked by 4)-glycosidic bonds and has the ability to solubilize lipophilic compounds 
through the formation of molecular inclusion complexes (Ohtani et al., 1989). To examine 
whether dMCD inhibits the adsorption of unsaturated fatty acids, or phospha- 
tidylcholines onto the steroid-free Helicobacter pylori cells, we carried out the following 
experiments. The heat-killed Helicobacter pylori cells that have no steroid in the membranes 
were incubated for 24 hours with a linoleic acid (100 µg/ml), an arachidonic acid (100 
µg/ml), or phosphatidylcholine variants (100 µg/ml), to which either a linoleic acid 
molecule or an arachidonic acid molecule is attached as the acyl group, in the serum-free 
medium containing a 0.2% dMCD with continuous shaking at 37C, and thereafter the 
membrane lipids were purified from the heat-killed cells recovered via the Folch method 
and analyzed by TLC. The membrane lipids obtained from the heat-killed cells incubated in 
the absence of dMCD contained tremendous amounts of linoleic acid and arachidonic acid, 
whereas the membrane lipids obtained from the heat-killed cells incubated in the presence 
of dMCD (0.2%) contained negligible amounts of those fatty acids. Surprisingly, the 
phosphatidylcholines contained in the membrane lipids of the heat-killed cells incubated in 
the presence of dMCD (0.2%) were larger amount than those contained in the membrane 
lipids of the heat-killed cells incubated in the absence of dMCD. In sum, dMCD has 
inhibited the binding of the unsaturated fatty acids to the membranes of Helicobacter pylori 
but promoted the binding of the phosphatidylcholines to the membranes of the organism. 
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These results indicate that dMCD obstructs the hydrophobic interaction between the 
unsaturated fatty acids and the Helicobacter pylori membranes by solubilizing those fatty 
acids, and thereby protects the organism from the bactericidal action of the unsaturated 
fatty acids, and probably LPC (Fig. 4). It is unclear why dMCD promotes the adsorption of 
the two phosphatidylcholines onto the Helicobacter pylori membranes. These findings, 
however, indicate that the anti-Helicobacter pylori action originates in the potencies of 
phosphatidylcholine-themselves and that the unsaturated fatty acids (linoleic acid and 
arachidonic acid), and the LPC (1-palmitoyl-sn-glycero-3-phosphocholine), which result 
from the hydrolysis of the phosphatidylcholines, do not contribute to this action. We have, 
thus, elucidated the bactericidal activity of phosphatidylcholine (PC) variants carrying 
either a linoleic acid molecule or an arachidonic acid molecule at the carbon-2 position of the 
glycerol backbone against the steroid-free Helicobacter pylori. 
 
 
Fig. 4. The role of 2,6-di-O-methyl--cyclodextrin (dMCD) on the anti-Helicobacter pylori 
action of lipophilic compounds 
5.2 Bacteriolysis in the steroid-free Helicobacter pylori caused by the cell adsorption 
of phosphatidylcholines 
To examine the antibacterial mechanism of phosphatidylcholine variants carrying either a 
linoleic acid molecule or an arachidonic acid molecule at the carbon-2 position of the 
glycerol backbone, we performed the following experiments. After the steroid-free 
Helicobacter pylori (108 CFU/ml) was incubated for 8 hours with each phosphatidylcholine 
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(100 µg/ml) in a serum-free medium (3 ml) with continuous shaking under microaerobic 
conditions, the supernatant recovered was subjected to the purification of proteins by an 
anion-exchange chromatography, and the proteins purified were analyzed by a sodium 
dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE). A number of protein bands 
with tremendous high densities were detected in the supernatant obtained from the steroid-
free Helicobacter pylori incubated with the phosphatidylcholines, in the SDS-PAGE analysis. 
Among those protein bands detected, the band for flavodoxin (FldA) protein was also 
contained. As FldA is an electron acceptor of the oxidoreductase that catalyzes acetyl-CoA 
synthesis in Helicobacter pylori cell (Hughes et al., 1995), we can assume that FldA is the 
intracellular protein. These results, in sum, indicate that the phosphatidylcholine variants 
attaching either a linoleic acid or an arachidonic acid as the acyl group to the carbon-2 
position in the glycerol backbone exert deleterious effect on the cell membranes of steroid-
free Helicobacter pylori and induce the bacterial cell lysis, resulting in abundant leakage of 
intracellular proteins (especially FldA protein) to outside of the bacterial cells. Incidentally, 
the SDS-PAGE analysis detected only negligible amount of proteins in the supernatant 
obtained from the steroid-free Helicobacter pylori incubated without either the 
phosphatidylcholines. 
5.3 Acquirement of phosphatidylcholine resistance in Helicobacter pylori conferred 
by assimilating steroid 
We next investigated whether the Helicobacter pylori with the assimilated steroid succumbs 
to the bactericidal action of the phosphatidylcholines, as with the steroid-free organism. 
When the steroid-free Helicobacter pylori is cultured for 24 hours in the serum-free medium 
containing free-cholesterol (50 µM concentration) with continuous shaking under 
microaerobic conditions, the organism recovered retains both free-cholesterol itself and 
glucosyl cholesterols (CGL, CAG and CPG) in the membranes. We, therefore, examined the 
anti-Helicobacter pylori action of the two phosphatidylcholine variants possessing the 
antibacterial action fatal to the steroid-free Helicobacter pylori by using the organism 
retaining the assimilated free-cholesterol that was prepared via the above culture procedure. 
When Helicobacter pylori (107 CFU/ml) with the assimilated free-cholesterol was incubated at 
various time points in a serum-free medium (3 ml) with shaking under microaerobic 
conditions in the presence or absence of each phosphatidylcholine (100 µg/ml), which 
carries either a linoleic acid molecule or an arachidonic acid molecule at the carbon-2 
position of the glycerol backbone, the Helicobacter pylori did not succumb to the antibacterial 
effects of the two phosphatidylcholine variants: the time-dependent growth-decline curve of 
Helicobacter pylori with each phosphatidylcholine roughly corresponded to the time-dependent 
growth-decline curve of the organism without either the two phosphatidylcholines, when 
the CFU values (log10 CFU/ml: vertical axis) and the incubation times (hour: horizontal axis) 
were plotted in a graph. Helicobacter pylori that had assimilated free-cholesterol (FC) has 
been, thus, found to resist the bactericidal action of phosphatidylcholine variants carrying 
either a linoleic acid molecule or an arachidonic acid molecule at the carbon-2 position of the 
glycerol backbone.  
As described above, Helicobacter pylori retains free-cholesterol in the form of glucosyl 
cholesterols (CGL, CAG and CPG). This raises the question as to whether the glucosyl 
cholesterols are more important rather than the free-cholesterol itself in the expression of 
phosphatidylcholine resistance in Helicobacter pylori. To resolve this question, we examined 
 




Fig. 5. The expression of phosphatidylcholine (PC) resistance in Helicobacter pylori with the 
assimilated steroids 
the phosphatidylcholine resistance in Helicobacter pylori with another assimilated steroid. We 
have shown that Helicobacter pylori efficiently absorbs and retains the female hormone 
estrone into the membranes, but fails to glucosylate the estrogen (Hosoda et al., 2009). In 
addition, we have also found that other female hormone estriol is not absorbed into the 
membranes of Helicobacter pylori. Therefore, we decided to use estrone and estriol as steroid 
tools that are not glucosylated by Helicobacter pylori. After the steroid-free Helicobacter pylori 
was cultured for 24 hours with estrone (50 µM concentration) in a serum-free medium with 
continuous shaking under microaerobic conditions, the recovered organism (107 CFU/ml) 
that had assimilated estrone without glucosylation in the membranes was incubated for 
further 24 hours with each phosphatidylcholine (100 µg/ml), which carries either a linoleic 
acid molecule or an arachidonic acid molecule at the carbon-2 position of the glycerol 
backbone, in a serum-free medium (3 ml) with continuous shaking under the same 
conditions. As with the Helicobacter pylori that assimilated free-cholesterol into the 
membranes, the organism with the assimilated estrone also resisted the bactericidal action of 
the two phosphatidylcholine variants, and the CFU was maintained to a high level (> 106 
CFU/ml) comparable to the control CFU (107 CFU/ml) of Helicobacter pylori incubated for 24 
hours without either the phosphatidylcholines. Helicobacter pylori has, in sum, expressed 
phosphatidylcholine resistance even when assimilated estrone (E1) without glucosylating it. 
In addition, this finding indicates that the glucosylation of steroid is so far not important in 
conferring resistance to the bactericidal action of phosphatidylcholine upon Helicobacter 
pylori, although the glucosylation of steroid is essential for Helicobacter pylori to evade the 
host immune systems. In contrast, the Helicobacter pylori treated for 24 hours with estriol (50 
µM concentration) succumbed to the bactericidal action of the two phosphatidylcholine 
variants as with the steroid-free organism, and the CFU level reduced from 107 CFU/ml to < 
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the phosphatidylcholine resistance in Helicobacter pylori with another assimilated steroid. We 
have shown that Helicobacter pylori efficiently absorbs and retains the female hormone 
estrone into the membranes, but fails to glucosylate the estrogen (Hosoda et al., 2009). In 
addition, we have also found that other female hormone estriol is not absorbed into the 
membranes of Helicobacter pylori. Therefore, we decided to use estrone and estriol as steroid 
tools that are not glucosylated by Helicobacter pylori. After the steroid-free Helicobacter pylori 
was cultured for 24 hours with estrone (50 µM concentration) in a serum-free medium with 
continuous shaking under microaerobic conditions, the recovered organism (107 CFU/ml) 
that had assimilated estrone without glucosylation in the membranes was incubated for 
further 24 hours with each phosphatidylcholine (100 µg/ml), which carries either a linoleic 
acid molecule or an arachidonic acid molecule at the carbon-2 position of the glycerol 
backbone, in a serum-free medium (3 ml) with continuous shaking under the same 
conditions. As with the Helicobacter pylori that assimilated free-cholesterol into the 
membranes, the organism with the assimilated estrone also resisted the bactericidal action of 
the two phosphatidylcholine variants, and the CFU was maintained to a high level (> 106 
CFU/ml) comparable to the control CFU (107 CFU/ml) of Helicobacter pylori incubated for 24 
hours without either the phosphatidylcholines. Helicobacter pylori has, in sum, expressed 
phosphatidylcholine resistance even when assimilated estrone (E1) without glucosylating it. 
In addition, this finding indicates that the glucosylation of steroid is so far not important in 
conferring resistance to the bactericidal action of phosphatidylcholine upon Helicobacter 
pylori, although the glucosylation of steroid is essential for Helicobacter pylori to evade the 
host immune systems. In contrast, the Helicobacter pylori treated for 24 hours with estriol (50 
µM concentration) succumbed to the bactericidal action of the two phosphatidylcholine 
variants as with the steroid-free organism, and the CFU level reduced from 107 CFU/ml to < 
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103 CFU/ml, when the estriol-treated organism was incubated for 24 hours in the serum-free 
medium containing the respective phosphatidylcholine variants (100 µg/ml) to which either 
a linoleic acid or an arachidonic acid is attached as the acyl group. These results, together 
with our findings on the free-cholesterol assimilation in Helicobacter pylori, indicate that 
bacteria of this species acquire a resistance against the bacteriolytic activity of 
phosphatidylcholine by assimilating the exogenous steroids into the membranes (Fig. 5). 
Phosphatidylcholine is not a single molecule, but a family of variants with different fatty 
acid compositions attached to the glycerol backbone of the phosphatidylcholine (Fig. 3). The 
predominant phosphatidylcholine in human serum has been known to carry a palmitic acid 
(C16:0) molecule and a linoleic acid (C18:2) molecule, and recently, the predominant 
phosphatidylcholine in the human gastric mucus has also been shown to carry the same two 
fatty acids (Orihara et al., 2001). One of the two phosphatidylcholines investigated as to the 
anti-Helicobacter pylori effect by our group is exactly its variant carrying a palmitic acid 
molecule and a linoleic acid molecule: 2-linoleoyl-1-palmitoyl-sn-3-phosphocholine. In sum, 
the phosphatidylcholine attaching a palmitic acid and a linoleic acid to the carbon-1 position 
and to the carbon-2 position in the glycerol backbone is the most prevalent 
phosphatidylcholine in humans. Helicobacter pylori colonizes the human gastric epithelium 
and inhabits the human stomach for many years. On this basis, we can assume that Helico- 
bacter pylori is constantly exposed to various phosphatidylcholine variants, particularly the 
phosphatidylcholine carrying a palmitic acid molecule and a linoleic acid molecule. Our 
recent study, in sum, indicates that the steroid assimilation in Helicobacter pylori plays an 
important role in reinforcing the membrane lipid barrier and conferring resistance to the 
bacteriolytic action of hydrophobic compounds such as phosphatidylcholine. 
6. The 3=O steroids and Helicobacter pylori 
Testosterone, androstenedione and progesterone possess an oxo (3=O) group at the carbon-3 
position of the steroid framework. Our recent studies have revealed that Helicobacter pylori 
cannot use as the membrane lipid components these 3=O steroids and rather succumbs to 
the antibacterial action of certain 3=O steroids. This paragraph describes the 3=O steroids as 
bactericidal agents to Helicobacter pylori. 
6.1 Testosterone and Helicobacter pylori 
Like estriol, testosterone also was not utilized as the membrane lipid component of 
Helicobacter pylori: the TLC analysis did not detect testosterone in the membrane lipid 
compositions of Helicobacter pylori cultured for 24 hours with this androgen at the 50 µM 
concentration (Hosoda et al., 2009). Testosterone did not, therefore, contribute to the 
phosphatidylcholine resistance upon Helicobacter pylori (Shimomura et al., 2009). In addition, 
this 3=O steroid at the 50 µM concentration hardly affected the growth of Helicobacter pylori. 
6.2 Androstenedione and Helicobacter pylori 
When Helicobacter pylori (105 CFU/ml) was cultured for 24 hours in the serum-free medium 
(3 ml) containing androstenedione at concentrations ranging from 10 to 100 µM with 
continuous shaking under microaerobic conditions, this 3=O steroid exhibited inhibitory 
effect on the growth of Helicobacter pylori at concentrations grater than 50 µM. Andro- 
stenedione was, however, relatively low potency in inhibiting the growth of Helicobacter 
pylori. The decrease in CFU (104 CFU/ml) of Helicobacter pylori cultured with 
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androstenedione at the 100 µM concentration was slight compared to the baseline CFU (105 
CFU/ml) immediately after the culture initiation (Hosoda et al., 2011). 
6.3 Progesterone and Helicobacter pylori 
Of the three 3=O steroid hormones (testosterone, androstenedione, and progesterone) 
investigated, the progesterone has demonstrated the most effective anti-Helicobacter pylori 
action. Progesterone efficiently inhibited the growth of Helicobacter pylori by a manner 
dependent on the greater doses added into the medium, and the CFU of the organism in the 
presence of progesterone at the 100 µM concentration was below the limits of detection (< 10 
CFU/ml), when Helicobacter pylori (106 CFU/ml) was cultured for 24 hours in the serum-free 
medium (3 ml) containing progesterone at concentrations ranging from 10 to 100 µM with 
continuous shaking under microaerobic conditions (Hosoda et al., 2011). 
6.4 Progesterone derivatives and Helicobacter pylori 
We have discovered the effective anti-Helicobacter pylori action of progesterone. Progesterone 
has at least two derivatives, namely, 17-hydroxyprogesterone and 17-
hydroxyprogesterone caproate. The derivatives, 17-hydroxyprogesterone and 17-
hydroxyprogesterone caproate are modified by a hydroxyl group and an acyl group 
(caproic acid), respectively, at the carbon-17 position of the progesterone framework. 17-
hydroxylprogesterone is a natural progesterone derivative, while 17-hydroxyprogesterone 
caproate is a synthetic progesterone derivative. Noting this, we have examined the anti-
Helicobacter pylori action of these progesterone derivatives. When Helicobacter pylori (106 
CFU/ml) was cultured for 24 hours in a serum-free medium (3 ml) containing 17-
hydroxyprogesterone with continuous shaking under microaerobic conditions, surprisingly, 
this natural progesterone derivative had no influence on the growth of Helicobacter pylori: 
even in the presence of 17-hydroxyprogesterone at the 100 µM concentration, the CFU was 
comparable to the control CFU (108 CFU/ml) of Helicobacter pylori cultured for 24 hours 
without steroid. In contrast, 17-hydroxyprogesterone caproate had a stronger anti-
Helicobacter pylori action than progesterone, and the CFU was below the limits of detection 
(< 10 CFU/ml), when the organism (106 CFU/ml) was cultured for 24 hours with 17-
hydroxyprogesterone caproate at the 10 µM concentration in a serum-free medium with 
continuous shaking under microaerobic conditions. Incidentally, caproic acid (C6:0), a 
constituent of 17-hydroxyprogesterone caproate, did not affect the viability of Helicobacter 
pylori even when added into the bacterial cell suspension at a 100 µM concentration (Hosoda 
et al., 2011). These findings suggest that the acylation at the carbon-17 position in the 
progesterone framework plays an important role in reinforcing the anti-Helicobacter pylori 
action of progesterone. 
6.5 Antibacterial effects of progesterone and its derivative on Helicobacter pylori 
To ascertain the antibacterial potencies of progesterone and 17-hydroxyprogesterone 
caproate, we investigated the time-dependent antibacterial effects of these two gestagens on 
Helicobacter pylori (Fig. 6A). When Helicobacter pylori (approximately 107 CFU/ml) was 
incubated with progesterone (100 µM) or 17-hydroxyprogesterone caproate (100 µM) in a 
serum-free medium (3 ml) at various time points with shaking under microaerobic 
conditions, the CFUs of the organism incubated with progesterone (PS) moved along a  
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Fig. 6. Antibacterial effects of progesterone (PS) and 17-hydroxyprogesterone caproate 
(17PSCE) on Helicobacter pylori 
gently-sloping curve, falling below the limits of detection (< 10 CFU/ml) by 24 hours after 
the start of incubation. In contrast, the CFUs of Helicobacter pylori incubated with 17-hy- 
droxyprogesterone caproate (17PSCE) dropped off sharply, falling the limits of detection 
within 4 hours after the start of incubation. In sum, 17-hydroxyprogesterone caproate 
(17PSCE) has been found to be much more prompt in conferring the antibacterial action 
fatal to Helicobacter pylori than progesterone (PS). 
6.6 Bacteriolysis in Helicobacter pylori caused by the cell surface binding of 
progesterone and its derivative 
To clarify the antibacterial mechanism of progesterone and 17-hydroxyprogesterone 
caproate against Helicobacter pylori, we measured an optical density (OD660 nm) in the 
bacterial cell suspensions after Helicobacter pylori (108 CFU/ml) was incubated for 24 hours 
with progesterone (100 µM) or 17-hydroxyprogesterone caproate (100 µM) in a serum-free 
medium (3 ml) with continuous shaking under microaerobic conditions. The decline of 
OD660 nm means that the bacterial cells in suspension had been lysed via certain physical or 
chemical actions. As it turned out, the OD660 nm of the bacterial cell suspension incubated 
with progesterone or 17-hydroxyprogesterone caproate declined to half value of that of the 
control cell suspension of Helicobacter pylori incubated for 24 hours in the absence of steroid 
(Fig. 6B). 
To confirm the cell lysis of Helicobacter pylori, we examined the bacterial morphologies using 
a differential interference microscope (Fig. 7). When Helicobacter pylori (107 CFU/ml) was 
incubated for 24 hours in a serum-free medium in the presence or absence of the two 3=O 
steroids, the control cell suspension of Helicobacter pylori incubated without the steroids 
harbored the organisms in both mixed rod and coccoid forms. In contrast, the cell 
suspension of the Helicobacter pylori incubated with progesterone (100 µM) or 17-
hydroxyprogesterone caproate (100 µM) harbored hardly any organisms, although objects 
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such as cellular debris were observed. These results, together with the findings from the 
measurement of OD660 nm in the bacterial cell suspension, suggest that Helicobacter pylori cells 




Fig. 7. Cell lysis on Helicobacter pylori induced by progesterone (PS) and 17-
hydroxyprogesterone caproate (17PSCE) 
Next, we carried out a series of experiments to examine whether progesterone and 17-
hydroxyprogesterone caproate induce the cell lysis of Helicobacter pylori via membrane 
injury. After Helicobacter pylori (109 CFU/ml) was incubated for 5 hours with progesterone 
(100 µM) or 17-hydroxyprogesterone caproate (100 µM) using phosphate-buffered saline 
(PBS: 10 ml), in place of the serum-free medium, with continuous shaking under 
microaerobic conditions, the proteins in the bacterial cell supernatant were analyzed by 
SDS-PAGE. The protein bands detected in the cell supernatant of Helicobacter pylori 
incubated with progesterone or 17-hydroxyprogesterone caproate were considerably 
denser than the protein bands detected in the control cell supernatant of Helicobacter pylori 
incubated for 5 hours without steroid. A band for flavodoxin (FldA), an intracellular 
protein, was also found among the other protein bands. Though progesterone conferred 
the remarkable antibacterial effect to Helicobacter pylori suspended into the PBS, the 
potency of progesterone to decrease the CFU of Helicobacter pylori was somewhat lower 
than that of 17-hydroxyprogesterone caproate. In addition, the control CFU of 
Helicobacter pylori suspended into PBS without steroid was also decreased, but the 
decrease magnitude in the CFU was slight. The amount of FldA protein detected in the 
bacterial cell supernatant correlated closely with the decreases of CFU: the FldA protein 
band became more noticeable when the CFU decreased by a greater magnitude. In sum, a 
large amount of FldA protein has leaked from the Helicobacter pylori cells to outside, when 
the organism was exposed to progesterone and 17-hydroxyprogesterone caproate. These 
results indicate that progesterone and 17-hydroxyprogesterone caproate injure the 
membranes of Helicobacter pylori and thereby induce the cell lysis more promptly than 
autolysis (Hosoda et al., 2011). 
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such as cellular debris were observed. These results, together with the findings from the 
measurement of OD660 nm in the bacterial cell suspension, suggest that Helicobacter pylori cells 
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determined the minimum inhibitory concentrations (MICs) of these 3=O steroids by the 
following method. Progesterone or 17-hydroxyprogesterone caproate was serially diluted 
2-fold with a dimethyl sulfoxide (DMSO) solution and added to agar plates of serum-free 
medium. Bacterial cell suspension (10 µl) adjusted to approximately 107 CFU/ml was dotted 
onto agar plates containing progesterone or 17-hydroxyprogesterone caproate (from 1.6 
µM to 100 µM) and cultured for 1 week under microaerobic conditions. The MICs (µM) of 
progesterone and 17-hydroxyprogesterone caproate for the four Helicobacter pylori strains 
(NCTC 11638, ATCC 43504, the clinical isolates A-13 and A-19), Escherichia coli strain NIH 
JC-2, Pseudomonas aeruginosa strain ATCC 10145, Staphylococcus aureus strain FDA 209D, and 
Staphylococcus epiderimidis strain sp-al-1 were determined by confirming the growth of 
colonies from the organisms on the agar plates. As it turned out, the MICs of progesterone 
and 17-hydroxyprogesterone caproate for the four Helicobacter pylori strains were 50 µM 
and 3.1 µM, respectively (Table 1). Intriguingly, progesterone and 17-hydroxyprogesterone 
caproate had no influence on the growth of the other four bacterial species, namely, 
Escherichia coli, Pseudomonas aeruginosa, Staphylococcus aureus, and Staphylococcus epiderimidis: 
all four species grew even in the presence of progesterone or 17-hydroxyprogesterone 
caproate at 100 µM (the highest concentration examined). The antibacterial spectra of 
progesterone and 17-hydroxyprogesterone caproate have, thus, been remarkably narrow. 
The four bacterial species, Escherichia coli, Pseudomonas aeruginosa, Staphylococcus aureus, and 
Staphylococcus epiderimidis have no capability to incorporate exogenous steroids into the 
membranes. Given the unique feature of Helicobacter pylori as an aggressive assimilator of 
exogenous steroids, we can assume that progesterone and 17-hydroxyprogesterone 
caproate attacked Helicobacter pylori without targeting the other four bacterial species. 
 
 
Table 1. MICs of progesterone (PS) and 17-hydroxyprogesterone caproate (17PSCE) for 
various bacterial species 
7. Investigation of the steroid-binding site on Helicobacter pylori 
As described above, we have demonstrated the relationship between Helicobacter pylori and 
steroids. Certain steroids such as free-cholesterol and estrone have been found to be 
beneficial for the survival of Helicobacter pylori. Conversely, other steroids such as estradiol 
and progesterone have been found to impair the viability of Helicobacter pylori. From these 
findings, in sum, Helicobacter pylori seems to bind various steroids to the identical regions on 
the cell surface. In light of this, we hypothesized that progesterone and free-cholesterol act 
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to steroid-binding sites existing on the Helicobacter pylori cell surface. To verify this 
hypothesis, we carried out the following experiments (Hosoda et al., 2011). After a 24-hour 
preculture of Helicobacter pylori (106 CFU/ml) with progesterone (5 µM or 10 µM) in a serum-
free medium (30 ml), the Helicobacter pylori cells (108 CFU/ml) recovered were incubated for 
4 hours in a serum-free medium (30 ml) containing free-cholesterol fixed-beads (free-
cholesterol concentration: 250 µM). Thereafter, the amount of free-cholesterol absorbed into 
the Helicobacter pylori cells was quantified via the ferric chloride-sulfuric acid reagent 
method. The amount of free-cholesterol per CFU obviously tended to reduce by 
preculturing Helicobacter pylori with progesterone. These results suggest that progesterone 
strongly binds to the Helicobacter pylori cell surface and thereby obstructs the free-cholesterol 
absorption of Helicobacter pylori by inhibiting the cell surface binding of free-cholesterol. 
Incidentally, progesterone had no influence on the viability of Helicobacter pylori at the 5 and 
10 µM concentrations: the CFUs of the Helicobacter pylori cultured for 24 hours with 
progesterone were similar to the control CFU (108 CFU/ml) of the Helicobacter pylori 
cultured for 24 hours without progesterone. 
Helicobacter pylori glucosylates the absorbed free-cholesterol and synthesizes glucosyl 
cholesterols (CGL, CAG and CPG). With this in mind, we decided to examine the influence 
of progesterone on the glucosylation of free-cholesterol. After a 24-hour preculture of 
Helicobacter pylori (106 CFU/ml) in the presence or absence of progesterone (10 µM) in a 
serum-free medium (30 ml), the Helicobacter pylori cells (108 CFU/ml) recovered were 
incubated for 4 hours with free-cholesterol fixed-beads (free-cholesterol concentration: 250 
µM) in a serum-free medium (30 ml), and the membrane lipids were purified to analyze the 
glucosyl cholesterol levels in the membrane lipid compositions by TLC. The TLC analysis 
detected the glucosyl cholesterols (CGL, CAG and CPG) in the membrane lipids of 
Helicobacter pylori precultured with progesterone, although no free-cholesterol was found to 
have accumulated within the lipids. Meanwhile, the glucosyl cholesterol levels detected in 
the membrane lipids of Helicobacter pylori precultured with progesterone were similar to the 
glucosyl cholesterol levels detected in the membrane lipids of Helicobacter pylori precultured 
without progesterone. Progesterone has been found to exert no inhibitory effects on the 
enzymes involved in the glucosyl cholesterol synthesis. 
Next, we examined whether free-cholesterol conversely inhibits the anti-Helicobacter pylori 
action of progesterone. When the Helicobacter pylori (106 CFU/ml) was cultured for 24 hours 
with free-cholesterol fixed-beads at various volumes (free-cholesterol concentration: 30 to 
90 µM) in a serum-free medium (15 ml) containing progesterone (30 µM), the free-chole- 
sterol did not inhibit the anti-Helicobacter pylori action of progesterone: the CFU increase was 
not observed in any concentrations of free-cholesterol, and the CFU levels hardly altered 
from the control CFU (106 CFU/ml) of Helicobacter pylori cultured for 24 hours with 
progesterone in the absence of free-cholesterol fixed-beads. These results, at least, indicate 
that free-cholesterol does not competitively inhibit the anti-Helicobacter pylori action of 
progesterone. This compelled us, in sum, to examine the inhibitory effect of a high 
concentration of free-cholesterol on the anti-Helicobacter pylori action of progesterone. When 
the Helicobacter pylori (106 CFU/ml) was cultured for 24 hours with progesterone at 
concentrations ranging from 10 to 30 µM in a serum-free medium (15 ml) containing free-
cholesterol fixed-beads (free-cholesterol concentration: 500 µM) or simple-beads (the 
volumes similar to the free-cholesterol fixed-bead volumes), free-cholesterol at the highest 
concentration (500 µM) had a noticeable influence on the anti-Helicobacter pylori action of the  
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Fig. 8. The obstruction of free-cholesterol (FC) absorption in Helicobacter pylori by 
progesterone (PS) 
progesterone: the growth-inhibitory curve of Helicobacter pylori cultured with progesterone 
in the presence of free-cholesterol fixed-beads shifted from the control growth-inhibitory 
curve of Helicobacter pylori cultured with progesterone in the presence of simple-beads to the 
right side, when the CFU values (log10 CFU/ml: vertical axis) and the progesterone 
concentrations (µM: horizontal axis) were plotted in a graph. These results indicate that free-
cholesterol noncompetitively inhibits the anti-Helicobacter pylori action of progesterone. In 
combination with the results of the inhibitory effect of progesterone on the binding of free-
cholesterol onto the Helicobacter pylori cells, they also strongly suggest that progesterone 
non-reversibly binds to the Helicobacter pylori cells and thereby induces the cell lysis, and/or 
inhibits the free-cholesterol absorption of the organism. 
Our recent study has shown that progesterone inhibits the free-cholesterol absorption of 
Helicobacter pylori, and conversely, that a relatively high concentration of free-cholesterol 
inhibits the anti-Helicobacter pylori action of progesterone. Progesterone and free-cholesterol, 
in sum, seem to bind to identical sites on the Helicobacter pylori cell surfaces and thereby 
obstruct each other’s effects (Fig. 8). This suggests that Helicobacter pylori may express a 
certain component, such as a steroid-binding protein, on the cell surface. Further 
investigations will be required to elucidate whether such a steroid-binding protein does 
indeed exist in Helicobacter pylori. 
8. Conclusion 
Our current basal research has revealed the following relationship between Helicobacter 
pylori and steroid hormones: pregnenolone (PN), dehydroepiandrosterone (DEA), 
epiandrosterone (EA), and estrone (E1) are absorbed into the membranes of Helicobacter 
pylori and play an important role to reinforcing the membrane lipid barrier, and thereby 
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Helicobacter pylori acquires the phosphatidylcholine resistance. Conversely, estradiol, 
androstenedione, and progesterone are harmful for the survival of Helicobacter pylori, and 
especially progesterone (PS) exhibit more effective antibacterial action to Helicobacter pylori 
than the other steroid hormones (Fig. 9). In addition, we have discovered that the acylation 
at the carbon-17 position of progesterone framework considerably augments the anti-
Helicobacter pylori action of progesterone and that the hydroxylation at the same carbon 
position of progesterone framework conversely cancels out this action of progesterone. In 
sum, 17-hydroxyprogesterone caproate (17PSCE) exhibits much stronger anti-Helicobacter 
pylori action than progesterone, whereas 17-hydroxyprogesterone has no anti-Helicobacter 
pylori action. These findings are expected to contribute to the development of a novel 
antibacterial steroidal medicine that targets Helicobacter pylori as an aggressive assimilator of 
exogenous steroids. Particularly, progesterone may be useful as a fundamental structure for 













Fig. 9. The relationship between Helicobacter pylori and steroid hormones 
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1. Introduction 
Globally, ovarian cancer is the 6th most common malignancy in developed countries, 
responsible for 100,300 new cases and 64,500 deaths annually (Jemal et al., 2011). 
Approximately 90% of ovarian cancers arise within the ovarian surface epithelium (OSE) or 
the fallopian tube surface epithelium; the remainder of ovarian malignancies develops from 
other ovarian tissues (sex cord-stromal, germ cell, or mixed cell tumors). The overall 
prognosis for epithelial ovarian carcinoma (EOC) is poor: Diagnosis is typically late-stage 
due to the lack of effective screening methods and vague presenting symptoms, with 5-year 
survival at 40% for stage III and 20% for stage IV patients (Heintz et al., 2006).  Despite 
excellent initial activity, the standard treatment consisting of cytoreductive surgery followed 
by platinum- and taxane-based chemotherapy often fails with a recurrence rate of over 80% 
in stage III and IV disease. Therefore, novel therapeutic approaches are needed to improve 
the outcomes in this population. 
Research efforts have yielded insight into the etiology, signaling mechanisms, and 
progression of ovarian cancer, yet much remains poorly understood.  Physiologically, 
steroid hormones are intimately involved in ovulation, reproduction, and function of 
normal OSE cells. There is growing evidence that estrogen, progesterone, and other 
hormones also play a role in the development and progression of ovarian cancer (Leung & 
Choi, 2007). “Incessant ovulation” with repetitive injury and repair of OSE and subsequent 
cumulative DNA damage is one of the hypothesized risk factors for ovarian cancer 
(Fathalla, 1971), yet this does not explain the occurrence of the majority of ovarian 
carcinomas well after the reproductive years (Berek & Hacker, 2010). Interestingly, although 
oral contraceptives (OCs), increasing parity, and prolonged breastfeeding all decrease 
cumulative risk (Gwinn et al., 1990; Risch et al., 1994), progestin-only contraceptives offer 
just as much protective benefit as estrogen-containing OCs without prohibiting ovulation 
(Risch, 1998).  Another hypothesis for the development of ovarian cancer, the “gonadotropin 
hypothesis,” stipulates that gonadotropins contribute to ovarian carcinogenesis through 
follicle stimulating hormone (FSH)- and luteinizing hormone (LH)-mediated excess 
stimulation of ovarian tissue. This hypothesis is consistent with the protective effect of OCs, 
and the observation that the majority of cases of epithelial ovarian cancer develop 
postmenopausally after a surge in gonadotropin levels. In vitro, gonadotropins such as FSH 
activate mitogenic pathways and stimulate ovarian epithelial cell proliferation (Choi et al., 
2002). In addition to gonadotropins, excess androgens and estrogen have also been linked to 
the progression and possibly development of ovarian cancer. In vivo treatment of mice with 
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estrogen significantly increases tumor growth (Armaiz-Pena et al., 2009). These observations 
suggest that in addition to regulation of the menstrual cycle, certain steroid hormones may 
promote the progression—and possibly development—of ovarian cancer, while others offer 
a protective benefit. The objectives of this chapter are to summarize the signaling 
mechanisms involved in normal human OSE and its neoplastic counterparts, to highlight 
the effects of these steroid hormones on ovarian cancer cell growth, and to discuss the 
current clinical trials utilizing anti-hormonal approaches in ovarian cancer patients.  
2. Steroid hormone signaling in normal ovarian surface epithelium and 
ovarian cancer 
2.1 Steroid signaling in normal ovarian surface epithelium 
Human ovarian surface epithelium is formed by a single layer of squamous to cuboidal cells 
covering the outermost layer of the ovary. While the exact function of OSE is unclear, with 
each ovulatory cycle, the OSE undergoes damage and repair. This damage incites an 
inflammatory response, the sequelae of which have been implicated in neoplastic 
transformation to tumor cells (Murdoch & Martinchick, 2004; Ness et al., 2000). Although 
steroid synthesis takes place elsewhere in the ovary, both normal and malignant OSE 
display estrogen, progesterone, and androgen receptors (Karlan et al., 1995; Lau et al., 1999; 
Li et al., 2003), and take part in steroid signaling. OSE also have FSH and LH receptors, 
though in vitro studies suggest these stimulate cellular growth and proliferation rather than 
steroidogenesis in OSE (Choi et al., 2004; Ji et al., 2004).  
2.1.1 Estrogen and progesterone signaling in normal ovarian surface epithelium 
Though the purpose of steroid signaling within the OSE remains uncertain, the effects of 
these steroids have been characterized in vivo and in vitro. The estrogen receptor (ER) and 
progesterone receptor (PR) are intracellular nuclear hormone receptors, which upon 
localization to the nucleus prompt transcriptional activity. Furthermore, the estrogen 
receptor participates in pathway crosstalk with known mitogenic pathways which have 
been associated with tumor progression and drug resistance, including transforming growth 
factor-Beta (TGF-β), human epidermal growth factor receptor 2 (HER-2/neu), and the 
insulin-like growth factor (IGF) receptors (Arpino et al., 2008; Band & Laiho, 2011; Fagan & 
Yee, 2008). In OSE, low doses of estrogen cause proliferation of ovarian surface epithelial 
cells in vitro, which involves the interleukin-6 (IL-6)/signal transducer and activator of 
transcription 3 (STAT-3) pathway (Syed et al., 2002). Others, however, have documented no 
effect at low doses of estrogen (Choi et al., 2001b; Karlan et al., 1995), or an inhibitory effect 
at high doses in OSE (Wright et al., 2005). In vivo, estrogen exposure causes rabbit OSE cell 
proliferation and an increase in the number of papillae but does not result in spontaneous 
development of tumors (Bai et al., 2000). In comparing normal OSE to ovarian carcinoma 
cell lines, Lau et al. (1999) found loss of ERα, PR, and androgen receptor (AR) mRNA in 
neoplastic cells compared to OSE, suggesting this loss may contribute to neoplastic 
transformation. Though the role of ERβ in Lau’s work was uncertain, others assert that the 
ERβ receptor subtype promotes apoptosis in OSE (Bardin et al., 2004).  
While estrogen has an unclear effect on cellular proliferation in OSE, progestins have a 
consistent effect of inhibiting cell growth and inflammation, and promoting apoptosis 
(Ivarsson et al., 2001; Karlan et al., 1995; Rae et al., 2004a). In vivo, macaques treated with 
progestin exhibited upregulation of apoptosis in OSE cells (Rodriguez et al., 1998). Though 
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the exact mechanism by which progesterone exhibits growth-inhibitory effects is not fully-
understood, Syed and Ho (2003) demonstrated involvement of the caspase 8 Fas/FasL 
pathway in progesterone-mediated apoptosis in OSE.  
Culturing OSE in vitro with the inflammatory mediator IL-1 results in upregulation of 
several inflammation-associated genes, specifically HSD11B1, which plays a role in 
conversion of cortisone to cortisol (Rae et al., 2004b). With well-documented anti-
inflammatory effects, cortisol prohibits downstream inflammatory signaling and may 
therefore exhibit a protective effect on the OSE. Together with the anti-inflammatory and 
growth-inhibitory effects of progesterone, glucocorticoids and progestin may serve to 
protect the OSE from inflammatory damage resulting from ovulation (Rae & Hillier, 2005).  
2.1.2 Gonadotropin signaling in normal ovarian surface epithelium    
The gonadotropins FSH and LH are members of a glycoprotein hormone family which also 
include thyroid stimulating hormone (TSH) and human placental chorionic gonadotropin 
(hCG). Gonadotropin receptors belong to the G protein-coupled receptor family (GPCR), 
which harbor seven transmembrane domains and upon their activation convert guanosine 
diphosphate (GDP) to guanosine triphosphate (GTP). This subsequently results in 
downstream activation of the phosphatidylinositol-3-kinase (PI3K) pathway; a pathway 
whose involvement in oncogenesis has been well-characterized. The type I isoform of 
gonadotropin-releasing hormone (GnRH) and its receptor are found on OSE, and 
interestingly, GnRH analogs appear to inhibit growth of OSE and ovarian cancer cells in 
vitro (Kang et al., 2000). The GnRH type II isoform also has growth inhibitory effects in vitro. 
(Choi et al., 2001a). While the exact mechanism of growth inhibition is not fully-understood, 
it is discussed in more detail later in the chapter.  
Synthesized in the anterior pituitary, the gonadotropins FSH and LH regulate the menstrual 
cycle: FSH stimulates follicular growth and the FSH receptor (FSHR) is expressed mainly in 
granulosa cells, while LH triggers ovulation and the LH receptor (LHR) is expressed mostly 
in theca but also by granulosa cells. FSHRs and LHRs are found in both OSE and ovarian 
cancer cells (Minegishi et al., 2000; Parrott et al., 2001).  Leung and Choi (2007) characterized 
the signaling pathway of FSHR in preneoplastic immortalized OSE, and found that 
Extracellular-Related Signaling Kinase 1/2 (ERK 1/2), c-myc, and HER2/neu were 
upregulated, and cell growth was accelerated in response to FSHR overexpression. 
Epidermal growth factor receptor (EGFR) is also upregulated via the ERK 1/2 and 
PI3K/Akt pathways in immortalized OSE treated with gonadotropins (Choi et al., 2005). 
Others have similarly confirmed increased proliferation in OSE in response to FSH and LH 
administration (Choi et al., 2002; Syed et al., 2001). In vitro, treatment with FSH results in 
upregulation oncogenic  genes and downregulation of tumor suppressor genes RB1, BRCA1, 
and BS69 (Ji et al., 2004).   
2.2 Steroid signaling in ovarian cancer 
Steroid hormone signaling in ovarian cancer involves complex pathways which are not yet 
fully understood. Figure 1 depicts some of the established routes of signaling in EOC.  
2.2.1 The role of estrogen in ovarian cancer 
Although the influence of exogenous estrogen in OSE is ambiguous, it most certainly 
triggers proliferation and cellular growth in ovarian cancer cells (Choi et al., 2001b). This is  
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Fig. 1. Steroid hormone signaling in ovarian cancer.  
accomplished in part through activation of the PI3K/Akt pathway and the transcription 
factor c-myc (Chien et al., 1994), and via estrogen receptor crosstalk with other pathways 
such as IGF-1, TGF-α, and EGFR (Simpson et al., 1998; Wimalasena et al., 1993). Estrogen 
also inhibits apoptosis via bcl-2, an anti-apoptotic protein (Choi et al., 2001b), and increases 
invasive capacity via upregulation of ezrin (Song et al., 2005), fibulin-1 (Galtier-Dereure et 
al., 1992), cathepsin D (Galtier-Dereure et al., 1992), and kallikreins (Yousef et al., 2003).  In 
ovarian cancer cell lines treated with 17-B-estradiol, pro-angiogenic hypoxia-inducible 
factor-1 (HIF-1) expression was increased, the effect of which was abrogated by the Akt 
inhibitor snf and via Akt short-interfering RNA (siRNA) (Hua et al., 2009).  
Both ER subtypes α and β are expressed in EOC. It has been suggested that ERα is mainly 
responsible for proliferation in the ovary, while ERβ modulates differentiation (Britt & 
Findlay, 2002). This is supported by the fact that ERβ is abundant in OSE and benign 
tumors, and ERα is mainly found in malignant ovarian tumors (Brandenberger et al., 1998; 
Hillier et al., 1998). An increased ERα: ERβ ratio has also been observed in ovarian cancer 
(Cunat et al., 2004), with an increase in ERα and inverse decrease in ERβ expression 
throughout tumor progression (Brandenberger et al., 1998). Overexpression of ERβ in an 
ovarian cancer cell line decreased proliferation by 50%.    
In vivo studies support the role of 17-β-estradiol in accelerating tumor growth. Using a 
transgenic mouse model, Laviolette et al. (2010) showed that treatment of tumors with 17-β-
estradiol resulted in the earlier onset of tumors, decreased survival time, and papillary 
histology, while treatment with progesterone resulted in no difference. Armaiz-Pena et al. 
(2009) similarly showed that treatment with 17-β-estradiol increased ovarian tumor growth, 
and inoculation with tumor cells during the proestrus when estrogen levels are high 
significantly increased tumor burden, compared to inoculation during the estrus phase. 
Furthermore, treatment with 17-β-estradiol resulted in increased vascular endothelial 
growth factor (VEGF), increased cell adhesion in ER positive cells, increased migratory 
potential, and mitogen-activated protein kinase (MAPK) upregulation.  
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Correspondingly, the estrogen antagonist tamoxifen abrogates the estrogen effect in 
epithelial ovarian cancer cell lines, and is surprisingly effective in both ER-positive and ER-
negative and platinum-resistant ovarian carcinomas (Mabuchi et al., 2004; Markman et al., 
1996). In ER-negative ovarian carcinomas, tamoxifen functions independently of estrogen 
via ERK, c-Jun N-terminal protein kinase (JNK), and p38 (Mabuchi et al., 2004).   
2.2.2 The role of progesterone in ovarian cancer 
Progesterone decreases cellular proliferation in vitro via multiple pathways. Blumenthal et 
al. (2003) demonstrated that progesterone activated the cyclin-dependent (CDK) pathway 
and promoted a more differentiated cell type. In the ovarian cancer cell line SKOV3, 
progesterone inhibited invasion and suppressed urokinase plasminogen activator (UPA), 
thereby decreasing the metastatic potential of cells (McDonnel & Murdoch, 2001). As in OSE 
cells, progesterone induces apoptosis via caspases and the FasL pathway (Syed & Ho, 2003), 
and enhances tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced cell 
death (Syed et al., 2007). Recent evidence supports that progesterone also causes apoptosis 
by upregulating the proapoptotic gene expression of p53 and BAX, and decreasing 
antiapoptotic gene expression of BCL-2 in ovarian cancer cells, thereby preventing oxidative 
damage (Nguyen & Syed, 2010).  
In vivo, treatment of athymic mice with progesterone suppressed tumorigenesis after 
inoculation with the ovarian cancer cell line SKOV3 and increased survival (McDonnel et al., 
2005). Furthermore, progesterone treatment in athymic nude mice inoculated with 
platinum-resistant SKOV3 enhanced platinum activity and sensitivity (Murdoch et al., 2008). 
However, the actions of progesterone in ovarian carcinomas is complex, and clinical trials 
utilizing progesterone have not proved as promising as in vivo and in vitro observations. In 
part, this may be due to the action of progesterone receptor membrane component 1 
(PGRMC1), which recently in vitro was found to promote ovarian tumor cell proliferation, 
while its depletion slows cellular growth (Peluso et al., 2008). In vivo, PGRMC1-depleted 
mice had fewer and smaller tumors, again supporting the pro-oncogenic nature of PGRMC1 
(Peluso et al., 2009).  
As is the case with estrogen receptors, different progesterone receptor isoforms exist, including 
isoforms A and B. Akahira et al. examined the expression of PRA and PRB in the normal 
ovary, and in benign, borderline, and malignant ovarian tumors (2002). Using 
immunohistochemistry and RT-PCR in normal and malignant tissue and cell lines, they found 
that PRA receptor expression declined (p<0.05) during the transition from benign to borderline 
to malignant tissues, whereas there was no significant difference in PRB expression. They 
suggest that downregulation of PRA is associated with the development of ovarian cancer. 
2.2.3 The role of gonadotropins in ovarian cancer 
An alternative theory to the incessant ovulation hypothesis is that excessive gonadotropin 
stimulation leads to the development of ovarian cancer. Early animal models simulated 
hypogonadism, which prevented development of ovarian tumors in mice (Marchant, 1961). 
Oral contraceptives, which are proven to reduce the risk of EOC, also provide negative 
feedback on the gonadotropin axis and reduce circulating gonadotropins, which further 
supports this hypothesis. Additionally, the peak incidence of ovarian cancer occurs 
postmenopausally, with a temporal relationship to an increase in circulating gonadotropins 
(Choi et al., 2007).  
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Fig. 1. Steroid hormone signaling in ovarian cancer.  
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potential, and mitogen-activated protein kinase (MAPK) upregulation.  
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Correspondingly, the estrogen antagonist tamoxifen abrogates the estrogen effect in 
epithelial ovarian cancer cell lines, and is surprisingly effective in both ER-positive and ER-
negative and platinum-resistant ovarian carcinomas (Mabuchi et al., 2004; Markman et al., 
1996). In ER-negative ovarian carcinomas, tamoxifen functions independently of estrogen 
via ERK, c-Jun N-terminal protein kinase (JNK), and p38 (Mabuchi et al., 2004).   
2.2.2 The role of progesterone in ovarian cancer 
Progesterone decreases cellular proliferation in vitro via multiple pathways. Blumenthal et 
al. (2003) demonstrated that progesterone activated the cyclin-dependent (CDK) pathway 
and promoted a more differentiated cell type. In the ovarian cancer cell line SKOV3, 
progesterone inhibited invasion and suppressed urokinase plasminogen activator (UPA), 
thereby decreasing the metastatic potential of cells (McDonnel & Murdoch, 2001). As in OSE 
cells, progesterone induces apoptosis via caspases and the FasL pathway (Syed & Ho, 2003), 
and enhances tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced cell 
death (Syed et al., 2007). Recent evidence supports that progesterone also causes apoptosis 
by upregulating the proapoptotic gene expression of p53 and BAX, and decreasing 
antiapoptotic gene expression of BCL-2 in ovarian cancer cells, thereby preventing oxidative 
damage (Nguyen & Syed, 2010).  
In vivo, treatment of athymic mice with progesterone suppressed tumorigenesis after 
inoculation with the ovarian cancer cell line SKOV3 and increased survival (McDonnel et al., 
2005). Furthermore, progesterone treatment in athymic nude mice inoculated with 
platinum-resistant SKOV3 enhanced platinum activity and sensitivity (Murdoch et al., 2008). 
However, the actions of progesterone in ovarian carcinomas is complex, and clinical trials 
utilizing progesterone have not proved as promising as in vivo and in vitro observations. In 
part, this may be due to the action of progesterone receptor membrane component 1 
(PGRMC1), which recently in vitro was found to promote ovarian tumor cell proliferation, 
while its depletion slows cellular growth (Peluso et al., 2008). In vivo, PGRMC1-depleted 
mice had fewer and smaller tumors, again supporting the pro-oncogenic nature of PGRMC1 
(Peluso et al., 2009).  
As is the case with estrogen receptors, different progesterone receptor isoforms exist, including 
isoforms A and B. Akahira et al. examined the expression of PRA and PRB in the normal 
ovary, and in benign, borderline, and malignant ovarian tumors (2002). Using 
immunohistochemistry and RT-PCR in normal and malignant tissue and cell lines, they found 
that PRA receptor expression declined (p<0.05) during the transition from benign to borderline 
to malignant tissues, whereas there was no significant difference in PRB expression. They 
suggest that downregulation of PRA is associated with the development of ovarian cancer. 
2.2.3 The role of gonadotropins in ovarian cancer 
An alternative theory to the incessant ovulation hypothesis is that excessive gonadotropin 
stimulation leads to the development of ovarian cancer. Early animal models simulated 
hypogonadism, which prevented development of ovarian tumors in mice (Marchant, 1961). 
Oral contraceptives, which are proven to reduce the risk of EOC, also provide negative 
feedback on the gonadotropin axis and reduce circulating gonadotropins, which further 
supports this hypothesis. Additionally, the peak incidence of ovarian cancer occurs 
postmenopausally, with a temporal relationship to an increase in circulating gonadotropins 
(Choi et al., 2007).  
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Similar to estrogen, FSH promotes ovarian cancer cell growth in vitro. One way this occurs is 
through inhibition of apoptosis through activation of survivin via the PI3K/Akt pathway, 
and downregulation of the programmed cell death gene 6 (PCDG6) and death receptor 5 
(DR5) (Huang et al., 2010).  Promotion of cell growth through FSH also occurs through 
activation of the MAPK, PI3K/Akt pathways (Choi et al., 2002). Overexpression of the FSH 
receptor promotes well-established oncogenic signaling pathways including upregulation of 
EGFR (Choi et al., 2004), and angiogenesis promotion via VEGF upregulation (Schiffenbauer 
et al., 1997; Wang et al., 2002). In ovarian cancer cell lines, both FSH and LH exploit the 
PI3K/Akt pathway to upregulate cyxlooxygenase (COX)-1 and COX-2, resulting in 
increased cell motility and invasion (Lau et al., 2010).   The FSH receptor (FSHR) is also 
prominent in ovarian carcinomas—Ji et al reported higher levels of the FSHR in cancerous 
ovarian tissue compared to normal controls (2004). The role of LH is controversial; in one 
study, LHR mRNA expression decreased in the transition from benign to malignant ovarian 
lesions (Lu et al., 2000). LH also appears to abrogate the proliferative effects of FSH (Zheng 
et al., 2000), but also has been reported to stimulate growth of OSE and contribute to tumor 
progression (Tashiro et al., 2003).  
In vivo, treatment of rats with gonadotropins increased OSE proliferation (Stewart et al., 
2004); similarly, mice treated with gonadotropins experienced increased ovarian cellular 
proliferation and decreased apoptosis (Burdette et al., 2006). Mice displaying 
hypergonadotropism from overexpression of FSH develop multicystic hemorrhagic ovaries, 
while overexpression of LH resulted in the formation of granulosa cell tumors (Kumar et al., 
1999; Risma et al., 1995). However, it is important to note that these tumors formed in 
stromal or granulosa cells—not epithelial cells—and to date, no evidence exists establishing 
that gonadotropins can initiate malignant transformation of the ovarian epithelium.  
2.2.4 The role of androgens in ovarian cancer 
The role of androgens in promoting growth, tumorigenesis, and tumor progression in 
prostate cancer is well-established. In ovarian cancer cell lines, androgens 5α-
dihydrotestosterone (DHT) and testosterone also cause cell proliferation which is mediated 
by upregulation of interleukin-6 (IL-6) (Syed et al., 2001; Syed et al., 2002). Levine and Boyd 
(2001) found that androgen receptor allele length influenced age at diagnosis with ovarian 
cancer; those patients with a shorter AR allele length were diagnosed 7 years earlier than 
those with normal allele length. In vitro, androgens decrease TGF-β receptors levels, which 
provides a mechanism for ovarian cancer cells to evade the growth inhibitory effects of TGF-
β (Evangelou et al., 2000). Shi et al. (2011) examined the role of DHT, testosterone, and 
dehydroepiandrosterone (DHEA) in breast and ovarian cancer cell lines, and found that 
DHT but not the other androgens induced the degradation of the tumor suppressor p27 in 
both cell lines. Furthermore, in ovarian carcinoma cell lines, testosterone and 
androstenedione were found to increase cell viability, and induce telomerase activity which 
was blocked by PI3K inhibitors (Nourbakhsh et al., 2010). Sheach et al. (2009) found that the 
ovarian cancer cell lines OVCAR3 and OSEC2 expressed the androgen receptor, and 
treatment with androgen upregulated 121 genes, including G-protein-related genes Rab25 
and Rab35. Level of gene expression correlated with tumor grade as well.  
2.2.5 The role of GnRH in ovarian cancer 
Two of twelve vertebrate GnRH isoforms exist in humans: GnRHI and GnRHII. GnRHI and 
its receptor are present in 80% of biopsies of ovarian carcinomas (Emons et al., 1989). While 
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GnRH functions in a paracrine manner systemically, there is evidence that GnRH functions 
in an autocrine manner in epithelial ovarian cancer, with GnRHI and GnRHII mRNA 
identified in both ovarian carcinoma and OSE (Choi et al., 2001a; Kang et al., 2000). 
Although the traditional gonadotropin GnRH signaling pathway involves Gαq, protein 
kinase C, and MAP kinases, the autocrine mechanism of GnRH-related signaling in ovarian 
carcinomas differs (So et al., 2008).  Interestingly, it appears that GnRH receptors in ovarian 
malignancy function via the pertussis toxin-sensitive protein Gαi, and activate protein 
phosphatase (Imai et al., 2006). This alternate pathway is responsible for the antiproliferative 
effects of GnRH in ovarian carcinomas; however, the antiapoptotic function of GnRHI 
remains controversial.  GnRHI and its agonists exert an inhibitory effect in ovarian cancer in 
vitro and  in vivo, reducing cell growth and inducing cell cycle arrest in G0/G1 (Kim et al., 
1999). However, GnRH agonists are in fact protective against apoptosis in ovarian cancer cell 
lines treated with doxorubicin (Sugiyama et al., 2005).  Somewhat paradoxically, there is 
also emerging evidence that GnRH promotes tumor cell migration, metastasis, and invasion. 
In vitro, GnRHII enhances Akt pathway activation, and increased nuclear beta-catenin 
accumulation. This was reversed with siRNA targeting the GnRH receptor, and with 
treatment of cells with a PI3K/Akt inhibitor. GnRH treatment also increases type I matrix 
metalloproteinase (MT-1MMP) levels, thereby increasing cells’ invasiveness and metastatic 
potential  which increases cell migration and invasion during tumor progression through 
activation of Rho GTPases and accumulation of p120 catenin, with reversible effects upon 
inhibition of p120 (Cheung et al., 2010). In vivo, mice treated with a GnRH agonist displayed 
increased tumor weight (Romero et al., 2009).  Thus, while GnRH and its agonists work via 
Gαi to decrease cellular growth and proliferation, it also enhances other pathways which 
promote cellular migration and invasion, essentially increasing metastatic potential.  
3. Endogenous steroid hormones and ovarian cancer 
3.1 Endogenous hormones 
Population-based studies have supported the in vitro findings that progestins harbor 
protective effects against ovarian cancer. Conditions in which excess progesterone is present 
decrease cumulative risk of developing EOC, including multiple gestations, multiparity 
with an additional 10% decrease in risk with each birth, and breastfeeding (Lambe et al., 
1999; Risch et al., 1994). While these findings support the incessant ovulation hypothesis by 
sparing the epithelium from monthly ovulations and repetitive damage, there is also 
evidence that progesterone independently increases the magnitude of benefit by promoting 
cellular apoptosis (Rodriguez et al., 1998). 
3.2 Hormone receptors 
Much effort has been directed at correlating hormone receptor status and outcomes in 
ovarian cancer. Geisler et al. (1996) examined estrogen and progesterone receptor status as 
prognostic indicators in patients with optimally cytoreduced stage IIIC serous carcinoma of 
ovary. Out of 96 patients, those with an estrogen receptor level <10 fmol/mg had better 
mean survival (41 vs 34 mos) than patients with higher levels of ER, whereas there was no 
correlation between PR status and survival. Others have found opposing results: One study 
examined ER mRNA expression in 35 stage III-IV ovarian carcinoma patients receiving 
neoadjuvant chemotherapy, and in multivariate analysis found that elevated baseline ER 
mRNA levels predicted prolonged progression-free survival (p=0.041) and overall survival 
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Similar to estrogen, FSH promotes ovarian cancer cell growth in vitro. One way this occurs is 
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et al., 1997; Wang et al., 2002). In ovarian cancer cell lines, both FSH and LH exploit the 
PI3K/Akt pathway to upregulate cyxlooxygenase (COX)-1 and COX-2, resulting in 
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study, LHR mRNA expression decreased in the transition from benign to malignant ovarian 
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et al., 2000), but also has been reported to stimulate growth of OSE and contribute to tumor 
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1999; Risma et al., 1995). However, it is important to note that these tumors formed in 
stromal or granulosa cells—not epithelial cells—and to date, no evidence exists establishing 
that gonadotropins can initiate malignant transformation of the ovarian epithelium.  
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prostate cancer is well-established. In ovarian cancer cell lines, androgens 5α-
dihydrotestosterone (DHT) and testosterone also cause cell proliferation which is mediated 
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and Rab35. Level of gene expression correlated with tumor grade as well.  
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GnRH functions in a paracrine manner systemically, there is evidence that GnRH functions 
in an autocrine manner in epithelial ovarian cancer, with GnRHI and GnRHII mRNA 
identified in both ovarian carcinoma and OSE (Choi et al., 2001a; Kang et al., 2000). 
Although the traditional gonadotropin GnRH signaling pathway involves Gαq, protein 
kinase C, and MAP kinases, the autocrine mechanism of GnRH-related signaling in ovarian 
carcinomas differs (So et al., 2008).  Interestingly, it appears that GnRH receptors in ovarian 
malignancy function via the pertussis toxin-sensitive protein Gαi, and activate protein 
phosphatase (Imai et al., 2006). This alternate pathway is responsible for the antiproliferative 
effects of GnRH in ovarian carcinomas; however, the antiapoptotic function of GnRHI 
remains controversial.  GnRHI and its agonists exert an inhibitory effect in ovarian cancer in 
vitro and  in vivo, reducing cell growth and inducing cell cycle arrest in G0/G1 (Kim et al., 
1999). However, GnRH agonists are in fact protective against apoptosis in ovarian cancer cell 
lines treated with doxorubicin (Sugiyama et al., 2005).  Somewhat paradoxically, there is 
also emerging evidence that GnRH promotes tumor cell migration, metastasis, and invasion. 
In vitro, GnRHII enhances Akt pathway activation, and increased nuclear beta-catenin 
accumulation. This was reversed with siRNA targeting the GnRH receptor, and with 
treatment of cells with a PI3K/Akt inhibitor. GnRH treatment also increases type I matrix 
metalloproteinase (MT-1MMP) levels, thereby increasing cells’ invasiveness and metastatic 
potential  which increases cell migration and invasion during tumor progression through 
activation of Rho GTPases and accumulation of p120 catenin, with reversible effects upon 
inhibition of p120 (Cheung et al., 2010). In vivo, mice treated with a GnRH agonist displayed 
increased tumor weight (Romero et al., 2009).  Thus, while GnRH and its agonists work via 
Gαi to decrease cellular growth and proliferation, it also enhances other pathways which 
promote cellular migration and invasion, essentially increasing metastatic potential.  
3. Endogenous steroid hormones and ovarian cancer 
3.1 Endogenous hormones 
Population-based studies have supported the in vitro findings that progestins harbor 
protective effects against ovarian cancer. Conditions in which excess progesterone is present 
decrease cumulative risk of developing EOC, including multiple gestations, multiparity 
with an additional 10% decrease in risk with each birth, and breastfeeding (Lambe et al., 
1999; Risch et al., 1994). While these findings support the incessant ovulation hypothesis by 
sparing the epithelium from monthly ovulations and repetitive damage, there is also 
evidence that progesterone independently increases the magnitude of benefit by promoting 
cellular apoptosis (Rodriguez et al., 1998). 
3.2 Hormone receptors 
Much effort has been directed at correlating hormone receptor status and outcomes in 
ovarian cancer. Geisler et al. (1996) examined estrogen and progesterone receptor status as 
prognostic indicators in patients with optimally cytoreduced stage IIIC serous carcinoma of 
ovary. Out of 96 patients, those with an estrogen receptor level <10 fmol/mg had better 
mean survival (41 vs 34 mos) than patients with higher levels of ER, whereas there was no 
correlation between PR status and survival. Others have found opposing results: One study 
examined ER mRNA expression in 35 stage III-IV ovarian carcinoma patients receiving 
neoadjuvant chemotherapy, and in multivariate analysis found that elevated baseline ER 
mRNA levels predicted prolonged progression-free survival (p=0.041) and overall survival 
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(p=0.01), independently of pathological grade and age (Zamagni et al., 2009). Another group 
examined hormone receptor status in older and younger patients with advanced papillary 
serous ovarian carcinoma (Liu et al., 2009). They reported a higher percentage of ER-
positivity and PR-negativity in older patients, while both groups were largely Her2/neu 
receptor-negative. Although there was no significant association between receptor status 
and survival, for the younger cohort, those who expressed both ER and PR receptor types 
had better overall survival (OS) (p=0.056) at 51 months, compared to 35 months in those not 
expressing both receptors. In a large cohort of Danish patients with ovarian cancer, Hogdall 
et al (2007) examined the prognostic value of ER and PR status via immunohistochemistry 
and microarray analysis in 582 women with EOC and 191 patients with serous borderline 
ovarian tumors. They noted that ER positivity increased with stage (p=0.0003), PR positivity 
increased with increasing grade (p=0.0006), and tissue ER and/or PR expression greater 
than 10% pointed to a more favorable prognostic outcome.  
Estrogen receptor subtypes have also received attention in predicting ovarian cancer 
outcome. Halon et al. (2011b) examined ERβ via immunohisto- and immunocytochemistry 
in 43 patients pre-chemotherapy and 30 patients post-chemotherapy with stage III ovarian 
cancer. They determined that patients with higher initial ERβ expression (>30% of cells) 
enjoyed longer OS and progression-free survival (PFS) (p=0.0016, p=0.032, respectively). 
Similarly, Halon et al. (2011a) looked at ERα expression in the same group of patients and 
found that loss of ERα expression predicted significantly shorter OS and PFS.   
Another group (Yue et al., 2010) also examined steroid receptors as possible prognostic 
markers in EOC. They described the steroid and xenobiotic receptor (SXR, also known as the 
pregnane X receptor), which regulates gene transcription and triggers proliferation of 
ovarian cancer cells in vitro and in vivo and induces drug resistance (Gupta et al., 2008). In 
141 cases of EOC, SXR immunostaining was correlated with older patient age, clear cell 
histology, higher grade, and ER- and PR-positive tissues. SXR expression correlated with a 
higher likelihood of recurrence, and worse disease-free and overall survival. However, ER 
and PR status were not associated with disease-free survival (DFS) or OS.  
3.3 Circulating hormones 
In general, there is no documented consistent association between circulating hormone 
levels and the risk of developing EOC. Studies have addressed serum FSH and LH, and 
have not found any relationship between serum levels and ovarian cancer incidence 
(Akhmedkhanov et al., 2001; Arslan et al., 2003).  Although there is no known association 
between the development of EOC and LH levels, high LH levels have been observed in 
BRCA1 mutation carriers compared to controls without BRCA1 mutations, which may 
comprise part of the BRCA1 phenotype (Jernstrom et al., 2005). While serum circulating 
levels of gonadotropins are nonpredictive, high levels of gonadotropins in ovarian cysts and 
peritoneal fluid are associated with malignancy. In comparing patients with and without 
malignant ovarian neoplasms, there was no difference in serum levels of LH or FSH, but 
ovarian cyst fluid levels of LH and FSH were elevated in serous ovarian carcinomas 
compared to benign tumors (Kramer et al., 1998).   Similarly, peritoneal fluid aspirates 
contained elevated levels of FSH and LH in ovarian carcinoma versus benign tumors 
(Chudecka-Glaz et al., 2004; Halperin et al., 2003). One recent study actually found that in 67 
patients with ovarian cancer versus controls, increased circulating levels of FSH were 
correlated with a reduced prediagnostic risk of EOC, which argues against the excess 
gonadotropin hypothesis in ovarian carcinogenesis (McSorley et al., 2009).  
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In a large European study, 192 ovarian cancer cases and 346 matched controls were 
compared for serum levels of testosterone, androstenedione, dehydroepiandrostenedione, 
and sex hormone binding globulin (SHBG) (Rinaldi et al., 2007). Free testosterone levels 
were inversely related to risk of EOC (p=0.01) in postmenopausal women, whereas free 
testosterone was positively associated with EOC risk in women under age 55, though this 
was not statistically significant. Other circulating androgens were not associated with risk. 
In a nested case-control study of 31 cases of ovarian cancer and 63 controls, FSH and LH 
were measured (Helzlsouer et al., 1995). Mean FSH was lower in the cases (p=0.04) 
compared to controls, and LH was also lower but the difference was not statistically 
significant. The risk of ovarian cancer increased with higher androstenedione levels (p=0.03) 
and higher DHEA levels (p=0.02). Lukanova et al. (2003) followed by evaluating pre-
diagnostic levels of serum testosterone, DHEA-sulfate, estrone, and SHBG in a case-control 
study nested within three cohorts, including 132 patients with primary EOC matched with 2 
controls per case. There was no apparent association between any of the five hormone levels 
and ovarian carcinoma risk. Increased levels of circulating androstenedione in 
premenopausal patients did increase overall risk, but the low number of subjects in that 
subgroup precluded a definitive association.  
In nonepithelial ovarian cancer (NEOC), circulating levels of steroid hormones may provide 
information about risk of NEOC development (Chen et al., 2010). In a case-control study 
within the Finnish Maternity Cohort, serum specimens were obtained from women with a 
singleton pregnancy that preceded their diagnosis of NEOC: 41 women had sex cord 
stromal tumors (SCST), and 21 had germ cell tumors (GCT). Doubling of testosterone, 
androstenedione, and 17-hydroxyprogesterone were associated with a two-fold increased 
risk of SCST compared to matched controls, a trend which remained after exclusion of 
women with a 2-, 4-, or 6-year time lag between blood donation and SCST diagnosis. 
4. Exogenous hormones and ovarian cancer 
4.1 Infertility treatment and risk of ovarian cancer 
The relationship between infertility and steroid hormones is a controversial one. Many 
initially speculated that exogenous treatment with FSH and LH in infertility patients would 
lead to subsequent epithelial proliferation and tumorigenesis. In a case-control study, 
Whittemore et al. (1992) concluded that infertility patients who used infertility medications 
were at an increased risk of EOC compared to infertile women not using infertility 
medications. Since that time, however, other studies have emerged refuting that theory, and 
in fact it seems that infertility itself rather than gonadotropin use is an inherent risk for 
ovarian cancer (Ness et al., 2000; Tworoger et al., 2007).  Brinton et al. reported on the 
relationship between ovarian cancer and infertility in a retrospective cohort study of 12,193 
subjects (2004a). There were 45 identified cases of ovarian carcinoma, and infertility patients 
had a significantly elevated risk when compared to the general population, with a higher 
rate for primary versus secondary infertility, and the highest rate for those patients with 
endometriosis (Relative Risk or Hazard Ratio: RR=2.72 for patients with primary infertility 
and endometriosis). Examining the same patient cohort, they also reported on the risk of 
ovarian cancer with ovulation-stimulating drugs (Brinton et al., 2004b).  They concluded a 
“slight but insignificant elevation in risk associated with drug usage among certain 
subgroups,” including those using clomiphene citrate, which warrants continued 
surveillance.  
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(p=0.01), independently of pathological grade and age (Zamagni et al., 2009). Another group 
examined hormone receptor status in older and younger patients with advanced papillary 
serous ovarian carcinoma (Liu et al., 2009). They reported a higher percentage of ER-
positivity and PR-negativity in older patients, while both groups were largely Her2/neu 
receptor-negative. Although there was no significant association between receptor status 
and survival, for the younger cohort, those who expressed both ER and PR receptor types 
had better overall survival (OS) (p=0.056) at 51 months, compared to 35 months in those not 
expressing both receptors. In a large cohort of Danish patients with ovarian cancer, Hogdall 
et al (2007) examined the prognostic value of ER and PR status via immunohistochemistry 
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In a large European study, 192 ovarian cancer cases and 346 matched controls were 
compared for serum levels of testosterone, androstenedione, dehydroepiandrostenedione, 
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In a nested case-control study of 31 cases of ovarian cancer and 63 controls, FSH and LH 
were measured (Helzlsouer et al., 1995). Mean FSH was lower in the cases (p=0.04) 
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4.2 Hormone replacement therapy  
The topic of hormone replacement therapy (HRT) use and ovarian cancer risk has sparked 
much debate and controversy. Several large cohort studies deserve mention.  
In a large study as part of the Cancer Prevention Study II Nutrition Cohort, a group of 
54,436 postmenopausal women were followed starting in 1992 (Hildebrand et al., 2010). 
Over 15 years of follow-up, 297 incident cases of EOC were identified. Relative to never 
users, estrogen-only HRT was associated with a twofold higher relative risk (RR=2.07) of 
ovarian cancer, each 5-year increment of use was associated with a 25% higher risk, and 
greater than or equal to 20 years with a threefold higher risk (RR=2.89). Neither current nor 
former combination estrogen and progesterone use was associated with an increased 
ovarian cancer risk.  
The UK Million Women Study enrolled 948,576 women and followed them for an average of 
5.3 years for incident ovarian cancer (Beral et al., 2007). They identified 2273 cases of ovarian 
cancer, with 1591 associated deaths, and reported that current users of HRT were 
significantly more likely to develop (RR=1.2, p=0.0002) and die (RR=1.23, p=0.0006) from 
EOC versus never users.  As in other studies, risk increased with duration of use, but 
interestingly did not differ by type of HRT used, and past users were not at an increased 
risk.  
In a large prospective study, Rodriguez et al. (2001) examined the effects of postmenopausal 
estrogen use and risk of ovarian cancer. Of 211,581 women prospectively enrolled in the 
American Cancer Society’s Prevention Study II, 944 ovarian cancer deaths were recorded 
over 14 years. Ovarian cancer mortality in women using estrogen replacement therapy 
(ERT) was higher than never users (RR=1.51), and risk was slightly but not significantly 
increased in former ERT users (RR=1.16). They noted that duration of use was correlated to 
risk, baseline current use for ≥10 years resulted in an RR of 2.20, versus former use for ≥10 
years which resulted in a decreased but still elevated relative risk of 1.59. Risk did, however, 
decrease with increasing time since last use. The increased risk of ovarian cancer mortality 
persisted for up to 29 years.   
Another large prospective cohort involved 329 women who developed ovarian cancer from 
a pool of 44,241 women in the Breast Cancer Detection Demonstration Project (Lacey et al., 
2002). After adjustment for age and OC use, ever use of ERT was the only form of HRT 
associated with ovarian cancer (RR=1.6), in a dose dependent manner with RR for 10-19 
years at 1.8 and more than 20 years at 3.2 (p<0.001). The addition of progesterone in an 
estrogen-progesterone regimen after estrogen-only use was still associated with an elevated 
risk (RR=1.5), but was not significant for estrogen-progesterone use only (RR=1.1). Women 
who used estrogen-only therapy for greater than 10 years were at a significantly increased 
risk of ovarian cancer, whereas estrogen-progestin only users were not at an increased risk.  
Data from the Women’s Health Initiative also merits mention (Anderson et al., 2003). This 
was a randomized, double-blind, placebo-controlled trial with 16,608 postmenopausal 
women given a daily tablet of estrogen-progesterone versus placebo. They identified 32 
cases of ovarian cancer, and the hazard ratio for HRT use was 1.58, suggesting that 
continuous combination therapy may increase EOC risk. 
In the clear cell and endometrioid non-serous subtypes of epithelial ovarian cancer, 
endometriosis is a known precursor lesion to the development of these malignancies. 
Correspondingly, there have been reports that HRT use is more strongly associated with 
clear cell and endometrioid histologic subtypes than serous EOC (Riman, 2003; Risch, 
2002).  
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In light of these large cohort studies and the lack of definitive molecular evidence that 
steroid hormones initiate carcinogenesis, it is most likely that exogenous hormones hasten 
and perhaps fuel pre-existing lesions. As Risch points out, given the long latency between 
HRT use and development of these neoplasms, it is unlikely that these agents cause 
malignant transformation (2002).   
4.3 Oral contraceptives and BRCA carriers 
Whereas hormone replacement therapy may increase risk of ovarian carcinoma, oral 
contraceptive use diminishes the risk of EOC. Use over five years decreases risk by up to 
50% lasting 10 to 15 years (Gwinn, 1985; Gwinn et al., 1990). While the exact protective 
mechanism is unknown, it is hypothesized that the apoptotic effects of progesterone are 
responsible for this effect.  In a case-control study of 546 women with ovarian cancer and 
4228 controls, women who had used OCs had a 40% reduction in risk compared to those 
who had never used them, with a protective effect lasting for 15 years (The Centers for 
Disease Control, 1987). BRCA mutation carriers harbor an especially high lifetime risk of 
development of EOC, ranging from 40 to 45% in BRCA1 carriers and 15-20% amongst 
BRCA2 mutation carriers (Narod et al., 2002). Studies support the use of OCs in high-risk 
women. Narod et al. particularly addressed this subgroup, and conducted a cohort study on 
207 women with hereditary ovarian cancer, with 161 of their sisters serving as controls 
(1998). Lifetime history of oral contraceptive use was obtained, and the investigators found a 
decreased odds ratio of 0.5 for ovarian cancer associated with oral contraceptive use, with 
adjustment for age and parity. As in prior studies, the risk decreased with increasing 
duration of use, with a 60% reduction in risk with use for 6 or more years. In specifically 
examining BRCA mutation status, OR for OC use and development of EOC for BRCA1 
carriers was 0.5, and was 0.4 for BRCA2 mutation carriers. A subsequent study in 1311 
matched pairs of women with BRCA1 and BRCA2 mutations, however, revealed a modest 
increase in breast cancers in BRCA1 mutation carriers (OR=1.2) compared to controls, 
whereas there was no increased risk for BRCA2 mutation carriers (OR=0.94) (Narod et al., 
2002).  While oral contraceptives undoubtedly provide benefit in ovarian cancer prevention 
and are recommended in young BRCA mutation carriers, there is a minimal increased risk 
of breast cancer which must be weighed against the benefits.  
5. Clinical trials with hormonally-targeted therapeutics in ovarian cancer 
Several clinical trials in ovarian cancer have examined the utility of hormonal therapy in 
ovarian carcinoma, including antiestrogens (tamoxifen, fulvestrant), aromatase inhibitors 
(letrozole), progestins and progesterone receptor antagonists (medroxyprogesterone acetate, 
megestrol acetate, mifepristone), GnRH agonists (leuprolide acetate, triptorelin, goserelin), 
and antiandrogens (flutamide). Virtually all the trials examine these agents in the recurrent 
setting or in combination with other therapies; rarely are they studied as a component of up-
front therapy. Given the overall low response rate to chemotherapy in recurrent ovarian 
cancer, most hormonal agents have a modest effect, with tamoxifen used the most frequently. 
Hormone-directed therapy is particularly popular in the setting of “chemical recurrence,” in 
other words a rising CA-125 without clinical or radiographic evidence of disease. In this 
situation, clinicians are reluctant to initiate cytotoxic chemotherapy as early initiation does not 
prolong OS (Rustin et al., 2010), while patients often experience anxiety waiting for full return 
of their disease. With much more acceptable side effects than cytotoxic chemotherapy, 
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hormonal therapeutics offer some activity and are generally well-tolerated. Not surprisingly, 
levels of endocrine receptor expression correlate positively with response; however, even 
patients without high receptor expression may enjoy clinical benefit.  
5.1 Estrogen antagonists 
5.1.1 Selective estrogen receptor modulators 
Tamoxifen is a selective estrogen receptor modulator (SERM) with mixed estrogen agonist 
and antagonist activity. In the endometrium, it acts in an agonistic manner and has been 
associated with endometrial carcinoma (Bland et al., 2009); in the breast it is an antagonist. 
Use in ovarian carcinoma is generally restricted to the setting of recurrence or maintenance, 
with modest effects. Nonetheless, it is an attractive option for patients with biochemical 
recurrence and a rising CA-125 in the absence of obvious radiologic disease or symptoms. In 
this situation, early treatment offers no advantage and unnecessary toxicity, yet watchful 
waiting often causes patient anxiety. In this regard, tamoxifen may offer some activity while 
maintaining a favorable side effect profile.  
Markman et al. explored this particular patient group in a retrospective review of patients 
with recurrent small-volume disease who received tamoxifen prior to initiation of cytotoxic 
chemotherapy (2004). Of 56 patients, the median duration of treatment was 3 months, but 
42% of patients remained on tamoxifen for over 6 months, and 19% were still on tamoxifen 
at 9 months. They concluded that while tamoxifen is a reasonable treatment option, it is 
unknown whether the delay in chemotherapy resulted from the tamoxifen itself or the 
natural history of the patients’ disease.  
In a prospective trial, the Gynecologic Oncology Group (GOG) examined 105 patients with 
stage III or IV epithelial ovarian cancer whose disease recurred or persisted after surgery 
and were treated with tamoxifen 20 mg twice daily (Hatch et al., 1991). They reported an 
18% response rate: 10% of patients had a complete response (CR) with a median duration of 
7.4 months, while 8% experienced a partial response (PR), and 38% of patients had short-
term disease stabilization. Median duration for PR or stable disease (SD) was 3 months. Of 
those with a complete response, 89% had elevated ER levels, versus 59% in SD or PR groups. 
Markman et al. (1996) followed with an ancillary report on the group, examining those 
patients with platinum-refractory disease. They reported an objective response rate of 13% 
in patients with platinum-resistant ovarian cancer, and a median duration of response of 4.4 
months. The Mid-Atlantic Oncology Program (MAOP) conducted three separate phase II 
trials in patients with refractory ovarian carcinoma, and treated patients with either high-
dose megestrol acetate, high-dose tamoxifen, or aminoglutethimide (Ahlgren et al., 1993).  
Of 30 patients who received high-dose megestrol acetate (800 mg/day for 30 days, then 400 
mg/day thereafter), there were no identified responses. Among 29 patients treated with 
tamoxifen (80 mg /day for 30 days, then 40 mg/day thereafter), 17% responded, and two of 
those responses exceeded five years. Finally, aminoglutethimide was administered at a dose 
of 1g/day to 15 patients, and no responses were observed. 
A more recent trial explored the role of tamoxifen versus thalidomide and its effects on VEGF 
expression in a randomized phase III trial in 138 women with stage III or IV EOC, primary 
peritoneal cancer, or fallopian tube carcinoma who were disease-free following first line 
chemotherapy and experienced a “biochemical” recurrence only as defined by rising CA-125 
(Hurteau et al., 2010). Thalidomide was not superior to tamoxifen on interim analysis, with a 
similar risk of progression, higher toxicity, and an increased risk of death, and the trial was 
closed. VEGF expression was also not a prognostic factor in determining response. 
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Tamoxifen has also been explored in combination with cytotoxic agents. In a phase II trial, 
50 patients with recurrent or progressive ovarian cancer after platinum-based chemotherapy 
received either 100 mg/m2 cisplatin or 400 mg/m2 carboplatin q3 weeks with tamoxifen 80 
mg/day for 30 days followed by 40 mg/day thereafter (Benedetti Panici et al., 2001). Overall 
response rate was 50% with a 30% CR and 20% PR, with a higher response rate (64%) in the 
platinum-sensitive group compared to platinum-resistant cases (39%).  Toxicity included 
nausea and vomiting, neuropathy, nephrotoxicity, and bone marrow suppression. While 
encouraging, it is difficult to interpret the effects of tamoxifen without a comparison group 
of platinum-alone, or platinum plus paclitaxel as is often used for recurrent platinum-
sensitive disease.   
In combination with the EGFR inhibitor gefitinib, tamoxifen was administered to 56 patients 
with platinum- and taxane-refractory EOC, peritoneal cancer, or fallopian tube cancer 
(Wagner et al., 2007).  Sixteen patients had stable disease, although there were no tumor 
responses and in 10% the medications were discontinued secondary to adverse events, the 
most common of which were rash and diarrhea. Median time to progression was 58 days, 
with a median survival of 253 days. The investigators concluded that the drug combination 
was not efficacious.  
5.1.2 Aromatase inhibitors 
Letrozole is a non-steroidal aromatase inhibitor. It competitively and reversibly binds to 
aromatase and thereby prevents conversion of androgens to estrogen. In the setting of 
relapsed ovarian cancer, aromatase inhibitors can achieve a response in 35.7% of patients 
and stable disease in 20-42% of patients (Li et al., 2008). In a phase II setting, Smyth et al. 
(2007) investigated letrozole 2.5 mg orally daily in previously-treated patients with ER+ 
ovarian carcinoma. Of 42 patients, 17% had CA-125 response (defined as a decrease >50%), 
and 26% had not progressed (defined as doubling of CA-125). In terms of radiologic 
response, 9% of patients had a partial response, and 42% had stable disease at 12 weeks. 
Progression free survival of greater than 6 months was observed in 26% of patients. 
Response correlated to level of ER expression as defined by immunohistochemistry.  
In another phase II trial examining patients with recurrent ovarian cancer, 50 patients 
received letrozole 2.5 mg daily (Bowman et al., 2002). Primary tumors were assessed for ER, 
PR, EGFR, erbB2, and HSP27 expression via immunohistochemistry. Though no PR or CR 
was observed, 10 patients experienced stable disease for at least 12 weeks. Those with stable 
disease exhibited significantly higher ER and PR levels, implying that endocrine receptor 
expression may help identify those patients most likely to benefit from treatment.  
Walker et al (2007) aimed to explore estrogen-related gene expression and its predictive 
value in patient response to letrozole. Protein expression was measured via 
immunohistochemistry in tissue sections of tumors from patients treated with letrozole, and 
eight genes were significantly differentially expressed amongst patients who responded or 
had disease stabilization versus those who progressed. They concluded that these results 
might help identify those patients who would benefit most from endocrine therapy.  
In 2010, Pan and Kao (2010) published a case report of two patients with endometrioid type 
histology.  Both patients with advanced ER+ endometrioid ovarian carcinoma were treated 
with letrozole. The first patient had undergone optimal debulking, followed by completion 
of carboplatin and paclitaxel, had residual disease on second look surgery, and was 
subsequently disease-free for 30 months with letrozole treatment. The second patient was on 
her third recurrence and also experienced a 30 month remission with letrozole.  
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Tamoxifen has also been explored in combination with cytotoxic agents. In a phase II trial, 
50 patients with recurrent or progressive ovarian cancer after platinum-based chemotherapy 
received either 100 mg/m2 cisplatin or 400 mg/m2 carboplatin q3 weeks with tamoxifen 80 
mg/day for 30 days followed by 40 mg/day thereafter (Benedetti Panici et al., 2001). Overall 
response rate was 50% with a 30% CR and 20% PR, with a higher response rate (64%) in the 
platinum-sensitive group compared to platinum-resistant cases (39%).  Toxicity included 
nausea and vomiting, neuropathy, nephrotoxicity, and bone marrow suppression. While 
encouraging, it is difficult to interpret the effects of tamoxifen without a comparison group 
of platinum-alone, or platinum plus paclitaxel as is often used for recurrent platinum-
sensitive disease.   
In combination with the EGFR inhibitor gefitinib, tamoxifen was administered to 56 patients 
with platinum- and taxane-refractory EOC, peritoneal cancer, or fallopian tube cancer 
(Wagner et al., 2007).  Sixteen patients had stable disease, although there were no tumor 
responses and in 10% the medications were discontinued secondary to adverse events, the 
most common of which were rash and diarrhea. Median time to progression was 58 days, 
with a median survival of 253 days. The investigators concluded that the drug combination 
was not efficacious.  
5.1.2 Aromatase inhibitors 
Letrozole is a non-steroidal aromatase inhibitor. It competitively and reversibly binds to 
aromatase and thereby prevents conversion of androgens to estrogen. In the setting of 
relapsed ovarian cancer, aromatase inhibitors can achieve a response in 35.7% of patients 
and stable disease in 20-42% of patients (Li et al., 2008). In a phase II setting, Smyth et al. 
(2007) investigated letrozole 2.5 mg orally daily in previously-treated patients with ER+ 
ovarian carcinoma. Of 42 patients, 17% had CA-125 response (defined as a decrease >50%), 
and 26% had not progressed (defined as doubling of CA-125). In terms of radiologic 
response, 9% of patients had a partial response, and 42% had stable disease at 12 weeks. 
Progression free survival of greater than 6 months was observed in 26% of patients. 
Response correlated to level of ER expression as defined by immunohistochemistry.  
In another phase II trial examining patients with recurrent ovarian cancer, 50 patients 
received letrozole 2.5 mg daily (Bowman et al., 2002). Primary tumors were assessed for ER, 
PR, EGFR, erbB2, and HSP27 expression via immunohistochemistry. Though no PR or CR 
was observed, 10 patients experienced stable disease for at least 12 weeks. Those with stable 
disease exhibited significantly higher ER and PR levels, implying that endocrine receptor 
expression may help identify those patients most likely to benefit from treatment.  
Walker et al (2007) aimed to explore estrogen-related gene expression and its predictive 
value in patient response to letrozole. Protein expression was measured via 
immunohistochemistry in tissue sections of tumors from patients treated with letrozole, and 
eight genes were significantly differentially expressed amongst patients who responded or 
had disease stabilization versus those who progressed. They concluded that these results 
might help identify those patients who would benefit most from endocrine therapy.  
In 2010, Pan and Kao (2010) published a case report of two patients with endometrioid type 
histology.  Both patients with advanced ER+ endometrioid ovarian carcinoma were treated 
with letrozole. The first patient had undergone optimal debulking, followed by completion 
of carboplatin and paclitaxel, had residual disease on second look surgery, and was 
subsequently disease-free for 30 months with letrozole treatment. The second patient was on 
her third recurrence and also experienced a 30 month remission with letrozole.  
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5.1.3 Estrogen receptor antagonists 
Fulvestrant is a pure estrogen receptor antagonist without agonistic effects on other tissues. 
It competitively binds the ER, blocking estrogen binding and causing degradation and 
internalization of the estrogen receptor. In a phase II trial of fulvestrant in 26 women with 
ER positive recurrent ovarian or primary peritoneal carcinoma, patients received 500 mg IM 
on day 1, 250 mg IM on day 15, and 250 mg IM on day 29 and every 28 days thereafter 
(Argenta et al., 2009). The group had been heavily pretreated, with a median of 5 
chemotherapy regimens prior to enrollment. Half of women experienced disease 
stabilization, though there was only one complete response and one partial response. 
Median time to progression was 62 days, and the regimen was well tolerated.  
5.2 Progesterone  
Given its promising apoptotic effects in vitro and in vivo, clinical trials with progestins have 
been disappointing. Several trials have used megestrol acetate or medroxyprogesterone 
acetate in the recurrent setting. Zheng et al. provide a nice summary of 13 trials, with 432 
patients total (2007). Complete response was observed in 10 patients (2.3%), with a partial 
response in 4.9% of patients and stable disease in 47 or 10.9% of patients. They note that of 
the ten patients, 6 of them were reported in one study which also noted an overall 45% 
response rate (Geisler, 1985). A higher dose regimen does not appear to provide any 
additional benefit: In a phase II trial of 800 mg/day for 1 month followed by 400 mg/day 
thereafter, patients did not experience an overall increased benefit from higher doses, with 
an overall response rate of 10% (Veenhof et al., 1994) and 3 thromboembolic events. 
Interestingly, combination therapy with medroxyprogesterone acetate and ethinyl estradiol 
yielded a partial response rate of 17% and stable disease in 24% of 25 patients with recurrent 
EOC, all patients had ER+ tumors (Fromm et al., 1991). Surprisingly, combination of 
progestins with tamoxifen does not appear to provide any clinical benefit (Jakobsen et al., 
1987); nor does combination with chemotherapy. Based on in vitro evidence that megestrol 
acetate may reverse P-glycoprotein-mediated drug resistance, a phase I trial investigating 
the combination of megestrol acetate and paclitaxel was initiated (Markman et al., 2000). In 
44 patients with paclitaxel-resistant EOC, four patients exhibited a response. However, 32% 
of patients experienced peripheral neuropathy, four patients developed venous blood clots, 
and one patient suffered from a stroke. Given the relatively low level of activity and 
significant toxicity, the authors did not recommend further study of the treatment regimen.  
Mifepristone is a progesterone antagonist, more commonly known for its abortifacent 
properties. Rocereto et al. (2000) conducted a phase II study of mifepristone in the treatment 
of recurrent of persistent EOC, fallopian tube, or primary peritoneal cancer. Patients with 
persistent or recurrent disease less than 1 year after chemotherapy were eligible, and 
received mifepristone 200 mg daily for 28 day cycles. Of 44 patients enrolled, 34 were 
evaluable and 9 (26.5%) of patients experienced a response (9% CR, 17.5% PR). Duration of 
response was 1 to 3 months, except in one patient who continues to respond after three 
years. The major cited toxicity was rash.  
5.3 GnRH agonists  
GnRH agonists, principally leuprolide acetate, triptorelin, and goserelin, have been 
investigated in recurrent ovarian cancer. Emons & Schulz reported on 245 published phase 
II trials in patients with recurrent disease, mostly platinum-refractory, treated with GnRH 
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agonists: 9% had an objective remission and 26% experienced disease stabilization (2000). 
Compared to estrogen-directed endocrine therapy, responses are minimal and GnRH 
agonist therapy is generally not used in this setting anymore. 
Initial studies with GnRH agonists were small, with 5 to 37 patients, and employed 
leuprolide acetate in the setting of recurrent EOC.  Of 161 combined patients in 7 studies, 
there were 2 reported CRs, 15 PRs, and a disease stabilization rate of about 24% (So et al., 
2008).   
Triptorelin was the next generation GnRH agonist examined in EOC, and results were 
generally disappointing. In a large European Organisation for Research and Treatment of 
Cancer (EORTC) study, 74 patients with progressive ovarian cancer were treated with the 
LHRH agonist triptorelin via IM injections of 3.75 mg (on days 1, 8, and 28 followed by 
monthly injections thereafter) (Duffaud et al., 2001). There were no objective responses, and 
only 16% of patients experienced stable disease with a median PFS of 5 months for SD. 
Though the treatment was well-tolerated, the authors concluded that triptorelin exhibits 
only modest efficacy in this patient cohort. Emons et al. also conducted a large study, with 
the benefit of a prospective randomized double blind trial design (1996) in 135 patients with 
Stage III or IV EOC after cytoreduction. Patients received standard platinum-based 
chemotherapy and were randomized to placebo or triptorelin 3.75 mg IM. There was no 
difference in survival between the two groups.  
Following triptorelin, cetrorelix—a GnRH antagonist—was found in vitro to have better 
activity in ovarian carcinoma, and was hypothesized to act directly on the GnRH receptors 
in the tumor as well as centrally (Yano et al., 1994). A phase II study utilized cetrorelix 10 
mg subcutaneously daily in 17 patients with platinum-resistant recurrent EOC or mullerian 
carcinoma. Three patients had a PR of 9, 16, and 17 weeks, there was one grade 4 
anaphylactic reaction, and two patients exhibited a 20% increase in cholesterol not requiring 
treatment. Stable disease was observed in 35% of patients for up to 62 months. They also 
examined LHRH receptor status, and two of the three responding patients were LHRH 
positive.  
Goserelin, another GnRH agonist, was evaluated in combination with tamoxifen in a phase 
II trial for patients with recurrent advanced ovarian cancer (Hasan et al., 2005). Patients had 
received a median of 3 prior chemotherapy regimens, and 17 of 26 patients had platinum-
resistant disease. Tamoxifen was prescribed at 20 mg orally daily, and goserelin was 
provided subcutaneously at 3.6 mg once monthly. The overall response rate was 50%, with 
one CR, 2 PRs, and 10 with SD. Median PFI was 4 months, while median OS was 13 months. 
The regimen was well-tolerated.  Zidan et al. (2002) treated 15 patients with advanced 
recurrent disease with 3.6 mg of goserelin monthly; two of these patients had not received 
initial chemotherapy due to poor performance status. They reported one CR lasting 8 
months, one PR lasting 14 months, and disease stabilization in 20% for a median of 7.5 
months, and there was no significant toxicity.  Most recently, a 2007 study considered the 
activity of goserelin 3.6 mg subcutaneously monthly and bicalutamide (an oral anti-
androgen often used in prostate cancer) 50 mg orally daily in patients in their second or 
greater complete disease remission (Levine et al.). Of 35 patients, PFS for second disease 
remission was 11.4 months, and was 11.9 months for patients in their third or fourth disease 
remission. There was no association between androgen receptor expression and PFS. 
Toxicities included liver function abnormalities, fatigue, and hot flushes. They concluded 
that the combination did not prolong PFS in patients with second or greater disease 
remission. 
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agonists: 9% had an objective remission and 26% experienced disease stabilization (2000). 
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leuprolide acetate in the setting of recurrent EOC.  Of 161 combined patients in 7 studies, 
there were 2 reported CRs, 15 PRs, and a disease stabilization rate of about 24% (So et al., 
2008).   
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generally disappointing. In a large European Organisation for Research and Treatment of 
Cancer (EORTC) study, 74 patients with progressive ovarian cancer were treated with the 
LHRH agonist triptorelin via IM injections of 3.75 mg (on days 1, 8, and 28 followed by 
monthly injections thereafter) (Duffaud et al., 2001). There were no objective responses, and 
only 16% of patients experienced stable disease with a median PFS of 5 months for SD. 
Though the treatment was well-tolerated, the authors concluded that triptorelin exhibits 
only modest efficacy in this patient cohort. Emons et al. also conducted a large study, with 
the benefit of a prospective randomized double blind trial design (1996) in 135 patients with 
Stage III or IV EOC after cytoreduction. Patients received standard platinum-based 
chemotherapy and were randomized to placebo or triptorelin 3.75 mg IM. There was no 
difference in survival between the two groups.  
Following triptorelin, cetrorelix—a GnRH antagonist—was found in vitro to have better 
activity in ovarian carcinoma, and was hypothesized to act directly on the GnRH receptors 
in the tumor as well as centrally (Yano et al., 1994). A phase II study utilized cetrorelix 10 
mg subcutaneously daily in 17 patients with platinum-resistant recurrent EOC or mullerian 
carcinoma. Three patients had a PR of 9, 16, and 17 weeks, there was one grade 4 
anaphylactic reaction, and two patients exhibited a 20% increase in cholesterol not requiring 
treatment. Stable disease was observed in 35% of patients for up to 62 months. They also 
examined LHRH receptor status, and two of the three responding patients were LHRH 
positive.  
Goserelin, another GnRH agonist, was evaluated in combination with tamoxifen in a phase 
II trial for patients with recurrent advanced ovarian cancer (Hasan et al., 2005). Patients had 
received a median of 3 prior chemotherapy regimens, and 17 of 26 patients had platinum-
resistant disease. Tamoxifen was prescribed at 20 mg orally daily, and goserelin was 
provided subcutaneously at 3.6 mg once monthly. The overall response rate was 50%, with 
one CR, 2 PRs, and 10 with SD. Median PFI was 4 months, while median OS was 13 months. 
The regimen was well-tolerated.  Zidan et al. (2002) treated 15 patients with advanced 
recurrent disease with 3.6 mg of goserelin monthly; two of these patients had not received 
initial chemotherapy due to poor performance status. They reported one CR lasting 8 
months, one PR lasting 14 months, and disease stabilization in 20% for a median of 7.5 
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that the combination did not prolong PFS in patients with second or greater disease 
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Emons et al. recently reported on a novel compound, AEZS-108, which is composed of [D-
Lys]LHRH linked to doxorubicin (2010). In a phase I dose escalation trial of 17 women with 
metastatic unresectable EOC, endometrial, or breast cancer and immunohistochemical 
LHRH positivity, a total of 6 patients exhibited responses, both in the highest dose group. 
Dose-limiting toxicities included leukopenia and neutropenia.  
5.4 Antiandrogens in ovarian cancer 
Few studies exist assessing the efficacy of antiandrogenic therapy in ovarian cancer. 
Flutamide, a nonsteroidal antiandrogen, has been studied in the phase II setting 
(Vassilomanolakis et al., 1997). In 24 patients with relapsed stage III or IV ovarian cancer, 
flutamide was given at a dose of 100 mg three times daily. There was one partial response 
lasting 3 months, and two patients with stable disease for 7 and 8 months. Reported toxicity 
was mild. Another trial utilized flutamide in 68 pretreated patients with EOC (median prior 
chemotherapy of two regimens), dosed at 750 mg/daily for at least 2 months (Tumolo et al., 
1994). Of 68 patients, there was one complete and one partial response lasting 44 and 72 
weeks, and 28% of patients experienced stable disease for a median of 24 weeks.  Toxicities 
included nausea and vomiting in 34.5% of patients. The authors concluded that flutamide 
was ineffective in heavily pretreated patients, in light of the significant percentage of side 
effects. 
5.5 Ongoing clinical trials with hormonally-targeted therapeutics in ovarian cancer 
While there are many clinical trials open to ovarian carcinoma patients, there are not many 
currently investigating hormonally-directed agents. There is currently one phase II trial 
exploring tamoxifen in combination with the EGFR tyrosine kinase inhibitor ZD839 in 
patients with recurrent ovarian cancer refractory to platinum and taxane-based therapy 
(NCT00189358).   
There are a few trials exploring the newer SERMs. One of the newer agents, arzoxifene, is a 
SERM with higher potency than raloxifene. A current study, NCT00003670, is examining 
arzoxifene in patients with metastatic refractory EOC or peritoneal cancer in the phase II 
setting, and aims to correlate response to serum estradiol, FSH, LH, and SHBG. Another 
SERM, toremifene citrate, has just finished assessment in the recurrent ovarian cancer 
population, but results have not yet been published (NCT00003865). Endoxifen, a tamoxifen-
related compound with higher affinity for the estrogen receptor, is undergoing evaluation in 
the setting of hormone-receptor positive breast, solid, desmoid, or gynecologic tumors 
which have not responded to standard chemotherapy (NCT01273168).   
Some studies with aromatase inhibitors have completed recruitment. One study with 
combination anastrozole and gefitinib, an EGFR inhibitor, has completed enrollment in a 
phase II trial for patients with relapsed ovarian cancer (NCT00181688). Exemestane has also 
been utilized in a phase II trial in patients with recurrent stage II to IV ovarian cancer 
(NCT00261027). The trial has completed enrollment, and initial results presented at the 
American Society of Clinical Oncology reported that in 24 patients, 36% experienced stable 
disease lasting a median duration of 23 weeks (Verma et al., 2006). One patient had stable 
disease lasting greater than 95 weeks.   
Though there are no current trials investigating progesterone-based compounds and active 
disease, NCT00445887 is studying the use of oral levonorgestrel to prevent ovarian 
carcinoma in patients at high risk of developing EOC.  
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6. Granulosa cell tumors of the ovary 
As aforementioned, while it is generally agreed upon that gonadotropins contribute to 
tumor progression in ovarian carcinoma, there is a lack of clear evidence that they can 
initiate carcinogenesis in EOC. Claims that gonadotropins may cause EOC are derived from 
in vivo studies, in which rodents treated with excess gonadotropins formed sex cord stromal 
tumors, specifically granulosa cell tumors. In α-inhibin deficient mice, which results in a 
lack of negative feedback on the gonadotropin axis and resultant excess gonadotropins, 
gonadal stromal tumors formed (Matzuk et al., 1992). However, the tumors failed to form in 
these α-inhibin deficient mice in the absence of gonadotropins (Kumar et al., 1996). Dorward 
et al. (2007) treated hypogonadotropic immunodeficient mice with grafted ovaries from 
prepubertal genetically susceptible mice with an LH analog or FSH, and found that LH-
treated mice developed granulosa cell tumors, while FSH-treated mice did not. 
The role of granulosa cells in the ovary is well-established: they convert androgens to 
estradiol via aromatase, and are stimulated to do so by FSH. They also produce 
progesterone during the later stages of the menstrual cycle. Similarly, steroid signaling in 
granulosa cells has been extensively studied in vivo. In granulosa cells, FSH activates several 
pathways, including ERK, MAPK, and PI3K (Hunzicker-Dunn & Maizels, 2006). Estrogen 
protects against FasL-mediated apoptosis in the G1 to S phase transition of the cell cycle 
(Quirk et al., 2006), and GnRH agonists stimulate apoptosis (Takekida et al., 2003). In 
malignant granulosa cell tumors (GCTs), ER2 is upregulated (Chu et al., 2000). Nearly all 
GCTs express progesterone receptors, while about 30% express estrogen receptors (Hardy et 
al., 2005).  
Granulosa cell tumors comprise approximately 5% of all ovarian tumors (Schumer & 
Cannistra, 2003), and often present with symptoms associated with estrogen excess—such as 
vaginal bleeding or virilization in postmenopausal women, or precocious puberty in 
juveniles. Given their relative rarity, there is a paucity of clinical trials, but antihormonal 
therapy has had activity in recurrent disease.  There have been reports of disease 
stabilization or response after administration of megestrol acetate, goserelin, leuprolide, and 
anastrozole (Fishman et al., 1996; Freeman & Modesitt, 2006; Malik & Slevin, 1991; 
Martikainen et al., 1989).   
7. Conclusions 
In summary, steroid signaling plays an important part in both normal ovarian surface 
epithelial cells and in malignant epithelial ovarian carcinoma. The pathways that promote 
growth and inhibit apoptosis in OSE are often exploited and upregulated in EOC, while 
protective components are downregulated, thereby allowing evasion of apoptosis as well as 
cellular migration and invasion. While estrogen and FSH promote cellular growth and 
tumor progression in vitro and in vivo, there is no definitive evidence that they can initiate 
ovarian carcinogenesis. Progesterone impressively enhances apoptosis, and is valuable in 
preventive efforts, yet treatment with progestins in ovarian cancer has not yielded equally 
impressive results in the clinical setting. The reasons for this remain unclear, and warrant 
further investigation into signaling pathways and receptor crosstalk mechanisms. Perhaps 
even more interesting, the GnRH signaling pathway appears to operate via dual and 
opposing mechanisms, inhibiting cell growth through one pathway yet increasing cellular 
migration and invasion through another. Efforts to exploit the growth inhibitory effects 
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growth and inhibit apoptosis in OSE are often exploited and upregulated in EOC, while 
protective components are downregulated, thereby allowing evasion of apoptosis as well as 
cellular migration and invasion. While estrogen and FSH promote cellular growth and 
tumor progression in vitro and in vivo, there is no definitive evidence that they can initiate 
ovarian carcinogenesis. Progesterone impressively enhances apoptosis, and is valuable in 
preventive efforts, yet treatment with progestins in ovarian cancer has not yielded equally 
impressive results in the clinical setting. The reasons for this remain unclear, and warrant 
further investigation into signaling pathways and receptor crosstalk mechanisms. Perhaps 
even more interesting, the GnRH signaling pathway appears to operate via dual and 
opposing mechanisms, inhibiting cell growth through one pathway yet increasing cellular 
migration and invasion through another. Efforts to exploit the growth inhibitory effects 
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while curbing the invasive component may generate more effective GnRH analogs. Despite 
our growing knowledge surrounding steroid hormone signaling in OSE and EOC, much 
still remains unknown. 
While serum levels of steroid hormones are generally not useful as disease markers in 
determining disease risk or prognosis, ovarian tumors undoubtedly contain elevated levels 
of gonadotropins. Whether or not these elevated levels are a byproduct of aberrant signaling 
pathways or a contributor to carcinogenesis remains to be determined. Tumor expression of 
estrogen and progesterone receptors does appear to correlate to treatment response in 
patients, though results regarding estrogen receptor expression and prognosis are mixed. 
Certainly, the shift in ERα: ERβ expression and loss of PRB in tumor progression merits 
further investigation, and indeed has triggered exploration into targeted therapy. Inhibiting 
these receptor subtypes may result in more robust, specific responses in disease. While 
fulvestrant is an ERα antagonist, attention has now turned towards developing ERβ 
agonists. Benzopyran-derived selective estrogen receptor beta-agonist-1 (SERBA-1) is a 
selective ERβ receptor agonist which has been studied in mice and prostate hyperplasia, 
with promising effects (Norman et al., 2006).  Monoaryl-substituted salicylaldoximes also 
show high ERβ affinity and are interesting new compounds (Bertini et al., 2011).  
The role of exogenous hormones in ovarian cancer also remains unclear. As Risch suggests, 
at best HRT may accelerate the proliferation of pre-existing malignancy (Risch, 2002). 
Despite the completion of multiple large cohort studies, confounding and bias are likely 
responsible for ambiguous results. Still, the use of HRT is best avoided in women at high 
risk of developing EOC, such as BRCA mutation carriers, or women with a strong family 
history of ovarian cancer. Conversely, use of oral contraceptive prophylaxis is 
recommended for women with a high risk of EOC, to be weighed against a perhaps slightly 
elevated risk of breast cancer with extended use.  
Hormonally-targeted therapeutics offer modest benefit for women with recurrent ovarian 
cancer, along with a much more tolerable side effect profile when compared to cytotoxic 
chemotherapy. In all fairness, clinical trials have not included hormone antagonists as first-
line agents; they are most frequently studied in recurrent disease when even cytotoxic 
chemotherapy yields little benefit. It is possible that antihormonals may offer even more 
activity when used up front in combination with cytotoxic compounds, and this is an area 
warranting further investigation.   
As is the case with emerging targeted therapies and resistance, inhibition of one pathway 
often results in upregulation of another, requiring combination with other therapeutics. 
Combination therapy of hormone antagonists with novel targeted agents offers exciting 
opportunities for overcoming resistance and improving patient outcomes. For example, the 
estrogen receptor pathway participates in crosstalk with multiple other mitogenic pathways, 
and concomitant inhibition of these pathways could produce a synergistic effect.  Targeting 
other portions of the hormone receptors themselves has also evoked interest. Small molecule 
inhibitors target alternative binding sites on the estrogen and androgen receptor, which may 
result in improved selectivity or novel interactions (Shapiro et al., 2011). Likewise, while 
estrogen and progesterone receptor expression does correlate with response to 
antihormonal therapy, those patients without receptor expression also experience some 
benefit. Thus, better markers for response are needed.  Post-translational modification of 
steroid receptors—particularly the estrogen receptor—include phosphorylation, 
ubiquitination, sumoylation, methylation, and palmitoylation, and affect receptor stability, 
localization, and perhaps drug resistance (Le Romancer et al., 2011).   
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Steroid hormones and their receptors participate in complex signaling which is not yet fully 
understood. Gaining insight into these interactions and downstream effectors is paramount 
to developing new targeted therapies and advancing the treatment of ovarian cancer.   
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1. Introduction 
Glucocorticoids are well known to play an important role in the regulation of most essential 
physiological processes (Atanasov & Odermatt,2007). Patients with Cushing`s syndrome show 
central obesity with insulin resistance, caused by hypersecretion of cortisol (F) (Arnaldi et 
al.,2004). Obese patients with type 2 diabetes often have symptoms usually observed in 
patients with Cushing`s syndrome, and F levels might reflect the severity of complications and 
metabolic abnormalities in diabetes (Chiodini et al.,2007). High levels of F are associated with 
activation or dysregulation of the hypothalamic-pituitary-adrenal (HPA) axis and increased 
volume of the adrenal glands (Pasquali et al.,2006, Godoy-Matos et al.,2006). 
Moreover, various metabolic abnormalities induced by enhanced glucocorticoid activity were 
found to be not only due to accelerated function of the HPA axis, but also by an impairment in 
11β-hydroxysteroid dehydrogenase (11β-HSD) enzymes within the target cells (Godoy-Matos 
et at.,2006). 11β-HSD has two isoforms: 11β-HSD type 1 (11β-HSD1) mainly works as a 
reductase which converts inactive cortisone (E) to active cortisol (F) in F target tissues (Walker 
& Andrew,2006). 11β-HSD type 2 (11β-HSD2) is expressed in mineralocorticoid target tissues 
such as the distal nephron, colon, and salivary glands (Tannin et al.,1991, Draper & Stewart, 
2005, Edwards et al., 1988), converting F to E to protect mineralocorticoid receptors from 
activation by F. 
Animal models demonstrated that activation of 11β-HSD1 exhibited features of metabolic 
syndrome (Masuzaki et al.,2004, Morton et al.,2004). It was also reported that 11β-HSD1 is 
increased in subcutaneous adipose tissue in obese patients (Rask et al.,2002, Paulmyer-
Lacroi et al.,2002), and higher 11β-HSD1 activity in adipose tissue is associated with features 
of metabolic syndrome in Caucasians and Pima Indians (Lindsay et al.,2003). Thus, it is 
suggested that F may play a crucial role in the regulation of adiposity in type 2 diabetes 
with obesity. On the other hand, the exact role of abnormal glucocorticoid metabolism in the 
pathogenesis of obesity has not fully been clarified yet. Salivary cortisol has been reported to 
be in closer agreement with the real adrenocortical function than serum cortisol 
concentration (Bolufer et al.,1989). Measurement of salivary cortisol was also reported to 
have several advantages, such as directly reflecting free cortisol level (Vining et al.,1983), 
and non-invasiveness for sampling (Chen et al.,1985). We, therefore, analyzed samples from 
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pathogenesis of obesity has not fully been clarified yet. Salivary cortisol has been reported to 
be in closer agreement with the real adrenocortical function than serum cortisol 
concentration (Bolufer et al.,1989). Measurement of salivary cortisol was also reported to 
have several advantages, such as directly reflecting free cortisol level (Vining et al.,1983), 
and non-invasiveness for sampling (Chen et al.,1985). We, therefore, analyzed samples from 
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serum, saliva, and 24h-collected urine from obese type 2 diabetic patients as well as healthy 
subjects in order to evaluate clinical usefulness of salivary cortisol accurately measured by 
liquid mass spectroscopy in obese patients with type 2 diabetes. 
2. Subjects and methods 
2.1 Subjects 
Eighteen Japanese men without underlying diseases cooperated as the healthy subject group. 
As the patient group, 23 Japanese male patients with type 2 diabetes, admitted to the Department 
of Endocrinology and Metabolism in Yokohama Rosai Hospital between March 2006 and 
March 2007, who met the following conditions were selected:1) waist circumference of 85 cm or 
greater, 2) stage 1 or 2 diabetic nephropathy, 3) not treated with oral biguanide or thiazolidine 
derivatives, and 4)understanding the objective of this study and giving written consent. This 
study was approved by the research ethics committee of Yokohama Rosai Hospital. 
2.2 Measurement of serum and salivary steroids  
Five ml of blood and 1 ml of saliva were collected before breakfast and supper on the same 
day under regular conditions of daily life from the controls and patients. Furthermore, 5ml 
of blood and 1ml of saliva 2 hours after breakfast, lunch and supper, and 20 ml of 24-h 
accumulated urine were collected on the same day during hospitalization on 7 days after 
admission from the patient group. The diet consisted of 25kcal/kg for ideal body weight 
distributed in three meals. 
Blood samples were immediately centrifuged, and the sera were stored at -30C until 
measurement. Saliva and accumulated urine samples were stored with no processing at -30C.  
Cortisol and cortisone in the samples were measured by liquid chromatography-tandem mass 
spectrometry (LC-MS/MS) (Teikoku Hormone Mfg.-Asuka Pharmaceutical Co., Tokyo, Japan).  
2.3 Glucose clamp 
Euglycemic-hyperinsulinemic glucose clamping was performed in 14 of the patient group 
using an artificial pancreas (STG-22, Nikkiso, Tokyo, Japan), following the method 
described previously (Bergman et al.,1985, Nishikawa et al.,1996). Average age, HbA1c and 
BMI of these patients were not significantly different from those of the whole cases in  
 
 
(data expressed as mean ±SD) 
Table 1. Anthropometric measures and background of the subjects 
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patient group. In patients under drug treatment for diabetes, administration of sulfonylurea  
and a long-acting insulin preparation was suspended from the previous evening to avoid 
their influence on the test.  
2.4 Statistical analysis  
The subjects’ backgrounds are presented as the means  standard deviation, and the t-test 
was used to compare healthy subjects with patients. To analyze the correlation between 2 
variables, Spearman’s correlation coefficient was used, and a level of less than 5% was 
regarded as significant. 
3. Results 
3.1 Subject characteristics  
The characteristics of the healthy and patient group, including age and BMI, are described in 
Table 1. The mean duration of illness was 7.0  4.7 years in the patient group, and 14 (60.9%) 
and 8 (34.8%) patients were under treatment with insulin and oral drugs, respectively at the 
time of sample collection.  
 
 
Serum levels of F and E were not different between healthy subjects and diabetic patients (A), and the 
ratio of F to E was significantly higher in the patient group (B). A similar result was observed for saliva 
(C, D). Data are expressed as the means±S.D. Statistical significance between healthy and diabetic 
subjects is described inside the figure. 
Fig. 1. Comparison of F, E, and F/E ratios between healthy subjects and diabetic patients in 
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serum, saliva, and 24h-collected urine from obese type 2 diabetic patients as well as healthy 
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(data expressed as mean ±SD) 
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patient group. In patients under drug treatment for diabetes, administration of sulfonylurea  
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regarded as significant. 
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Table 1. The mean duration of illness was 7.0  4.7 years in the patient group, and 14 (60.9%) 
and 8 (34.8%) patients were under treatment with insulin and oral drugs, respectively at the 
time of sample collection.  
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Fig. 1. Comparison of F, E, and F/E ratios between healthy subjects and diabetic patients in 
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3.2 Relationship between F/E ratio and body weight 
As shown in Fig. 1, no significant difference was noted in the blood cortisol (F) level before 
breakfast between the healthy and patient group, but the cortisone (E) level was lower in the 
patient group. Accordingly, the ratio of F to E (F/E) in blood was significantly higher in the 
patient group (3.6 vs. 4.8, respectively, p<0.01). 
There was no significant difference in F or E level in saliva before breakfast between the 
healthy and patient group. Unlike the blood levels, E level was higher than F level in saliva. 
This is considered to be the influence of 11β-HSD2 expressed in the salivary gland (Tannin 
et al.,1991). However, the F/E ratio in saliva was significantly higher in the patient group, as 
in blood (0.13 vs. 0.19, respectively, p<0.01).  
There was no correlation between the blood F/E ratio before breakfast and body mass index 
(BMI) in healthy subjects (Fig.2A), while there was a strong positive correlation between the 
blood F/E ratio and BMI in the patient group (Fig.2B). This correlation also remained 
significant after correction with age, HbA1c and blood glucose level before breakfast. 
Furthermore, a similar result was observed in salivary samples.  The salivary F/E ratio 
tended to show a positive correlation with BMI in diabetic patients, but not in healthy 
subjects (Fig.2C, D).   
 
 
F/E ratio in blood was positively correlated with BMI only in diabetic patients (A, B). F/E ratio from 
salivary samples also showed a similar tendency, although the correlation was not statistically 
significant in diabetic patients (C, D). 
Fig. 2. Correlation between fasting F/E ratio and BMI. 
Fig. 3 shows the relationship between the fasting blood F/E ratio and fat volume assessed 
by abdominal CT in the patient group. The F/E ratio was positively correlated with the 
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subcutaneous fat area, but was not correlated with the area of visceral fat. Furthermore, the 
fasting blood and salivary F/E ratio was strongly correlated with serum leptin level 
(r=0.652, p<.0.01 for blood, r=0.469, p<.0.05 for saliva), but was not correlated with the 
plasma concentration of high molecular weight adiponectin or the severity of insulin 
resistance measured by glucose clamping (data not shown). 
 
 
Fasting blood F/E ratio positively correlated with subcutaneous fat area (A), but no correlation was 
found between F/E ratio and visceral fat area (B). 
Fig. 3. Relationship between fasting blood F/E ratio and body fat area assessed by CT scan. 
3.3 Relationship between salivary cortisol and insulin sensitivity  
Blood and saliva were collected at 4-time points: before breakfast and 2 hours after each 
meal in the patient group. Fig. 4 shows the diurnal variation of F after assessing the level 
before breakfast as 1.0. The F level significantly decreased with time and the variation was 
larger in saliva than in blood. The within-day variation of the F/E ratio was smaller than 
that of the F level. 
 
 
Solid line represents blood samples, and dotted line represents salivary samples. Both blood and saliva 
had a circadian rhythm in the patients, but salivary F fluctuated more dynamically than blood cortisol 
within a day.  
Fig. 4. Circadian rhythm of F (A) and F/E ratio (B) in diabetic patients. 
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The salivary F level after breakfast was strongly correlated with the severity of insulin 
resistance measured by the glucose clamp (Fig. 5). This relationship with insulin resistance 
was not significantly noted in blood F.  
 
 
Salivary F after breakfast showed the strongest negative correlation with GIR/IRI (A, B), while serum 
F(C, D) does not show significant correlation with insulin sensitivity. 
Fig. 5. Relationship between insulin sensitivity (GIR/IRI) and F. 
4. Discussion 
The present study clearly demonstrated that obese patients with type 2 diabetes had a 
higher fasting F/E ratio in blood and saliva in the morning, comparing with healthy control 
subjects. Consistent with our results, an elevated blood F/E ratio in patients with type 2 
diabetes has been reported (Valsamakis et al.,2004, Homma et al.,2001, Sinha & Caro 1998). 
Moreover, this is the first report demonstrating a significant increase in the F/E ratio in 
obese diabetic patients in saliva as well as in blood. Thus, it is suggested that overweight 
seems to induce much more F formation rather than E production via some mechanism(s) of 
changing steroidogenic enzymes, including 11β-HSD1 and 2.  
Our data also showed a positive relationship between the fasting F/E ratio and BMI, 
between the fasting F/E ratio and total fat volume, and between the fasting F/E ratio and 
leptin, in diabetic obese patients. It is, therefore, suggested that the fasting F/E ratio may 
reflect the severity of adiposity accumulated to both of subcutaneous and visceral areas in 
obese diabetics, since circulating leptin levels are reported to be the best predictor of total 
body fat mass (Sinha & Caro,1998). Thus it can be postulated that increased fat mass may 
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lead to increased F production, at least partly mediated by 11β-HSD1 in adipose tissue, 
resulting in an elevated F/E ratio after overnight fasting. It was also reported that the 
expression of 11β-HSD1 is increased in adipose tissue in simple obesity (Rask et al.,2002, 
Paulmyer-Lacroi et al.,2002, Lindsay et al.,2003), suggesting that the ratio of F to E is a 
biomarker for assessing the adiposity in obese patients. 
Oltmanns et al. (Oltmanns et al.,2006) recently reported that the level of salivary F of which 
sample was taken between breakfast and lunch was significantly related to metabolic 
findings in type 2 diabetes, such as fasting and postprandial blood glucose, urinary glucose, 
and glycosylated hemoglobin, although insulin sensitivity was not directly assessed in their 
study. Our data demonstrated that a circadian rhythm of F was apparently observed both in 
blood and saliva, and salivary F 2 hours after breakfast was shown to significantly correlate 
with insulin sensitivity assessed by euglycemic glucose clamping in obese patients with type 
2 diabetes. Salivary F has been reported to have a circadian rhythm, highest in the morning, 
with lunch followed by a peak (Rosmond et al.,1998), suggesting that the salivary level of F 
usually decreases before lunch under normal conditions. Thus, it is suggested from our data 
that the level of salivary F before lunch, reflecting insulin sensitivity, may be up-regulated 
by food intake after breakfast despite of decreasing ACTH level by diurnal rhythm, since 
eating was reported to stimulate F secretion and women with abdominal obesity have also 
been reported to have a greater rise of F in response to food than those with peripheral 
obesity in simple obesity (Pasquali et al.,1998, Duclos et al.,2005, Korbonits et al.,1996). It 
had been recently reported that U-shaped associations were apparent between diurnal slope 
in salivary F and both BMI and waist circumference (Kumari et al.,2010), and also that 6 wk 
of supplementation with fish oil significantly increased lean mass and decreased fat mass, 
which were significantly correlated with a reduction in salivary F following fish oil 
treatment (Noreen et al.,2010). 
Moreover, we should consider why salivary F could reflect insulin resistance in diabetic 
patients, while blood F could not. First, F measured in blood was the total of the free form 
and protein-bound form, while F in saliva reflected the biologically active blood unbound F 
level (Vining et al.,1983). The level of blood F can be altered by the concentration of blood F 
binding globulin (CBG), and CBG levels are shown to correlate negatively with BMI, waist-
to-hip ratio, and HOMA (Fernandez-Real et al.,2002). Hence, salivary F is supposed to 
indicate the level of ‘real’ F activity in vivo, and thus correlates strongly with insulin 
resistance. Second, as shown in Fig. 4, salivary F fluctuates more dynamically than blood F 
within a day. None of our patients were diagnosed as overt or subclinical Cushing 
syndrome, and their levels of F were within the normal range. However, even a small 
increase in blood F within the normal range may contribute to abnormal glucose metabolism 
in metabolic syndrome and type 2 diabetes (Khani & Tayek,2001), and salivary F seems to be 
more sensitive than blood F to detect subtle changes in the metabolic state. 
On the other hand, our results demonstrated that there is not significantly positive 
correlation between salivary F after breakfast and visceral fat mass. Visceral fat volume is 
known to be one of the most important factors to determine insulin resistance (Bergman et 
al.,2007), but our data suggest that F has a significant influence on insulin resistance, and 
intimately related to total fat volume. Furthermore, many factors including levels of glucose 
and insulin are supposed to modulate F metabolism after meals. Therefore, measuring 
salivary F after breakfast in obese diabetic patients may be a useful and noninvasive simple 
method to predict overall insulin sensitivity and severity of adiposity in such patients. 
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biomarker for assessing the adiposity in obese patients. 
Oltmanns et al. (Oltmanns et al.,2006) recently reported that the level of salivary F of which 
sample was taken between breakfast and lunch was significantly related to metabolic 
findings in type 2 diabetes, such as fasting and postprandial blood glucose, urinary glucose, 
and glycosylated hemoglobin, although insulin sensitivity was not directly assessed in their 
study. Our data demonstrated that a circadian rhythm of F was apparently observed both in 
blood and saliva, and salivary F 2 hours after breakfast was shown to significantly correlate 
with insulin sensitivity assessed by euglycemic glucose clamping in obese patients with type 
2 diabetes. Salivary F has been reported to have a circadian rhythm, highest in the morning, 
with lunch followed by a peak (Rosmond et al.,1998), suggesting that the salivary level of F 
usually decreases before lunch under normal conditions. Thus, it is suggested from our data 
that the level of salivary F before lunch, reflecting insulin sensitivity, may be up-regulated 
by food intake after breakfast despite of decreasing ACTH level by diurnal rhythm, since 
eating was reported to stimulate F secretion and women with abdominal obesity have also 
been reported to have a greater rise of F in response to food than those with peripheral 
obesity in simple obesity (Pasquali et al.,1998, Duclos et al.,2005, Korbonits et al.,1996). It 
had been recently reported that U-shaped associations were apparent between diurnal slope 
in salivary F and both BMI and waist circumference (Kumari et al.,2010), and also that 6 wk 
of supplementation with fish oil significantly increased lean mass and decreased fat mass, 
which were significantly correlated with a reduction in salivary F following fish oil 
treatment (Noreen et al.,2010). 
Moreover, we should consider why salivary F could reflect insulin resistance in diabetic 
patients, while blood F could not. First, F measured in blood was the total of the free form 
and protein-bound form, while F in saliva reflected the biologically active blood unbound F 
level (Vining et al.,1983). The level of blood F can be altered by the concentration of blood F 
binding globulin (CBG), and CBG levels are shown to correlate negatively with BMI, waist-
to-hip ratio, and HOMA (Fernandez-Real et al.,2002). Hence, salivary F is supposed to 
indicate the level of ‘real’ F activity in vivo, and thus correlates strongly with insulin 
resistance. Second, as shown in Fig. 4, salivary F fluctuates more dynamically than blood F 
within a day. None of our patients were diagnosed as overt or subclinical Cushing 
syndrome, and their levels of F were within the normal range. However, even a small 
increase in blood F within the normal range may contribute to abnormal glucose metabolism 
in metabolic syndrome and type 2 diabetes (Khani & Tayek,2001), and salivary F seems to be 
more sensitive than blood F to detect subtle changes in the metabolic state. 
On the other hand, our results demonstrated that there is not significantly positive 
correlation between salivary F after breakfast and visceral fat mass. Visceral fat volume is 
known to be one of the most important factors to determine insulin resistance (Bergman et 
al.,2007), but our data suggest that F has a significant influence on insulin resistance, and 
intimately related to total fat volume. Furthermore, many factors including levels of glucose 
and insulin are supposed to modulate F metabolism after meals. Therefore, measuring 
salivary F after breakfast in obese diabetic patients may be a useful and noninvasive simple 
method to predict overall insulin sensitivity and severity of adiposity in such patients. 
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In conclusion, we tried to investigate the role of blood and salivary F and E in the regulatory 
mechanisms of obesity in obese men with type 2 diabetes. They had a higher fasting F/E 
ratio in both blood and saliva than that in healthy controls. Moreover, the fasting F/E ratio 
showed a significant correlation with total fat volume, suggesting that the fasting ratio of F 
to E in saliva and blood seems to directly reflect the adiposity in type 2 diabetic patients 
with obesity. Our data also demonstrated that salivary F after breakfast is suggested to be 
one of the most useful markers of insulin sensitivity in these patients. On the other hand, 
our study was conducted with a cross-sectional design, which does not allow us to assume 
any direct causality of F to insulin resistance. The role of F metabolism in adipogenesis and 
insulin resistance in type 2 diabetes will require further investigation with a prospective 
design.  
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1. Introduction 
Music and medicine have always been closely related. This remains true even in hunter-
gatherer cultures that are thought to reflect primitive human forms, as clarified by cultural 
anthropological and ethno-musicological studies (Lee & Daly, 2005; Merriam & Merriam, 
1964). Interestingly, music has also been used for the treatment of neuropsychiatric 
disorders in hunter-gatherer cultures (Lee & Daly, 2005; Merriam & Merriam, 1964). 
However, in westernized societies, no established music therapy exists for neuropsychiatric 
disorders such as stress disorders, mood disorders (depression), and dementia. Experience 
has shown that music has certain therapeutic effects on neuropsychiatric disorders (both 
functional and organic disorders), and music therapy is currently being used in the United 
States and Europe in clinical and welfare settings. However, the mechanisms of action 
underlying music therapy remain unknown. 
Various studies have examined the effects of listening to music on the brain (Bermudez & 
Zatorre, 2005; Nan et al., 2008). The study by Rauscher et al. on the “Mozart effect” is one of 
the most famous studies and has had both positive and negative impacts on music therapy 
(Rauscher et al., 1993). However, many subsequent studies have questioned the reliability of 
those results, and Chabris et al. published a study disproving the Mozart effect (Chabris, 
1999). However, the fact that music affects the human body and mind was not disproved. In 
fact, more scientific studies on music have been conducted in recent years, mainly in the 
field of neuroscience, and the level of interest among researchers is increasing (Zatorre, 
2003; Zatorre & McGill, 2005). Results of past studies have clarified that music influences 
and affects cerebral nerves in humans from fetuses to adults (Abbott, 2002). 
The most significant finding has been that music enhances synaptic changes in the brain. In 
other words, studies comparing musicians and non-musicians and music learners and non-
learners have clarified that music brings about cerebral plasticity. Music affects neuronal 
learning and readjustment (response of brain cells to sound and music stimuli, and changes 
in cell counts), and this effect lasts for a long period (Abbott, 2002). For example, even when 
neurodegenerative diseases such as Alzheimer’s disease cause memory loss, patients can 
still remember music from the past, and listening to music can facilitate the recovery of 
other memories. This type of memory recovery is accompanied by the reconfiguration of 
existing neuron networks, which may allow access to long-term memory. However, most 
studies have been based on brain imaging modalities such as positron emission tomography 
(PET) or functional magnetic resonance imaging (fMRI). The effects of music at a cellular 
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level have not been clarified, and the mechanisms of action for the effects of music on the 
brain have not been elucidated. 
The effects of steroids on changes in the brain have been documented in many animal 
species. For instance, vocal communication is a common characteristic among many 
vertebrates, and steroid hormones are implicated in the formation of neural mechanisms of 
vocal behavior in fish, amphibians, birds, and mammals (including primates) (Bass, 2008). 
The most fully known relationship between steroids and cerebral plasticity is vocal (singing) 
behavior in birds. The development of vocal behavior in singing birds involves complicated 
processes including neurons and muscles, and steroid hormones (testosterone and 17-
estradiol) are involved during many steps, such as neuron organization, neuron survival, 
and neural song-system formation (Fusani & Gahr, 2006; Nottebohm, 1981). 
In humans, steroid hormones are associated with spatial perception and cognition. The 
relationship between testosterone and cognitive abilities is negative in men and positive in 
women (Gouchie & Kimura, 1991; Grimshaw et al., 1995a; Grimshaw et al., 1995b; Kimura & 
Hampson, 1994; O’Connor et al., 2001; Silverman et al., 1999). In women, the equilibrium of 
testosterone and 17-estradiol associated with the menstrual cycle alters cognitive abilities 
(Silverman et al., 1999; Silverman & Phillips, 1993). Furthermore, in women, age-related 
decreases in 17-estradiol are thought to be involved in cognitive dysfunction, memory 
disorder, learning disorder, depression, and other mood disorders. Numerous studies have 
also examined the relationship between 17-estradiol and Alzheimer’s disease accompanied 
by marked cognitive dysfunction (Gillies & McArthur, 2011; Wharton et al., 2001). The level 
of 17-estradiol is lower for Alzheimer patients than for healthy individuals, and this 
decrease in estrogen level may lead to the progression of Alzheimer’s disease and facilitate 
amyloid beta accumulation, one of the causes of memory disorders. Furthermore, 
testosterone administration to elderly men reportedly improves cognitive function  
(Gruenewald & Matsumoto, 2003). 
The correlation between musical ability and spatial cognition is well recognized (Cupchik, 
2001; Hassler, 1992; Hassler & Birbaumer, 1984). Many studies have investigated the relation 
between musical ability and spatial perception and cognition in humans. The assumption 
that some correlation exists between musical ability and steroid hormones also appears 
reasonable. In fact, Hassler discovered that the relationship between testosterone and 
musical ability (music composition) corresponded to that between testosterone and other 
forms of spatial perception and cognition (Hassler, 1991, 1992). 
Furthermore, the relationship between music and steroid hormones is not confined to 
musical ability. Many studies in the field of behavioral endocrinology and 
neuroendocrinology have documented that musical stimulation (listening) affects various 
biochemical substances (Hassler et al., 1992; Kreutz et al., 2004; VanderArk & Ely, 1993). 
2. Music and human physiology 
The fact that music has an effect on the human body, particularly on stress and easing pain 
or anxiety, has been generally known since the Greeks (Aristoteles). Music influences the 
endocrine system to keep the body normal, as shown by many studies (e.g., Gardner et al., 
1960; Logan & Roberts, 1984; Maslar, 1986; Standley, 1986; Hodges, 1996). Musical behavior 
is believed to invigorate several parts of the nervous system, as auditory information passes 
through the limbic and paralimbic systems including the thalamus, the hypothalamus, and 
amygdala, to the neocortex, and influences the pituitary gland; as a result, various 
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physiological effects are induced. Much research has been done regarding the physiologic 
effects of music, with results showing increases or decreases in respiration, heart rate, blood 
pressure, skin temperature, GSR (galvanic skin response), and electroencephalogram 
findings (Hodges, 1996). However, because of problems with experimental methods, results 
are inconsistent. Unfortunately, there is still no unified concept regarding the physiological 
effects of music, although the fact that music causes physiological effects in the human body 
is well accepted. Enormous advances have been made in recent years toward an 
understanding of the brain structures involved in music. Using the brain imaging 
techniques of PET, fMRI, and magnetoencephalography, the brain structures and activity 
related to music were clarified (Koelsch, 2010; Zatorre, 2003). Interestingly, these structures 
(limbic and paralimbic structures) are involved in the initiation, generation, detection, 
maintenance, regulation, and termination of emotions that have survival value for the 
individual and the species (Koelsch, 2010). Needless to say, emotions are deeply affected by 
steroids (Garcia-Segura, 2009). 
3. Effects of steroids on auditory and musical behavior 
Recently, endocrinologic research on human behavior has progressed. Evidence to date 
suggests that hormones not only have organizational effects but also affect cognition, 
perception, and other behaviors. Because the endocrine and nervous systems do not 
function in isolation but as an integrated whole, many aspects of neuronal functioning are 
affected by hormones (gonadal steroids). However, we still lack data regarding the effect of 
music on hormones. In addition, although knowledge regarding endocrinologic function 
and music has begun to accumulate, results are contradictory. Some studies indicate that 
music influences humans endocrinologically and other studies indicate that hormones 
influence musical behavior. Below we will review the substances that have been examined 
thus far and explore the physiological function of music. 
Many reports support the correlation between hormones and hearing or vocal behaviors. 
The fact that testosterone influences growth of the larynx is well known. It is believed that 
testosterone also influences the auditory sense and the vocal organ (Kelley & Brenowitz, 
1992; Marler et al., 1988; Silver, 1992). Reports also indicate that the utterance of song birds is 
influenced by testosterone (Nottebohm, 1972; Marler et al., 1988) and point to the existence 
of similarities between the vocal tract of song birds and humans (Bridgeman, 1988). The fact 
that the auditory sense of the human females undergoes cyclical changes affected hormones 
has been reported (Wynn, 1971). Moreover the female voice is also influenced by 17-
estradiol (Abitbol et al., 1989). The hypothesis that the perception of sound is influenced by 
hormones is based on the idea that hormones influence dorsal division and reticular 
formation in the auditory pathways.  
Testosterone influences the development of the neural pathways of the brain and stimulates 
cerebral lateralization (Geschwind & Galaburda, 1985). As Lovejoy said, this provides males 
with right brain superiority, which results in making him proficient in spatial ability, such 
as securing food and adapting to the environment (Lovejoy, 1981). Other reports also show 
that spatial ability is influenced by sex hormones; for example, men with lower testosterone 
levels performed better than men with higher testosterone levels whereas women with 
higher testosterone levels performed better than women with lower testosterone levels on 
spacial ability tests (Gouchie & Kimura, 1991; Hampson & Kimura, 1992; Nyborg, 1983). 
Further a relation between spatial ability and musical ability has been reported (Hassler et 
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al., 1985), and listening to music has been shown to improve spatial ability (IQ) (Rauscher et 
al., 1993).  
4. Musical behavior and steroids 
4.1 Cortisol 
Psychological and physiological stress affects testosterone and cortisol levels in both sexes. 
Generally, cortisol levels increase significantly in the presence of stress. It has been reported 
that music eases stress responses psychologically, physiologically, and endocrinologically. It 
is well known that listening to music reduces uneasiness (Gerdner & Swanson, 1993; 
Kaminski & Hall, 1996), depression, and fatigue (Field et al., 1997; Hanser & Thompson, 
1994), changes mood (Cadigan et al., 2001; Gfeller & Lansing, 1991; McCraty et al., 1998; 
Sousou, 1997), and suppresses pain (Allen et al., 2001; Browning, 2000; Maslar, 1986). 
However, some reports that compare listening to music with other relaxation methods show 
no differences in alleviation of anxiety, depression, and fatigue (Field et al., 1997; Hanser & 
Thompson, 1994) or reduction of heart rate (Guzzetta, 1989; Scheufele, 2000). In addition, 
some authors have reported that there is differences in psychological and physiological 
responses among different genres of music (classical, hard rock, “favorite music,” 
“relaxation music”) (Allen & Blascovich, 1994) and others have reported no such differences 
(Burns, 1999). 
Most of these studies have been on the stress-reducing effects of listening to music, and 
listening to music has been reported to cause a reduction in the cortisol levels. Cortisol is 
involved in many vital functions such as glucose metabolism and immune function, but in 
cases of chronic stress, it has been known to induce symptoms such as hypertension and 
impaired cognitive function (Lundberg, 2005). In addition, increasing cortisol levels with 
age may lead to a decline in memory or progression of Alzheimer’s disease (Huang et al., 
2009). Thus, the reduction of cortisol through the passive activity of listening to music may 
be useful for the treatment and prevention of diseases and disabilities.  
Listening to music for short periods could lower cortisol regardless of the subject’ s mental 
state (Field et al., 1998; Möckel et al., 1994), and music has been shown to significantly lower 
(Escher et al., 1993; Miluk Kolasa et al., 1994; Rider et al., 1985) or suppress cortisol levels 
(Schneider et al., 2001) even during surgery. Other papers reported that not only listening to 
music but also playing music (percussion instruments) lowered cortisol levels (Bittman et 
al., 2001; Burns et al., 2001). In addition, studies have shown that cortisol responses differed 
by music experience, such as (Vander Ark & Ely, 1992, 1993) and the subject’s preference 
(Gerra et al., 1998). However, so far results are contradictory and there is no consensus 
regarding the relation between cortisol and music category or preference. However, judging 
from published research results, listening to one’s favorite music decreases cortisol levels 
(Fukui, 1996). 
4.2 Testosterone 
Contrary to cortisol, several investigations have been conducted on the relationship between 
music and testosterone. 
Testosterone has been shown to influence musical ability (Hassler, 1991), and its effects 
produce discrepancies between the sexes (Schumacher & Balthazart, 1986). Hassler 
hypothesized the existence of an optimal testosterone level in proportion to musical ability. 
Reports also discuss the existence of a correlation between hormone levels (testosterone) 
 
Music and Steroids – Music Facilitates Steroid–Induced Synaptic Plasticity 
 
155 
and musical ability in puberty (Durden-Smith & Simone, 1983; Hassler, 1987; Hassler and 
Birbaumer 1987). Another report indicates that during puberty, children show poor results 
in music tests because of low testosterone levels at this stage (Serafine, 1988). Moreover, 
there is a report that composition has a seasonality that might be influenced by the 
circannual rhythm of testosterone (Fukui, 1995). In addition, most composers are male, and 
composers tends to show a low level of testosterone compared with control (Hassler et al., 
1990).  Further reports show that musicians have a tendency to demonstrate relatively low 
levels of sex-role stereotyping (Kemper, 1990), which again, may be related to testosterone 
levels. The point is that testosterone influences musical ability. 
Regarding musical ability and testosterone, there is a high positive correlation between 
spatial cognitive ability and musical ability (talent) (Rauscher et al., 1993). A high correlation 
is also found between spatial cognitive ability and testosterone (Nyborg, 1983). 
Furthermore, these correlations differ between males and females. Hassler reported that 
male composers had relatively low testosterone levels, and that testosterone values 
increased as musical ability increased in female composers (Hassler, 1991). 
On the other hand, only one report is available on sex-related differences in testosterone 
responses associated with music playing or listening. Fukui examined testosterone level 
changes between before and after listening to a wide variety of music, including favorite 
music, pop, jazz, and classical, in male and female students, and showed sex-related 
differences (Fukui, 2001). Specifically, testosterone values decreased in males and increased 
in females after listening to music, regardless of genre. Interestingly, the sex-related 
difference in testosterone levels while listening to music were the same as sex-related 
differences in stress responses. Grape et al. compared between patients with irritable bowel 
syndrome who took part in singing in a choir with those who took part in a group 
discussion and found that testosterone levels decreased in the singing group (Grape et al., 
2010). 
So far, there is no research investigating music and estrogen. 
5. Hypothesis and the study 
We propose that listening to music facilitates the regeneration and repair of cerebral nerves 
by adjusting the secretion of steroid hormones in both directions (increase and decrease), 
ultimately leading to cerebral plasticity. Music affects levels of cortisol, testosterone, and 
17-estradiol, and we believe that music also affects the receptor genes related to these 
substances and related proteins. 
5.1 Methods 
Subjects were recruited from healthy elderly women aged 60 or older who were 
participating in a 90 min. singing group (choir) as part of disease prevention and health-
promoting activities hosted by the local government. The session was taught by a music 
therapist. Inclusion criteria were as follows: attended all four sessions (once a month); 
healthy; and not taking any medications such as steroids that could affect endocrinologic 
factors. A total of 50 volunteers (8 males and 42 females) were enrolled, however because of 
missing value, male's data was not possible to use. Finally, 42 female volunteers were 
enrolled. Mean age was 72.9 years (range: 64-83 years). 
After obtaining informed consent, subjects participated in four choral sessions, once a 
month for 4 consecutive months. The sessions took place at a facility owned by the local 
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al., 1985), and listening to music has been shown to improve spatial ability (IQ) (Rauscher et 
al., 1993).  
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government. The flow of the experiment was as follows: first, health status and medication 
were checked. Then a saliva sample was collected before and after each session (about 90 
min). Saliva samples were stored at -20ºC in the freezer immediately after collection, and 
cortisol, testosterone, and 17ß-estradiol levels were measured by enzyme immunoassay. 
Intra- and inter-assay coefficients of variation ranged between 3.35–3.65% and 3.75–6.41% 
for cortisol, 2.5–6.7% and 7.9–8.6% for testosterone, and 6.3–8.1% and 6.0–8.9% for 17-
estradiol. 
The musical preference of subjects was ascertained before the study, and several pieces of 
music were selected for the session. The contents of all four sessions were the same. 
To assess depression and anxiety as psychological states, the Japanese version of the Profile 
of Mood States (POMS) as executed before and after the session (Yokoyama & Araki, 1994). 
The POMS is a highly reliable test that is often used in studies on mood states and the test 
we used were revised for use by the elderly in terms of terminology and style. In the present 
study, of the six subscales of POMS (“tension/anxiety” (TA), “depression/dejection” (DD), 
“anger/hostility,” “vitality,” “fatigue,” and “confusion,” the DD and TA subscales were 
used.  
Cognitive tests were carried out at the same time as the POMS. Tests performed were as 
follows: 1) Digit Symbol-Coding (WAIS: Wechsler Adult Intelligence Scale III) memory task 
(Silverman and Eals’ Object Location Memory Task), and 3) mental rotations test 
(Vandenberg and Kuse Mental Rotations test “3-dimensional”). 
5.2 Results 
Cortisol, testosterone, and 17ß-estradiol levels for subjects were biphasic, and subjects were 
divided into two groups (high and low) with respect to pre-session median values. Mean 
hormone levels prior to the choral session were 0.2243 µg/dL for cortisol, 66.0579 pg/mL for 
testosterone, and 6.1332 pg/mL for 17-estradiol. 
Analysis of variance (ANOVA) was conducted on changes in cortisol, testosterone, and 17-
estradiol levels before and after each session, between the high and low groups, and 
between each session. 
In terms of cortisol levels, the main effect of cortisol changes before and after the choral 
session was significant (F (1,122)=28.16, p=0.0000). In addition, the main effect between the 
high and low groups (F (1,122)=35.05, p=0.0000) was significant. Cortisol significantly 
decreased after each session in both the high and low groups (Fig. 1). 
The main effect of testosterone changes before and after the choral session (F (1,284)=4.26, 
p=0.0399), the main effect between the high and low groups (F (1,284)=289.99, p=0.0000), 
and the interaction between testosterone changes and the high and low groups (F 
(1,244)=15.04, p=0.0001) were significant. In the high group, testosterone levels significantly 
decreased after the choral session; in contrast, in the low group, testosterone levels increased 
significantly after the session (Fig. 2). 
The main effect of 17-estradiol changes (F (1,244)=23.23, p=0.0000), the main effect between 
the high and low group (F (1,244)=193.72, p=0.0000), and the interaction between 17-
estradiol changes and the high and low groups (F (1,244)=58.27, p=0.0000) were significant. 
In the high group, 17-estradiol levels significantly decreased after the choral session. 
Conversely, in the low group, 17-estradiol levels significantly increased after the session 
(Fig. 3). 
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ANOVA was conducted on changes in cortisol, testosterone, and 17-estradiol levels before 
and after each session, between the high and low groups, and between each session. No 
significant difference was found in any factor of the TA scores. The main effect of the DD 
scores was significant for cortisol (F (1,122)=4.02, p=0.0473), testosterone (F (1,117)=3.70, 
p=0.05), and 17-estradiol (F (1,119)=4.25, p=0.0414). The scores of high and low groups 
significantly decreased after the session. 
ANOVA was conducted on changes in cortisol, testosterone, and 17-estradiol levels before 
and after each session, between the high and low groups, and between each session. No 
significant difference was found in any factor of the Digit Symbol-Coding. For the memory 
task, only the main effect of high and low groups for 17ß-estradiol was significant (F 
(1,120)=10.85, p=0.0013). The main effect of the mental rotations test was significant for 
cortisol (F (1,123)=9.16, p=0.0030), testosterone (F (1,116)=8.48, p=0.0043), and 17-estradiol 
(F (1,120)=9.03, p=0.0032). The scores of high and low groups significantly increased after 
the session (Fig. 4, 5, 6). 
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The main effect of the mental rotations test was significant for 17-estradiol (F (1,120)=9.03, p=0.0032). 
The scores of high and low groups increased after the session. 
Fig. 6. Mean score of the mental rotations test in 17ß-estradiol levels 
6. Discussion 
Coristol, testosterone, and 17-estradiol were affected by musical behavior (chorus). Cortisol 
levels decreased after each choral session, whereas changes in testosterone and 17-estradiol 
levels were dependent on the subject’s baseline hormone level. After all sessions, testosterone 
and 17-estradiol levels increased in the low groups and decreased in the high groups. 
Anxiety and depression score (POMS) decreased after all sessions. The interesting finding 
was a result of the cognitive test (mental rotations test). The score increased regardless of the 
initial hormone level. Mental rotation involves spatial ability and is localized to the right 
hemisphere and is associated with intelligence (Hertzog & Rypma, 1991); Johnson, 1990; 
Jones & Anuza, 1982). It has been documented that music training improves verbal, 
mathematical, and visuo-spatial performance in children and adults (Brochard, 2004; Ho et 
al., 2003). However, no study has investigated music and mental rotation beside the “Mozart 
effects,” especially in elderly people (Cacciafesta, et al., 2010). Our study is the first report to 
show that music improved mental rotation ability in elderly women. 
Results of this study clarified that musical activities affect steroid secretion in elderly 
women and are likely to alleviate psychological states such as anxiety and tension. 
Furthermore, levels of steroids changed in both directions, increasing in subjects with low 
hormone levels and decreasing in subjects with high hormone levels. Thus, the hypothesis 
that listening to music affects the steroid hormone cascade and facilitates neurogenesis, 
regeneration, and repair of neuron appears highly plausible. 
This study has several limitations, including the fact that only data obtained from a small 
number of elderly women were analyzed. However, the finding that musical behavior 
(chorus in this study) altered steroid levels agrees with results of previous studies that have 
documented strong correlations between steroids and spatial perception and cognition and 
the effects of listening to music on steroid secretion.  
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At this point, the effects of music on steroids are unclear, but music appears to be involved 
with steroid production via the pathway from the auditory system to the auditory area, 
particularly the neural pathway (emotion circuits) mediated by the cerebral limbic system 
(hypothalamic-pituitary-adrenal axis and amygdaloid complex). In recent years, the possible 
involvement of nerve damage in neuropsychiatric disorders has been suggested, and 
musical activities may enable the protection, repair, and even regeneration of human 
cerebral nerves. 
Music is noninvasive, and its existence is universal and mundane. Thus, if music can be 
used in medical care, the application of such a safe and inexpensive therapeutic option is 
limitless. 
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The main effect of the mental rotations test was significant for 17-estradiol (F (1,120)=9.03, p=0.0032). 
The scores of high and low groups increased after the session. 
Fig. 6. Mean score of the mental rotations test in 17ß-estradiol levels 
6. Discussion 
Coristol, testosterone, and 17-estradiol were affected by musical behavior (chorus). Cortisol 
levels decreased after each choral session, whereas changes in testosterone and 17-estradiol 
levels were dependent on the subject’s baseline hormone level. After all sessions, testosterone 
and 17-estradiol levels increased in the low groups and decreased in the high groups. 
Anxiety and depression score (POMS) decreased after all sessions. The interesting finding 
was a result of the cognitive test (mental rotations test). The score increased regardless of the 
initial hormone level. Mental rotation involves spatial ability and is localized to the right 
hemisphere and is associated with intelligence (Hertzog & Rypma, 1991); Johnson, 1990; 
Jones & Anuza, 1982). It has been documented that music training improves verbal, 
mathematical, and visuo-spatial performance in children and adults (Brochard, 2004; Ho et 
al., 2003). However, no study has investigated music and mental rotation beside the “Mozart 
effects,” especially in elderly people (Cacciafesta, et al., 2010). Our study is the first report to 
show that music improved mental rotation ability in elderly women. 
Results of this study clarified that musical activities affect steroid secretion in elderly 
women and are likely to alleviate psychological states such as anxiety and tension. 
Furthermore, levels of steroids changed in both directions, increasing in subjects with low 
hormone levels and decreasing in subjects with high hormone levels. Thus, the hypothesis 
that listening to music affects the steroid hormone cascade and facilitates neurogenesis, 
regeneration, and repair of neuron appears highly plausible. 
This study has several limitations, including the fact that only data obtained from a small 
number of elderly women were analyzed. However, the finding that musical behavior 
(chorus in this study) altered steroid levels agrees with results of previous studies that have 
documented strong correlations between steroids and spatial perception and cognition and 
the effects of listening to music on steroid secretion.  
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At this point, the effects of music on steroids are unclear, but music appears to be involved 
with steroid production via the pathway from the auditory system to the auditory area, 
particularly the neural pathway (emotion circuits) mediated by the cerebral limbic system 
(hypothalamic-pituitary-adrenal axis and amygdaloid complex). In recent years, the possible 
involvement of nerve damage in neuropsychiatric disorders has been suggested, and 
musical activities may enable the protection, repair, and even regeneration of human 
cerebral nerves. 
Music is noninvasive, and its existence is universal and mundane. Thus, if music can be 
used in medical care, the application of such a safe and inexpensive therapeutic option is 
limitless. 
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